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1. Click chemistry is a new approach for the synthesis of drug-like molecules, which can 
accelerate the drug discovery process. Sharpless. 
2. In a field where simplicity and speed of reaction are crucial, it is only natural that 'click' 
chemistry began to emerge as an excellent radiolabelling technique. Chapter 2 
3. The use of MonoPhos as ligand results in accelerated click reaction, less precursor 
consumption and a higher radiochemical yield. Chapter 3 
4. The synthesis of [18F]Galacto-RGD is very complex and time consuming, therefore a better 
option is synthesising [18F]-RGD-KS offering a simplified procedure leading to robust clinical 
study and a short synthesis time. Chapter 6 
5. The imaging of integrin expression (using [18F]-RGD-KS) provides valuable information to 
determine the indication of surgical atherosclerotic plaques removal. Chapter 7 
6. Catalytic copper which is toxic at high micromolar concentrations is forming complexes with 
PET-labelled peptide. This is why considerable effort is put into developing Cu-free click 
chemistry. Chapter 8 
7. If the strain-promoted azide-alkyne cycloaddition methodology could be extended as 
pretargeting method to antibodies, the use of radionuclides for imaging such targets will not 
be limited to the longer-lived metallic radioisotopes, and higher resolution images using [18F] 
can be achieved. 
8. The most fundamental and lasting objective of synthesis is not production of new 
compounds, but production of properties. George S. Hammond, Norris Award Lecture, 1968 
9. In the PET-lab there is no excuse for not wearing safety glasses and a radiation badge. 
10. Being a good scientist is being a good seller because ''In science credit goes to the man who 
convinces the world, not to the man to whom the idea first occurs". F. Darwin 
11. To increase the productivity in science, brainstorm as much as you can, and only test the 
most probable ideas. You may miss the possibility of the rare accidental discovery, but your 
approach is more logical than being dependent on pure luck. 
12. There are sadistic scientists who hurry to hunt down errors instead of establishing the truth. 
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Positron Emission Tomography 
Positron Emission Tomography (PET) is an imaging technology in nuclear medicine that 
is able to provide 3D functional images of the human body. It is based on radioactive 
positron emitting atoms that are incorporated in pharmaceuticals [Joliot, 1934]. These 
radionuclides undergo decay, and when this happens they emit a positron, called �+ decay. 
After having travelled a short distance in the tissue the emitted positron meets an electron. 
This combination will result in annihilation of both particles under the emission of two 
photons. During this reaction, mass is converted into energy following E=mc2• The emitted 
photons have an energy of 511 keV and move in opposite directions [Phelps, 2000]. During 
a PET scan a subject is injected with a positron emitting radiopharmaceutical. After 
radioactive decay the emitted photons are detected and subsequently it can be determined 









Figure 1.1. Principle of PET, the readily used FDG molecule with 18F emitting two photons, 




There are several radionuclides that can be used for PET. Amongst several others, 150, 
13N, 11C and 18F are positron emitters that are very frequently used. Because of the relatively 
short half life, the radionuclides are produced on-site using a cyclotron. 18F is most often 
used because of its half life of 110 min [Schirrmacher, 2007]. A commonly used 
radiopharmaceutice compound for PET is the glucose analogue 2-[18F]Fluoro-2-0eoxy-0-
Glucose (FOG). FOG can, just as glucose, be phosphorylated by hexokinase. The difference 
with glucose is that the phosphorylated product of FOG, FOG-6-P04 is not significantly used 
in subsequent reactions in the body on the PET timescale. The FOG-6-P04 will remain in the 
cell where it was phosphorylated thereby giving a measure of the extent to which glucose is 






Figure 1.2. Phosphorylation of FOG and resulting PET images. 
From: http: //radiographies. rsna .orq/ content/24/2/523/F3 .expansion. html 
Several diseases are biological processes that often require more energy, as in the form 
of glucose, than normal processes especially in cases like that of cancer where tumors are 
fast growing. The injected FOG will be phosphorylated in higher amounts in the cancerous 
areas than in other areas giving a good high resolution 30 image of the disease (Figure 
1.2). Besides FOG many other 18F-radiopharmaceuticals are being developed during the last 
decades for many different purposes as shown in table 1.1. 
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Click chemistry for PET 
There is a great need for versatile radiolabelling methods for the production of 18F­
radiopharmaceuticals to increase their availability. 
In most cases, 18F-labeling of small molecules to form PET imaging probes involves 
nucleophilic substitution by [18F]-fluoride of a precursor with the appropriate leaving group 
in compatible reaction media, such as acetonitrile, DMF or DMSO using temperatures of 80-
160 °c. Under such reaction conditions, the reactivity of [18F]fluoride can be influenced by 
steric and electronic effects within the target molecule. In addition, protecting groups for a 
variety of functional groups such as carboxylic acidic protons are required. Although a lot of 
knowledge exists on protecting groups the proper selection will have to be investigated in 
each new case. Therefore, this conventional way of 18F-fluorination cannot not be generally 
applied for the preparation of each 18F-radiopharmaceutical. 
Recently, click chemistry has been introduced as a potential method. The preparation of 
several receptor binding ligands, labeled with a positron emitting radionuclide, via a click 
reaction is described in this thesis. Sharpless et al. presented, in 2001, a review in which 
they introduced the concept of "click chemistry" [Kolb, 2001]. One of the most applied click 
reaction is the Huisgen 1,3 dipolar cycloaddition that is catalyzed by Cu (I). To be a "click 
reaction" a reaction needs to: 
be modular 
be applicable to a wide range of substrates 
produce high yields 
produce only inoffensive byproducts 
be orthogonal to other functional groups, 
that can be removed by non-chromatographic methods, be stereospecific, although 
not necessarily enantioselective. 
Ideally, the reaction conditions should be simple, involving no or benign solvents and the 
reaction itself should be insensitive to oxygen and water. To be able to obtain all of these 
characteristics these reactions need a high thermodynamic driving force. One could thus 
look at these reactions as being "spring loaded", so that as soon as the functional groups 
are in place the reaction can proceed easily and rapidly with high yields. The Huisgen 1,3 
dipolar cycloaddition involves the reaction between an alkyne and an azide to form a triazole 
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linkage as is extensively reviewed in chapter 2. The reaction is very suitable for application 
in 18F-radiochemistry. 
Aims of this thesis 
The goal of this research consists of two objectives. The first objective is to develop 
click chemistry for the synthesis of PET tracers with focus on 18F as radionuclide and the 
second objective part of the project is to apply click chemistry for the synthesis and 
evaluation of biologically active molecules. Thereby the triazole moiety will be applied as 
integral part of the molecule or as means to attach a prosthetic group. 
In Chapter 3, the results of a study towards optimization 18F click chemistry are 
presented. Research results obtained from work of Lachlan Campbell-Verduyn [Campbell­
Verduyn, 2008] are translated to 18F-radiochemistry. It is of utmost importance to accelerate 
the reaction to obtain high radiochemical yields with short-lived 18F. Furthermore minimizing 
the amounts of reagents will simplify purification and workup procedures. Our aim is to 
achieve rate acceleration and to perform a systematic study of the reaction parameters of 
the catalytic 1,3-dipolar cycloaddition of azides and alkynes using phosporamidite ligands for 
the application to PET- imaging precursors. 
In chapter 4, we will develop a rapid synthesis method of a 18F-labeled tracer aimed for 
imaging of cerebral beta adrenergic receptors (�-ARs). Using click chemistry the hydroxyl 
propylamine moiety ( crucial for binding to �-ARs) is partly maintained but 18F was 
introduced as a novel moiety, possibly not resulting in toxicity of the carazolol derivatives. A 
tracer based on the �-azidoalcohol motif is designed for targeting cerebral �-adrenergic 
receptors and its stability and binding affinity for the targeted receptors are investigated. 
In chapter 5, a study is presented on the synthesis of a new 18F-labeled bombesin derivative 
by click chemistry to achieve high tumor uptake and optimal pharmacokinetics for specific 
targeting of Gastrin-Releasing Peptide (GRP) receptors in human prostate cancer cells. 
Bombesin is a 14 amino acid peptide sequence which serves as a tumor marker for various 
cancers. Amino acids 7-14 are considered to be the sequence responsible for binding to the 
GRP-receptor. We use 1,3-dipolar cycloaddition to label the peptide modified at the lys3-




In chapter 6, the optimized 18F-click chemistry method as described in Chapter 3 will be 
applied on the synthesis of the PET-biomarker RGD KS. The optimized synthesis method will 
be compared with the current method as developed by Siemens and aspects to translate 
RGD-KS to the clinic will be elaborated in cooperation with the University Hospital in Leuven, 
Belgium. The described synthetic methodology can generally be applied for other click 
reactions using [18F]fluoroalkynes as prosthetic group. 
In chapter 7, the potential use of [18F]RGD-K5 for the diagnosis of vulnerable 
atherosclerotic plaques by avb3 integrin expression, such as cancer and inflammation will be 
investigated. In this study, for the first time we investigated whether it is feasible to detect 
av�3 integrin in human carotid endarterectomy (CEA) specimens using an ex vivo imaging 
method recently developed (Masteling, 2011). This method allows using high resolution 
microPET system to illustrate heterogeneous tracer uptake within atherosclerotic plaque and 
correlating tracer uptake with pathologic finding of plaques in different regions. 
In chapter 8, we investigate reaction conditions and substrates to apply copper-free 
click chemistry. Since copper is very toxic, when one can avoid copper the metal does not 
have to be removed afterwards. Furthermore it opens the possibility for reactions to occur in 
vivo. To this purpose new strained alkynes will be investigated. The neuropeptide bombesin 
will be used as model compound for testing the 18F-radiochemistry. Hydrophilicity can be 
tuned by selection of the proper complementary azide synthon. Furthermore stability of 
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Abstract 
Sharpless et al. presented, in 2001, a review in which they introduced the concept of 
"click chemistry". In this review a "new way" of making chemicals, with a particular 
emphasis on drugs, is presented. Current drugs are often based on natural products that 
were first extracted from plants or other organisms and then with enormous effort were 
synthetically reproduced by chemists. Sharpless et al. propose to shift the focus away from 
the structure, which chemists focus on when they synthesize natural products, towards the 
function of molecules. Rather than making natural products with known biological activity 
and using these as templates for small modifications, it is proposed to make large libraries 
of compounds using (mainly) modular chemistry. After all, when looking for new and better 
drugs, it is the function that matters rather than the structure. This approach mimics nature 
in that it involves making a great variety of different compounds starting from a relatively 
small number of building blocks via a set amount of reactions. These sets of reactions have 
been termed "click reactions" in which simple molecules with specific functionalities can be 
"clicked" to each other to form a large variety of compounds with relative ease that can 
subsequently be tested as potential drug candidates. For these "click reactions" Sharpless 
also looks to nature for inspiration. Ideally, the reaction conditions should be simple, 
involving no or benign solvents and the reaction itself should be insensitive to oxygen and 
water. 
It was found that copper not only accelerates the reaction but also controls the 
regioselectivity since in the presence of copper, only the 1,4-isomer is formed. The reaction 
proceeds in water, with or without co-solvent at room temperature and is relatively fast. The 
reaction is 100% atom efficient which means that there are no side products so the work up 
is usually simple. It can take place in a wide pH range which makes is suitable for biological 
compounds that require a specific pH. Furthermore the azide and alkyne functionalities are 
bioorthogonal, so theoretically, other functional groups present in a biological environment 
will not touch them. Finally the triazole product is biologically stable. 
18 
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Introduction 
Click chemistry is used to describe the copper(I)-catalyzed azide-alkyne cycloaddition 
that enables chemical building blocks to 11click11 forming an irreversible linkage (scheme 2.1). 
The click reaction was introduced in 2001 by Sharpless and co-workers [Sharpless, 2001]. 
The copper(I)-catalyzed azide-alkyne reaction has shown its value for conjugating small 
prosthetic groups to various biomolecules in vitro. In contrast, in vivo use of copper(I)­
catalyzed click chemistry for biomolecule labeling in living systems is prohibited by the 
requirement of the cytotoxic copper(!) catalyst. [Sharpless, 2001, 2002, 2003] 
Sharpless described the term click chemistry as a group of reactions that "must be modular, 
show broad scope, give very high yields, generate only inoffensive by-products that can be 
removed by non-chromatographic methods, and should be "stereospecific". [Sharpless, 
2003] Characteristics are simple reaction conditions. In the ideal case the reaction must be 
not sensitive to oxygen and water, utilizes readily available starting reagents, uses no or an 
environmentally benign solvent, that can easily be removed, and includes simple product 
isolation. 
Amongst all types of click chemistry, the most studied reaction is the Cu1 catalyzed 
formation of 1,2,3-triazoles using Huisgen 1,3-dipolar cycloaddition of terminal alkynes with 
azides. This reaction is highly regioselective leading to 1,4-disubstituted 1,2,3-triazoles (a 







Scheme 2.1. General scheme of the Huisgen "click" chemistry cycloaddition reaction. 
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Although the Cu(I) catalyzed 1,3-dipolar cycloaddition of terminal alkynes with azides 
gives the product in high yield and purity the transformation is still relatively slow and 
requires hours for completion. This is a major drawback especially when the reaction has to 
be applied in the synthesis of radiopharmaceuticals for Positron Emission Tomography (PET) 
when using short-lived radionuclides. [Tornoe,2002] 
Click chemistry using this Huisgen 1,3-cycloaddition can be highly versatile for application to 
18F-radiolabelled pharmaceuticals (possibly also for 68Ga and 1 1C) in PET. 18F is attractive for 
PET because it can be produced in very high yields and has favourable decay characteristics 
(half-life = 110 min and short positron range). Since the click reaction is orthogonal, no 
protective groups are required [Burgess,2005]. A potential additional advantage is that 
reactions can be carried out in water possibly enabling 18F-click reactions in vivo using 
pretargeting strategies [Burgess,2005]. This article gives an overview of the current status 
of click chemistry in relation with PET and will discuss directions to future developments. 
Cu(I)-CATALYZED HUISGEN 1,3-DIPOLAR CYCLOADDITION OF AZIDES 
AND TERMINAL ALKYNES 
The Cu(I)-catalyzed Huisgen 1,3-dipolar cycloaddition of azides and terminal alkynes to 
form 1,2,3-triazoles fulfills all the criteria of click chemistry. The reaction is extremely 
reliable and easy to use. This reaction regiospecifically yields 1,4-substituted triazole 
products. It typically does not require increased temperatures but if required the reaction 
can be performed over a wide range of temperatures (0-160°C) and pH values (S<pH<12) 
and in a variety of solvents (including water). 
When Cu(I) is applied as catalyst, the reaction proceeds 107 times faster than the 
uncatalyzed version. Purification essentially consists of product filtration [Maarseveen,2006]. 
Furthermore, the reaction is hardly affected by steric factors both for the azide and the 
alkyne. Two additional reasons for the popularity of this cycloaddition are that azides and 
terminal alkynes are quite easy to prepare and are very stable under standard conditions 
[Sharpless,2001]. Both starting materials are stable towards oxygen, water, common 
organic synthesis conditions, tolerate a wide range of functional groups, a large range of 
solvents and pH's, and the reaction conditions of living systems (reducing environment, 
20 
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hydrolysis, etc.) [Sharpless,2001, Maarseveen,2006]. Although the decomposition of 
aliphatic azides is thermodynamically favoured, there is a kinetic barrier that makes them to 
be stable in click chemistry conditions [Maarseveen,2006]. Therefore azides usually will only 
react when they meet a dipolarophile, such as an alkyne. [Maarseveen,2006]. 
Mechanism of Cu1-Catalyzed Alkyne-Azide coupling 
It has been suggested that the first step of the reaction involves n complexation of a 
Cu(I) dimer to the alkyne 1 (scheme 2.2). [Sharpless,2001] In the second step, 
deprotonation of the terminal hydrogen occurs resulting in the formation of a Cu-acetylide 
[Finn,2003]. Several forms of Cu-acetylide complexes are possible, which depend on the 
reaction conditions; compound 2 represents one of these possibilities [Kolb,2004]. The 
complexation of Cu(I) lowers the pKa of the terminal alkyne allowing deprotonation in an 
aqueous solvent without the addition of base [Sharpless,2002]. If a non-aqueous solvent 
such as acetonitrile was used, then a base, for example 2,6-lutidine or N,N'­





s- I / L ' l R1 Cu ......_ L_........Cu 
B-H 
..,_ Metallocycle ..,_ 
Scheme 2.2. Proposed mechanism of the catalytic cycle in the click reaction. 
Application of the radionuclide 18F in PET 
PET is a molecular imaging technique that is increasingly used for non-invasive 
detection of diseases [Sharpless,2001]. PET imaging systems create images based on the 
distribution of positron-emitting radiopharmaceuticals after intravenous administration to the 
patient. The injected radiopharmaceuticals contain a positron-emitting isotope, such as 18F, 
22 
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11C, 13N, or 150, that are covalently attached to a molecule which is then metabolized or 
trapped in the body or bound to receptor sites within the body. One of the most widely used 
PET molecular imaging probes is 2-deoxy-2-[18F]fluoro-D- glucose ([18F]FDG). 
[Sharpless,2001] 
In most cases, 18F-labeling of small molecules to form PET imaging probes involves 
nucleophilic substitution by [18F]-fluoride of a precursor with the appropriate leaving group 
in compatible reaction media, such as acetonitrile, DMF or DMSO using temperatures of 80-
160 °c. Under such reaction conditions, the reactivity of [18F]fluoride can be influenced by 
steric and electronic effects within the target molecule. In addition, protecting groups for 
functionalities with acidic protons are required. Although a lot of knowledge exists on 
protecting groups the proper selection will have to be investigated in each new case. 
Therefore, this conventional way of 18F-fluorination cannot not be generally applied for the 
preparation of each 18F-radiopharmaceutical. [Finn,2003, Wong,2003] 
Application of Click Chemistry in PET 
Radiochemistry development 
The use of click chemistry, in particular the Huisgen cycloaddition is receiving increasing 
interest in the field of radiopharmaceutical chemistry. In addition, there have been several 
reports recently based on the click-to-chelate approach for radiopharmaceutical applications 
for 99mTc-labelling reactions.[Brans,2006] Since non-invasive nuclear-imaging techniques, 
such as PET with high sensitivity have become available, radiolabeling of biologically active 
molecules has become an important tool to further develop and extent the clinical 
applications. Non-metallic positron-emitting isotopes, such as 18F and 1 1C, possessing short 
half-lives (t112=109.8 min and t112=20.3 min, respectively), have to be produced on-site in a 
cyclotron or within a short range of a production facility. As described above conventional 
18F-fluorination conditions are relatively harsh which are not suitable for the labeling of 
biomolecules of higher molecular weight since these molecules are generally not stable 
under these conditions. To overcome this conflict, a bifunctional approach is usually applied, 
where the 18F is incorporated into a small molecule that is subsequently attached to 
biomolecules, such as proteins and peptides, under mild conditions. 
23 
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Click chemistry has not been widely applied to the synthesis of 11C-labeled compounds 
for PET imaging, probably due to the very short half-life of 11C. The feasibility to apply click 
chemistry for the preparation of 11C-labeled compounds was investigated by Schirrmacher et 
al.[Schirrmacher, 2008] They reported a method to prepare a 1 1C-labeled compound within 
5-10 min under nontoxic aqueous conditions with the radiochemical yield of 60% at room 
temperature. 
Cu1 catalyzed 1,3-dipolar cycloaddition 'click chemistry' for PET has been mainly used to 
prepare 18F-radiolabeled peptides. Fluorine-18 labeled peptides are becoming more widely 
used as in vivo imaging agents [Bertozzi,2007]. Although a variety of 18F-labeled prosthetic 
groups has been developed, only a limited number of chemical reactions have been utilized 
to incorporate the prosthetic groups into peptides including acylation, alkylation, and oxime 
formation. 
Marik and Sutcliffe(2006) 
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Scheme 2.3. First 18F-Labelling approaches using Click chemistry 
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The first report on the use of click-chemistry for 18F-radiolabeling was by Marik and 
Sutcliffe in 2006, describing a procedure for obtaining 18F-fluoropeptides [Sutcliffe,2006]. ro­
[18F]fluoroalkynes (n= l-3) were reacted with peptides containing N-(3-azidopropionyl)­
groups (scheme 3). The syntheses of the three different 18F-fluoroalkynes, i.e. [18F]­
fluorobutyne, [18F]-fluoropentyne and [18F]-fluorohexyne was performed by reacting the 
corresponding tosylalkynes with 18F for 10 min, followed by a co-distillation with 
acetonitrile. The yields varied significantly. The 4-[18F]fluoro-1-butyne was obtained in a 
moderate RCY of 31 %, while s-[18F]fluoro-1-pentyne and 6-[18F]fluoro-1-hexyne were 
obtained with a yield of 81 % and 61 %, respectively. The subsequent reaction of the 
[18F]fluoroalkynes with the azide-derivatized peptides to provide 18F-labelled peptides 
proceeded with radiochemical yields of 10% within 30 min. Cu(II)sulfate was added as 
catalyst in the presence of sodium ascorbate. Cu(II) was reduced to Cu(I) in situ 
[Sharpless,2002]. Marik and Sutcliffe drastically improved radiochemical yields to nearly 
100% after 10 min reaction time by adding a nitrogen base to Cu(I) iodide. Furthermore 
sodium ascorbate was added to prevent the oxidation of Cu(I) by atmospheric oxygen. 
The synthesis of the co-[18F]fluoroalkyne and the subsequent reaction with the azide 
containing peptide precursor proceeded rapidly and in good radiochemical yields with final 
specific activities of >35GBq/µmol of the 18F-labeled peptides. 
In several papers the important role of the copper catalysts has been described 
[Wong,2003]. Cu(I) iodide with triethylamine and diisopropyl ethyl amine (DIPEA) or copper 
salts without base in organic solvents were investigated [Wong,2003]. It was shown that 
under water-free conditions, the absence of any base led to very slow reaction rates, 
probably due to the fact that the copper acetylide is not formed. Also the structure of the 
base is quite important e.g. the use of triethylamine resulted in no product formation, while 
the use of DIPEA gave yields of 38%.[Campbell-Verduyn,2008] 
Also DIPEA, pyridine and piperidine were tested as base. Although the reaction rate 
increased using piperidine, several unspecified by-products were formed. The best results 
were obtained with DIPEA, The nitrogen base was present in 10 fold excess relative to the 
Cu(I) iodide, or a 400 fold excess relative to the azide derivatized peptide. Glaser and 
Arstad [Arstad,2007] reported a click-labeling approach with 2-[18F]fluoroethylazide 
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[Sharpless,2003]. 18F-azides were chosen because alkynes as the "cold" precursors are more 
readily available and less hazardous than organic azides. 
2-Azidoethyl 4-methylbenzenesulfonate [Orlando, 1984 ,Drake, 1994, Fed an, 1984] was 
reacted with 18F in acetonitrile (scheme 2.3). After 15 min the 18F-azide was purified by 
distillation providing a RCY of 54%. Using 2-[18F]fluoroethylazide various 1,4-disubstituted 
triazoles were prepared. 
Different catalysts, including Cu(II)-sulfate with sodium ascorbate and copper powder 
were used. The best radiochemical yields (15-99%) were obtained by heating the reaction 
mixture to 80°C. At 80°C, Cu(II)sulfate proved to be the best catalyst for all studied 
alkynes. This approach also worked for peptide labeling. In this case a model peptide was 
first derivatized with propargylic acid [Arstad,2007]. The click reaction was subsequently 
performed at room temperature for 15 min providing excellent yields (92%) (scheme 3). 
In the same period Kim and co-workers [Chi,2007] described an alternative synthetic 
approach for preparation of 18F labeled biomolecules using the 'click reaction' with 
Cu5O4/Na-ascorbate and several model compounds such as small organic molecules, 
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Scheme 2.4. Schematic click conjugation strategy 
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Several optimization experiments of the 1,3-dipolar cycloaddition for the two-step 18F 
labeling procedure were performed using two Cu(I) species in water the mixed of organic 
solvent. organic solvent combinations e.q., acetonitrile, DMF, DMSO, and t-BuOH, The 1,3-
dipolar cycloaddition of 4-methoxybenzyl azide and phenyl acetylene was employed as a 
model reaction. Similar conditions were employed in various 1,2,3-triazole syntheses of 18F­
labeled azides or acetylenes and their corresponding azide or acetylene counterparts. 
[Chi,2007] 
Biological application of click chemistry in PET-studies 
Prante and co-workers reported studies on a dopamine D4 selective PET ligand 
[Tietze,2008]. The dopamine D4 receptor is an interesting target for the treatment of 
schizophrenia, Parkinson's disease, depression, and attention deficit hyperactivity disorder 
(ADHD). Ongoing efforts have been made to develop selective ligands with high D4 affinity. 
Employing D4 selective azaindoles as lead compounds, a library of carbocyclic arene 
bioisosteres was synthesized employing click chemistry.( scheme 2.5). Radiosynthesis 
resulted in formation of the [18F]-radioligand which showed a favourable logD of 2.8 and 
was determined to be highly stable in human serum (Scheme 2.6). 












Scheme 2.5. Reagents and conditions: (a) proparagyl acrylate, Cu(I)I, DMF, DIPEA, 35°C, 
10 h; (b) NMp,rt, 36h; (c) DMSO, rt, 16h. 
�F 
TsO 
Scheme 2.6. Synthesis of 18F-radioligand for the D4-receptor 
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Li et al. have applied click chemistry for 1BF-labeling of an RGD peptide and performed 
micro PET imaging of tumour integrin Ov�3 expression.[Li,2007] 
The cell adhesion molecule integrin plays a important role in tumor angiogenesis and 
metastasis. A series of 18F-labeled RGD peptides have been developed for PET based on 
primary amine reactive prosthetic groups. Nucleophilic fluorination of a tosyl-functionalized 
alkyne provided the corresponding lBF_alkyne in 65% radiochemical yield, which was then 
reacted with an RGD azide (RCY: 52%). It was demonstrated that the new tracer 1BF-FPTA­
RGD2 could be synthesized with high specific activity based on click chemistry. This tracer 
exhibited good tumor-targeting efficacy, relatively good metabolic stability as well as 
favorable in vivo pharmacokinetics. The new lBF labeling method might also find general 
application in labeling azido-containing bioactive molecules in high radiochemical yield and 
high specific activity for successful PET applications. [Li,2007] 
To investigate how a triazole moiety compares to more traditionally used prosthetic 
groups for peptide labelling, Sutcliffe et al. performed the lBF-"click" reaction as well as solid 
phase radiolabeling using 4-[1BF]fluorobenzoic and 2-[1BF]fluoropropionic acids. They 
present an evaluation of the feasibility of in vivo imaging with a [1BF]-labeled "click" probe. 
A20FMDV2, a peptide that selectively binds to the integrin av�6 was chosen as model 
peptide. They have shown in a mouse model that [1BF]FBA-A20FDMV2 can be used to 
selectively image Ov�6 expressing tumors. All three prosthetic groups were readily introduced 
at the N-terminus of a tumor targeting model peptide with similar overall radiolabeling 
yields. The "click" radiolabeling approach was fastest but required a relatively large amount 
of purified peptide precursor. During in vivo animal studies, they observed that the 
prosthetic groups had a significant effect on pharmacokinetics, especially on tumor uptake 
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Scheme 2.7. Peptides based on three different 1BF-labelling methods 
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Thonon et al. have worked on new strategy for the preparation of a peptide by reaction 
with 1-(azidomethyl)-4-[18 F]-fluorobenzene. This reaction can be applied to any peptide 
which is modified beforehand with a p-iodophenylalanine group (Scheme 2.8).1-
(Azidomethyl)-4-[18F]-fluorobenzene was produced after 75 min with a 34% radiochemical 
yield, using azido nitro benzene as a precursor. Favourable results for a four-step procedure 
have been obtained by solid phase supported reactions and the absence of the solvent 
evaporation process that allow minimalization of losses in time and radioactivity during 
reaction workup and purification. Conjugation of [18F]fluoroazide with a model alkyne­
neuropeptide produced the desired 18F-radiolabeled peptide in less than 15 min with a yield 
of 90% and excellent radiochemical purity. [Thonon,2009] 
NHOH 
R1 = H, R2= OH, Peptide chain 
Scheme 2.8. 1,3-dipolar Cycloaddition of 1-(Azidomethyl)-4-[18F]-fluorobenzene with 
alkyne functionalized peptide 
Smith et al. has reported the design, synthesis and biological characterization of a 
Caspase3/7 selective !satin by labelling with 2-[18F]fluoroethylazide. They have described 
the synthesis of the novel bifunctional probe featuring the 3-(trifluoromethyl)-3H diazirin- 3-
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yl group as well as an alkynyl side-chain. In a click reaction with the biotinyl azide the 
triazole was obtained. With the availability of biotinyl azides or fluorescence dyes containing 
an azide group, applications in chemical biology can be further exploited. Studies along 
these lines are currently being pursued. [Smith,2008] 
Scheme 2.9. Fluorination of 18F via click reaction 
Devaraj et al. have worked on 18F labeled nanoparticles for in vivo PET-CT imaging. 
They report the synthesis and in vivo characterization of a 18F modified trimodal 
nanoparticle (18F-CLIO). This particle consists of cross-linked dextran held together in core­
shell formation by a super paramagnetic iron oxide core and functionalized with the 
radionuclide 18F in high yield via "click" chemistry. The particle can be detected with positron 
emission tomography, fluorescence molecular tomography, and magnetic resonance 
imaging. The presence of 18F lowers the detection threshold of the nanoparticles, whereas 
the facile conjugation chemistry provides a simple platform for rapid and efficient 
nanoparticle labeling. Nanoparticles allow multivalent attachment of small affinity ligands. In 
combination with optimized pharmacokinetics of parent materials would allow a modular 
approach to rapidly building and testing such materials.[Devaraj,2009] 
Ross et al developed a fluorinated folic acid derivative. 19F-click folate showed nanomolar 
affinity for the folate receptor on KB tumour cells, which was in a comparable range to that 
of native folic acid. The click chemistry approach was successfully applied to the 
radiolabeling of the corresponding 18F-labeled folic acid derivative. 
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Scheme 2.10. Radiosynthesis of 18F-Click Folate ([18F]3) via the 1,3-dipolar Cu(I)-catalyzed 
cycloaddition of no carrier added (n.c.a.) 6-[18F]fluoro-1-hexyne ([18F]S) and y-(4-azido 
butyl)-Folic Acid Amide (6)a 4: 5-hexynyl-p-tosylate (precursor for [18F]S). 
In biodistribution studies, a high specificity of 18F-click folate to the (folate receptor) 
was observed. The high specificity of 18F-click folate proves the potential of this class of 
compounds; however, further investigations toward novel 18F-labeled folates with reduced 
lipophilicity are required to reduce non-specific uptake. [Ross,2008 ] 
Recently, Hatanaka et al.[Hatanaka,2010] presented a novel technique for labeling 
siRNA using succinimidyl 4-[18F]fluorobenzoate ([18F]SFB) as a fluorine 18 labeling reagent. 
The antisense strand must contain a 3'-amino C6 linker for the radioactive labeling of the 
siRNA duplex, which is obtained with a radiochemical yield of 7.9% (21.1% for the [18F]SFB 
synthesis and 37.9 % for the coupling with siRNA). Therefore, to avoid the necessity of the 
presence of this unique phosphorothioate monoester group or a 3'-amino C6 linker, and to 
increase the radiochemical yield, a radiosynthetic strategy was developed based on a click 
reaction. Among the click reactions reported to date, the Copper-Catalyzed Azide-Alkyne 
Cycloaddition (CuAAC) is the most extensively explored reaction. [Sharpless,2003] The 
applications of the CuAAC for nucleoside, nucleotide, and oligonucleotide modifications, 32 
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have been reviewed [Sharpless,2003]. More recently, the Luxen group presented the first 
direct labeling of siRNA by click chemistry. An original method to functionalize a single­
stranded oligonucleotides with alkyne has been described. [Luxen,2009]. After the 
annealing, the double stranded siRNA is engaged in the Huisgen 1,3-dipolar cycloaddition 
with the labeled synthon 1-(azidomethyl)-4- [18F]fluorobenzene or the 1-azido-4-(3-
fluoropropoxy) benzene to produce the [18F]-labeled siRNA which can be used for in vivo 
PET imaging studies. ( Scheme 2.11) 
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In the addition, the Pisaneschi group development of a new epidermal growth factor 
receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core. 
The epidermal growth factor receptor (EGFR/c ErbB1/HER1) is overexpressed in many 
cancers including breast, ovarian, endometrial, and non-small cell lung cancer. An EGFR 
specific imaging agent could facilitate clinical evaluation of primary tumors and/or 
metastases. The Pisaneschi group designed and synthesized a small array of fluorine 
containing compounds based on a 3-cyanoquinoline core. Molecular imaging techniques, 
such as PET (Positron Emission Tomography) have the potential to provide insights into 
EGFR biology. Potentially, PET with EGFR probes can determine in a non-invasive manner 
whether the target protein is overexpressed in a specific primary tumor or metastasis in 
vivo, the magnitude and duration of receptor occupancy, and target-drug interactions 
(including possibly the functional consequence of mutations that lead to reduced EGFR-drug 
interactions). A number of previously reported therapeutic agents have been labeled with 
radionuclides, including radiometals and radiohalogens, as potential ligands for imaging 
EGFR. More recent reports by Mishani et al [Mishani, 2008] have described the evaluation of 
radioligands based on irreversible EGFR inhibitors in which an electrophilic function is 
incorporated at C-6 of the quinazoline core. These derivatives bind covalently to the Cys 773 
located in the tyrosine kinase binding pocket of EGFR thus preventing washout by 
intracellular ATP and increasing potency [Mishani, 2008]. 
To enable selection of the most suitable candidate radiotracer the Pisaneschi group 
[Pisaneschi, 2010] designed a small array of fluorine containing derivatives with the 
intention of selecting the best candidate on the basis of high affinity to the receptor and 
ease of labeling. Derivatization of N-Boc-propargylamine and enyne containing quinoline in a 
manner amenable to the introduction of an 18F radiolabel was envisaged via 'click' 
cycloaddition with a fluorine containing azide partner. Propargylamine was therefore reacted 
with 1-fluoro-2-ethyl azide under Cu(I) catalysis and microwave irradiation to give 
fluorotriazole-containing quinoline as an HCI salt following Boe removal using HCI in 1,4-
dioxane. Similarly, enyne reacted with azide to give fluorotriazole-containing quinoline in 
32% yield. In both cases, the final yields were compromised by the apparent instability of 
the Michael acceptor precursors under the reaction conditions (Scheme 2.12). 
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Scheme 2.12. Reagent and condition : (a) AIMe3, CH2Cli, rt., (1) Ethyl (E)-4-(tert­
butoxycarbonyl-prop-2-ynyl-amino )-but-2-enoate, (2) Methyl (E)-pent-2-en-4-ynoate, 
( c ) Cu powder, Cu5O4, Water, MW 125°C, 15 min 
Potential applications for PET of click chemistry currently being 
employed in biomedical research 
Click chemistry is appl ied in diverse areas such as bioconjugation, drug discovery, 
materials science, and radiochemistry [Schibl i,2007] . Click chemistry has increasingly found 
appl ications in many aspects of drug discovery [Schibli,2007], by generating lead 
compounds through combinatorial methods. Bioconjugation via click chemistry is also 
employed in proteomics and nucleic research [ '  Schirrmachar,2008] . In radiochemistry, 
selective radiolabeling strategies of biomolecules for imaging and therapy have been 
realized [Schirrmachar,2008] . The following paragraphs describe several applications of click 
chemistry and their potential for PET is discussed. 
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Click chemistry in drug discovery, opportunities for PET application 
A problem in drug discovery is often the slow, complex synthesis of new compounds. 
Click chemistry offers the opportunity to simplify and optimize these syntheses, resulting in 
faster, efficient reactions, especially if combinatorial approaches are being employed. As an 
example, click chemistry was used to synthesize peroxisome proliferator-activated receptor 
y(PPAR-y) agonists for the treatment of type II diabetes [Devasthale,2009]. Acetylene 
derivatives of carbohydrates were clicked to the complementary azides for the preparation 
of a series of multivalent triazole-linked neoglycoconjugates. [Hernandez­
Mateo,2000,Morales-Sanfrutos,2003] This approach mimics the preparation of multivalent 
carbohydrates to increase the interaction between carbohydrates and receptors or enzymes. 
Another example is the 1,3-dipolar cycloaddition to prepare an AChE (acetylcholinesterase) 
inhibitor. [Barry,2002] 
The click reaction was carried out in the presence of the AChE, so that the association 
of the triazole click product with AChE would produce an inhibitor. [Radic,1994,Quinn,1987] 
It was shown that AChE catalyzed the 1,3-dipolar cycloaddition reaction of one of the azide­
alkyne combinations. When the active site of the enzyme was blocked, the triazole product 
was not formed. This triazole product displayed biological activities, such as anti-HIV activity 
[Alvarez,1994] and antimicrobial activity against Gram-positive bacteria. [Alvarez,1994] 
prepared a series of 1,2,3-triazole derivatives and evaluated their inhibitory activity against 
HIV-1 and HIV-2 in MT-4 and CEM cell cultures. No inhibition was observed against HIV-2, 
but one of the compounds displayed an EC50 for HIV-1 in both MT-4 and CEM cells at 3.7 
and 3.4 mM, respectively. It was also observed that additional groups at the triazole ring 
promoted 5-10-fold more inhibition to HIV-1 than the unsubstituted triazole. Genin et al. 
synthesized a series of 1,2,3- triazole derivatives and found that most compounds had 
substantial higher antibacterial activity against Gram-positive and Gram-negative bacterial 
strains than currently used antibiotics.[Anderson,2000] Natarajan et al. reported the 
synthesis of a divalent single-chain fragment of a monoclonal antibody by using click 
chemistry to produce the peroxisome proliferator-activated receptor g (PPAR-g) agonists for 
the treatment of type II diabetes [Natarajan,2007] 
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Scheme 2.13. Structure of one of the tested compounds for peroxisome proliferator­
activated receptor-Y 
Combinatorial approaches as described above using 18F-labelled azides or alkynes could 
lead to more rapid identification of potent PET-tracers. In addition, such approaches can 
increase the role of PET in drug development since suitable PET-tracers will become more 
readily available. 
Click chemistry in Bioconjugation 
Click chemistry has become an important tool for bioconjugation procedures in the 
development of bifunctional molecules. Bioconjugation involves the attachment of small 
labelled synthons to biomolecules, such as fusing two or more proteins together or linking a 
carbohydrate with a peptide. Although bioconjugation is applicable to the in vivo labeling of 
biomolecules, only a few reactions are actually useful. [Sharpless, 2001,2003] The use of 
click chemistry in bioconjugation was first demonstrated by Tornoe et al. for the preparation 
of peptidotriazoles via solid state synthesis. [Tonon,2009] The goal was the development of 
efficient synthetic methods to prepare a range of triazole pharmacophores for potential 
biologic targets. Various novel functional and/or reporter groups were introduced into 
peptides and proteins, DNA [Bertozzi,2007] and cell surfaces. [Gierlich,2008] 
Wang et al. labeled Cowpea mosaic virus (CPMV) with fluorescein in >95% 
yield.[Wang,2003] The labeling was performed by modifying the surface of the viral protein 




fluorescein-bearing complementary groups. Similarly, Link and Tirrell reported the 
modification of Eschericia coli with an azide-bearing outer membrane protein C (OmpC). The 
modified cell was then biotinylated by reacting with a biotin alkyne derivative using copper 
catalysis. [Link,2003] 
Most bioconjugation reactions, such as isothiocyanateamine, thiol-maleimide, and 
amine-carboxylic acid couplings, [Kolk,2008,Francis,2006] cannot be used for labeling in 
vivo because of competing nucleophiles and non-compatible reaction conditions. Also, 
condensation reactions between ketones or aldehydes and hydrazines or aminoxy 
derivatives, are not feasible. The reactions are usually carried out at pH of 5-6, under which 
condition the resulting hydrazone or oxime bond is not very stable. In addition, other 
ketones or aldehydes are usually present inside the cells.[ Kolk,2008] Click chemistry 
overcomes these obstacles by being bioorthogonal and by proceeding irreversibly in water 
at neutral pH and biocompatible temperatures (25-37°C) without any cytotoxic reagents or 
byproducts, provided that copper-free conditions can be applied. In vivo copper free click 
reactions would allow pretargeting strategies using first administration of targeted 
antibodies contained either an alkyne or an azide functionality with slow pharmacokinetics 
followed by a second administration of a 18F-labelled small molecule with the click 
counterpart functional group. 
A more reactive compound for labeling biomolecules eliminates the need for toxic metal 
catalyst [Bertozzi,2007]. To be able to eliminate the copper catalysts would make the 
cycloaddition biologically friendly and thus useful for labeling biomolecules in cells. It was 
shown that copper-free click chemistry can label cell surface carbohydrates 
[Sharpless,2002],, which then move inside the cell. This chemistry helped Bertozzi 
[Bertozzi,2007] to study dynamic biochemical processes that are otherwise difficult to follow 
in real time. Of particular interest was the study of glycosylation of proteins. This reaction is 
difficult to follow over time because the sugar molecules, or glycans, are continuously 
recycled. But azides can be used as a tag for labeling biomolecules. For in vivo, copper-free 
application a highly reactive difluorinated cyclooctyne (DIFO) reagent was developed which 
rapidly reacts with azides in living cells without the need for copper catalysis. The crucial 
property of the substituted cyclooctyne is the high ring strain and electron-withdrawing 
fluorine substituents that together promote the [3 + 2] dipolar cycloaddition with azides 
installed metabolically into biomolecules. This Cu-free click reaction showed comparable 
kinetics to the Cu-catalyzed reaction and proceeded within minutes in vivo with no apparent 
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toxicity. Laughlin et al. were able to image glycans in developing zebrafish using click 
chemistry. [ Laughlin,2008] Embryonic zebrafish were incubated with an azideperacetylated 
N-azidoacetylgalactosamine derivative (Ac4- GalNAz), which was then reacted with a 
difluorinated cyclooctyne attached to a dye (scheme. 2.14). 
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Scheme2.14. Schematic representation of metabolic labelling. 
Carbohydrates by click chemistry 
Multivalent carbohydrates are attractive synthetic targets as they often bind much 
stronger to the protein partner than their monovalent equivalents. Multivalency is often used 
to significantly increase affinity of weakly bound sugars [Kitov, 2000]. Many types of 
linkages of sugars to biological molecules have been explored and substantial affinity 
enhancements have been achieved [Fan, 2000- Kitov, 2000]. The copper-catalyzed click 
reaction has provided an additional tool for the easy construction of multivalent 
carbohydrates. The click method has already been applied for numerous systems. These 
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include protected carbohydrates but unprotected carbohydrates have also been used, 
demonstrating the chemoselective nature of the click reaction. 
In carbohydrates an azide group can easily be introduced, either at the anomeric center 
or via a spacer. Even before copper catalysis was reported, the uncatalyzed click reaction 
was used by Calvo-Flores group, for conjugating sugars to scaffold molecules aiming at 
preparing multivalent carbohydrates [Calvo-Flores,2000]. It was needed to perform the 
reaction for long times (30 h to 6 d) and both the 1,4- and 1,5-linked regioisomeric 1,2,3-
triazoles for each linkage were obtained. Prante and co-workers developed 1BF-labelling and 
glycosylation by click chemistry. A new mannosyl azide precursor was reported for the 
radiosynthesis of a 'clickable' 1BF-glycosyl donor as a hydrophilic prosthetic group. With this 
precursor, a simple and reliable click chemistry-based procedure involving !BF-labeling and 
glycosylation of alkyne-functionalized molecules in high radiochemical yields has been 
established. The described procedure for the introduction of an 1BF-glucopyranoside label is 
advantageous due to the stability of the precursor, which is stable for months at -20° C, the 
hydrophilic nature of the 1BF-labeled prosthetic group, its high-yielding and reliable 
radiochemistry, and its general applicability for 1BF-labeling and glycosylation of alkyne­
bearing molecules.( Prante,2009) (Scheme 2. 15). 
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Scheme 2.15. Reagent and condition by click chemistry : Cu5O4, sodium ascorbate, tert­
butanol, 60°C, 10 min. 
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Click chemistry for the in vivo targeting of inorganic nanoparticles 
The feasibility of "click" chemistry for the in vivo targeting of inorganic nanoparticles to 
tumors was investigated by von Maltzahn et al [Maltzahn,2007] Cyclic LyP-1 targeting 
peptides containing an alkyne group were linked to azido-nanoparticles and their binding to 
p32-expressing tumor cells in vitro was investigated. "Click" nanoparticles were able to 
stably circulate for hours in vivo after intravenous injection (>5 h circulation time), 
extravasate into tumors, and penetrate the tumor interstitium finally to specifically bind p32-
expressing cells in tumors. In the future, in vivo use of "click" nanomaterials should move 
them forward from ligand discovery to in vivo evaluation and develop approaches toward 
multifunctional nanoparticle development. 
• 




Cross-linked, fluorescent, superparamagnetic iron oxide nanoparticles were modified to 
display azido-PEG group. Conjugation of cyclic targeting peptide bearing pendant alkynes to 
azido-PEG nanoparticles via the copper(l)-catalyzed Huisgen 1,3-dipolar cycloaddition. 
The nanoparticles, functionalized by azido-PEG, were subsequently conjugated by 
copper catalysis to alkyne modified cyclic targeting peptides. 
This strategy opens the way to attach different tags, resulting in nanoparticles suitable for 
multimodality imaging, including MRI, PET and optical imaging. 
Conclusions 
Click chemistry is a highly valuable approach for biomedical application. One of the 
unique, important properties of click chemistry is its bio-orthogonal character. Covalent and 
rapid linkage of two components under environmentally friendly, nontoxic conditions are 
properties that are completely complementary to the development of novel agents for the 
development of both imaging and therapeutic products. Of course, there are areas in click 
chemistry that require further optimization, such as real time usage in living animals, 
imaging of living cells, and, ultimately, the substitution of the azide group with other less 
potentially hazardous species. Although these are significant challenges, taking into account 
the speed and number of applications that click chemistry facilitates for the development of 
novel biomolecules for preclinical evaluation, it can be anticipated that these requirements 
will be met in the near future. 
Novel labeling methods in 1BF-radiochemistry are highly desired to reduce the scale of effort 
necessary to obtain 1BF-labeled compounds for their application as imaging agents in nuclear 
medicine and life science. Great progress is currently made by many groups to find novel 
routes to introduce the 1BF-isotope into molecules for in vivo imaging using PET. A special 
focus is on the labeling of larger biomolecules such as peptides which have not been 
amenable to simple labeling procedures for a long time. From an economical point of view, 
to strengthen the role of radiochemistry in medicine and life science, it is necessary to find 
reliable methods for 1BF-labeling which can be applied by technicians on a daily basis to 
produce PET radiopharmaceuticals for various applications. The refinement and/or 
combination of the above described methods could be a crucial step into this direction. 
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Ideally, methodologies which are adaptable to a wide range of target molecules and 
prosthetic groups can be developed. The advantages gained from the intrinsic simplicity of 
such protocols would be achieved economically, practically and would benefit the fields of 
nuclear imaging and medicine. Click chemistry may offer the perfect platform for such 
advances in labelling due to its exquisite selectivity and tolerance to a wide range of 
conditions. 
The introduction of the Cu(I)-catalyzed 1,3-dipolar cycloaddition click reaction has 
greatly widened the scope of chemoselective (bio )conjugation reactions of carbohydrates 
and peptides. Moreover, the 1,3-dipolar cycloaddition has opened possibilities for the 
synthesis of new biomaterials based on peptides and carbohydrates. The number of dipolar 
cycloadditions, which can be performed under mild conditions, will rapidly expand as is 
highlighted in this review. 
Applications of Cu-free click chemistry include mammalian disease models where the 
bioavailability and pharmacokinetic properties of the reagents become important. The 
cyclooctynes that are currently employed for Cu-free click chemistry are not very soluble in 
aqueous solutions. The hydrophobicity of these cyclooctyne scaffolds could also promote 
binding to membranes or nonspecific binding to serum proteins, thereby reducing their 
bioavailable concentrations and increasing the noise in PET-images. 
Finally the suitability of azide labeling and Cu-free click chemistry should enable 
applications in many areas of glycobiology. For example, direct imaging of glycan trafficking 
under conditions of cell stimulation or pharmacological intervention has been demonstrated 
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Abstract 
Objectives The aim is to establish rate acceleration of the copper catalyzed 1,3-
dipolar cycloaddition using phosphoramidite ligands and to systematically explore 18F-click 
chemistry methodology for positron emission tomography imaging tracers. Preliminary 
studies to find optimal conditions for the 1,3-dipolar cycloaddition of the two-step 18F­
labeling procedure were performed in which the cycloaddition of 4-methoxybenzyl azide and 
phenylacetylene was employed as a model reaction. 
In addition, monodentate phosphoramidite ligands are used to accelerate the Huisgen 1,3-
dipolar cycloaddition rapidly yielding functionalized 1,4-disubstituted-1,2,3-triazoles. 
Methods To test our methodology on the required time scale of radiolabelling, we 
designed a small azido prosthetic group, [18F]-fluorinated 1-azido-4-fluorobutane and [18F]­
fluorinated 1-ethynyl-4-(fluoromethyl)benzene. 
After fluorination, the 18F-fluorinated tag was attached to its complementary acetylene or 
azide in the presence of CuSO4 · 5H2O, sodium ascorbate and the ligand MonoPhos. Further 
reaction optimization was performed by varying the amount of acetylene down to 0.01  mg 
and azide down to 0.05 mg in DMSO/H2O ( 1/3). 
Results Full conversion to the radiolabeled triazole was detected after 10 min. In the 
absence of MonoPhos under identical conditions, only minor conversion to the triazole 
product was observed ( < 20 %). 
One mol % of Cu5O4 proved to be a sufficient amount of catalyst, to achieve a short 
reaction time even using very small amounts of cold precursor. 
In conclusion The ligand-accelerated Cu(l)-catalyzed, 1,3-dipolar cycloaddition 'click 
chemistry' reaction was applied successfully to the synthesis of small, F-18-labeled 
molecules. [18F]Fluoroalkyne and azide were prepared in yields ranging from 36% to 81  %. 
Conjugation of [18F]fluoroalkynes and azides to varying amounts (> 0.01 mg) of acetylene 
or azide via the Cul mediated 1,3-dipolar cycloaddition yielded the desired 18F-labeled 
products in 10 min with yields of 54-99% in triplicate experiments. The total synthesis time 
was 30 min from the end of bombardment. 48 
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Introduction 
1BF-labeled compounds have been developed as the most commonly applied 
radiotracers for use in PET (positron emission tomography) (Kolb, 2001, 2003). Due to the 
low reactivity and high basicity of [1BF]fluoride, 1BF-labeled prosthetic groups are necessary 
for labeling complex biomolecules such as peptides and molecules with H-acidic functions 
(Huisgen,1962). Currently, peptide labeling is mostly confined to conjugation of free amino 
groups, either by direct acylation using 1BF-fluorinated activated esters (Huisgen,1962) or 
indirectly by functionalization, e.g., to an aminooxy group, which subsequently can undergo 
condensation with 1BF-fluorinated aldehydes. The high lipophilicity of the prosthetic groups 
can hamper application of peptide-based biomarkers. Therefore, new, efficient, and 
universally applicable synthetic strategies are needed. (Bertozzi, 2005) 
The discovery of the Cu(I)-catalyzed version of Huisgen's dipolar [2 + 3] cycloaddition 
of terminal alkynes and azides by the groups of Sharpless (Sharpless,2003) and Meldal 
(Agard,2004) had a great impact as demonstrated by the many reports describing its 
application in different areas of research (P'erez,1992). In general, the formation of 1,4-
disubstituted 1,2,3-triazoles by cycloaddition proceeds efficiently and selectively under 
aqueous reaction conditions and in the presence of various other functional groups 
(Huisgen,1962). This so-called "click reaction" (Glaser,2007) has also found application in 
the development of imaging agents (Campbell-Verduyn,2008,2009). The majority of 
reported applications of the click cycloaddition employ the 1, 2, 3-triazole formed as a stable 
linker to connect two chemical/biochemical entities. This conjugate design has been 
successfully applied to the preparation of optical (Candelon, 2008, Arduengo, 1999) and MR 
imaging agents (Brisford, 1995) and radioactive tracers suitable for SPECT and PET. 
Recently, Marik and Sutcliffe adopted this reaction for the preparation of F-18-labeled, 
short peptide fragments, thereby demonstrating its potential use in PET studies, in which 
the conjugation reaction of unprotected peptides was also tested to afford good yield and 
purity based on the reaction tolerance of the click reaction to other functional groups such 
as amines, alcohols, and acids.(Huisgen,1962) As a Cu(I) catalyst, they used Cul dissolved 
in acetonitrile, and not in water. (Glaser, 2007) However, considering both various substance 
dependent reaction conditions and the strong preference of aqueous media for 
biomolecules, an alternative reaction system is highly warranted. Furthermore, most 
previous studies were restricted to the use of peptides. Up to now, no systematic studies 
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have been published on optimization of reaction parameters for the 1BF-click reaction. 
Furthermore relatively high amounts of peptide precursor have been used so far which 
hamper its use, because the peptides are usually quite expensive. 
In applying the copper catalyzed cycloaddition to [1BF]-radiolabelling, additional studies 
towards acceleration this reaction, in particular by the use of ligands, are urgently needed. 
The more general ligand free 'click' reactions are too slow for 1BF-labeling in the absence of 
high copper concentrations. Monodentate phosphoramidite ligands are used to accelerate 
the Cu(I)-catalyzed 1,3-dipolar cycloaddition of azides and alkynes rapidly yielding a wide 
variety of functionalized 1,4- disubstituted-1,2,3-triazoles. Cu(I) and Cu(II) salts both 
function as the copper source and aqueous solutions can be used to provide excellent 
yields.(Campbell-Verduyn,2008) 
We report herein the first example of dramatic rate acceleration and a systematic study 
of the reaction parameters of the catalytic 1,3-dipolar cycloaddition of azides and alkynes 
using phosporamidite ligands for the application to PET- tracers. 
Experimental procedures 
General All reactions were carried out in oven dried glassware. Reagents and solvents 
were purchased from Sigma-Aldrich Co. Ltd. (Gillingham, United Kingdom) and used without 
further purification. The radio HPLC system was a Waters System Gold instrument equipped 
with a gamma detector (Bioscan Flow-count). A semipreparative column (Phenomenex 
prodigy 5µ C18, 250 xlO mm, with a flow rate of 4 ml/min) was used as the final 
purification of tracers. MeCN/H20 60-40% was used as an analytical and preparative HPLC 
solvent. 1H- 13C- and 19F-NMR were recorded on a Varian AMX400 ( 400 and 100.59 MHz, 
respectively) using CDCl3 as solvent. All reactions were monitored by thin layer 
chromatography on Merck F-254 silica gel plates or reversed phase HPLC. Mass spectra 
were recorded on an AEI-MS-902 mass spectrometer by EI (70 eV) measurements. Melting 
points are uncorrected. 
Safety Working with azides should always be done with great care. Organic azides, 
particularly those of low molecular weight, or with high nitrogen content, are potentially 
explosive. Heat, light and pressure can cause decomposition of the azides. Furthermore, the 
azide ion is toxic, and sodium azide should always be handled with gloves. Heavy metal 
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azides are particularly unstable, and may explode if heated or shaken. Any experiment in 
which azides are to be heated in the presence of copper should involve the use of a blast 
shield. 
Methods 
Bromo azido butane (1) and fluoro azido butane (2) 
To a stirred solution of the corresponding bromo chloro butane or fluoro bromo butane 
(1.0 eq) in a 50 ml water/acetone mixture (1 :4), NaN3 (1.5 eq) was added. The resulting 
suspension was stirred at room temperature for 24 h. Dichloromethane was added to the 
mixture and the organic layer was separated. The aqueous layer was extracted with 3 x 10 
ml aliquots of dichloromethane and the combined organic layers were dried over MgSO4• 
Solvent was removed under reduced pressure, and the azide was sufficiently pure to be 
used without further work up. (1)/H NMR (400 MHz, CDCl3) :  5 7.44 (d, J= 6.8 Hz, 4H), 
6.89 (d, ]= 8.8 Hz, 4H); 13C NMR (100.59 MHz, CDC'3) :  5 139.1, 132.7, 120.5, 117.7. 
Ethynyl toluenesulfonate methyl benzene (3) 
Ethynylbenzyl alcohol (10 mmol) was dissolved in 30 ml dichloromethane and 7 ml 
Et3N. After cooling to 0 °C, TsCI (12 mmol; 2.2 g) in dichloromethane was added dropwise. 
The reaction mixture was stirred for 2 h at room temperature. Aqueous saturated 
bicarbonate was added and the mixture was extracted with 50 ml dichloromethane. The 
organic layers were washed with dichloromethane and the combined organic fractions were 
dried on MgSO4• Solvents were evaporated under reduced pressure. The product was 
analyzed by TLC (4:1 hexane/ethyl acetate). Product 3 was purified by column 
chromatography on silica using hexane/dichloromethane 1 :1. 1H NMR (400 MHz, CDCl3) :  5 
6.96 (d, ]= 8.8 Hz, 4H), 6.89 (d, ]=  8.4 Hz, 4H), 3.79 (s, 6H); 13C NMR (100.59 MHz, 
CDCl3) :  5 156.9, 132.2, 119.9, 115.0, 55.4. 
51 
Chapter 3 
Ethynyl fluoro methyl benzene (4} 
To a cooled solution of 350 mg ethynyl benzyl alchohol in dichloromethane (7 ml), 
DAST 0.24 ml was added dropwise at -10°C over a period of 30 min, and the mixture was 
stirred overnight at room temperature. An aqueous solution of 5% NaHCO3 (30 ml) was 
added to the reaction mixture at o0c with vigorous stirring for 30 min. After extraction with 
chloroform, the organic phase was washed with water and dried over Na25O4 • Product 4 
was purified by column chromatography on silica using hexane/ether 8 : 1. 1H NMR (400 
MHz, CDCl3) :  o 7.27-7.39 (m, 3H), 7.00- 7. 11  (m, 2H), 4.30 (s, 2H); 13C NMR (100.59 MHz, 
CDCl3) :  o 162.5 (d, J=  328.7 Hz), 131.4, 129.9 (d, J =  1 1.4 Hz), 1 15.7 (d, J=  27.6 Hz), 54.0; 
19F NMR (200 MHz, CDCl3) :  o -112.3. 
Procedure for the Synthesis of 1,4-disubstituted Triazoles (5,6} 
CuSO4 · 5H2O 7.69 mmol (1.92 mg) of and 7.69 mmol (3.05 mg) sodium ascorbate were 
dissolved in 1.2 ml distilled water. To this mixture was added 62 µmol of MonoPhos 
(Campbell-Verduyn, 2008) in 0.4 ml DMSO. The resulting solution was vigorously stirred for 
15 min. 1.8 ml of the solution was then added to a 25 ml flask containing 0.854 mmol (100 
mg) of azide and 0.769 mmol (78.5 mg) of alkyne in 3 ml of a DMSO: H2O mixture (1 :3). 
The roundbottom flask was sealed and the reaction mixture was vigorously stirred. Upon 
completion of the reaction, 10 ml of H2O was added to the reaction mixture. For solid 
products, the reaction mixture was placed in an ice bath and the precipitated solid product 
was filtered and washed with 3 x 5 ml of cold water. For oil products, the resulting reaction 
mixture was extracted with 3 x 15 ml of dichloromethane. The organic layers were 
combined and dried over Mg5O4 and the solvent was removed by evaporation under 
vacuum. Crude oils were purified using silica gel chromatography (pentane:ether). The 
phosphoramidite ligands were also recovered from the mixture by column chromatography. 
52 
Ligand acceleration and exploration of reaction parameters of 18F Click chemistry 
1-( 4-fluorobutyl)-4-phenyl-lH-1,2,3-triazole (5) 
White solid: mp 54-55 °c. 90 % yield. 1H NMR (400 MHz, CDCl3): 5 7.82 (d, J= 10.0 Hz, 
2H), 7.76 (s, 1H), 7.42 (t, J= 10.0 Hz, 2H), 7.30-7.35 (m, 1H), 4.56 (t, J= 7.2 Hz, 1H), 
4.38-4.47 (m, 3H), 2.05-2.15 (m, 2H), 1.65-1.82 (m, 2H); 13C NMR (100.59 MHz, CDCl3): 5 
148.1, 130.8, 129.1, 128.4, 125.9, 119.7, 83.5 (d, J= 330.1 Hz), 50.1, 27.3 (d, J= 91.3 Hz), 
27.2. HRMS (EI) calcd for C12H14N3F 219.1172, found 219.1169. 
1-benzyl-4-( 4-fluoromethyl)phenyl)-lH-1,2,3-triazole { 6) 
White solid: mp 127-130 °c. 93 % yield. 1H NMR (400 MHz, CDCl3): 5 7.82 (d, J= 7.6 
Hz, 2H), 7.67 (s, 1H), 7.31-7.42 (m, 7H), 5.58 (s, 2H), 5.38 (d, J= 48.0 Hz, 2H); 13C NMR 
(100.59 MHz, CDC'3): 5 148.0, 136.3 (d, J= 16.8 Hz), 134.9, 131.3 (d, J= 3.1 Hz), 129.5, 
129.1, 128.3, 128.2 (d, J= 5.3 Hz), 126.1, 120.0, 84.6 (d, J= 166.4 Hz), 54.5. HRMS (EI) 
calcd for C15H14N3F 268.1245, found 268.1243. 
Radiochemistry [18F]2, [18F]4 
Non-carrier added [18F] fluoride was obtained by proton bombardment of an [180] 
enriched water target via the 18O(p,n)18F reaction. The radioactivity was trapped by passing 
the target water through a preactivated Sep-Pak light QMA cartridge (Waters). 1 ml 
solution of K2CO3 ( 4.5 mg) and Kryptofix 222 (20 mg) in water was used to elute the 
[18F]fluoride from the cartridge into a conical glass vial. This eluate was evaporated to 
dryness by three consecutive azeotropic distillations with acetonitrile (3 x 500 µl) under a 
gentle stream of nitrogen gas (130 °C). The dried [18F]-fluoride was then added to 3.0 mg 
of precursor 1 (17 µmol) or 3 (11 µmol) in 0.5 ml dry DMSO, and the mixture was heated 
at 140 °C for 10 min. The labeled product was absorbed on a C18-light Sep-Pak cartridge 
followed by washing with 10 ml H2O and eluted with 5 ml pure methanol. The Sep-Pak 
eluate containing [18F]2 or [18F]4 was then purified and separated from its precursor with 
semi-preparative HPlC on a semi-preparative C18-reversed phase column (mobile phase 




by radio-TLC (silica gel, Hexane/EtAc ( 4: 1)) (Rf values: [18F]2=0.4; [18F]4= 0.36) and 
HPLC analysis: tR [18F]2 10 min : [18F]4: tR= 12 min. 
Preparation of [18F]S, [18F]6 
[18F]2 or [18F]4 in MeCN / H2O was added to a solution of sodium ascorbate (0.278 
mg, 5 mol), CuSO4 (0.07 mg, 1 mol), and phenylacetylene or benzylazide the amounts as 
mentioned in figure 2 and 3. Monophos ligand 0.111 mg (0.26 µmol) was added in a solvent 
mixture of DMF/H2O 1ml with a ratio of 1 :4. The resulting light yellow solution was stirred 
vigorously at room temperature for 10 min. The reaction mixture was diluted with water (10 
ml) and preactivated with a C-18 light Sep-Pak cartridge. The product was trapped on the 
cartridge, washed with water (5 ml) and eluted with 5 ml methanol. The products were 
analyzed using analytical RP-HPLC, and conversion of the reaction was monitored by radio­
TLC ( silica gel, Hexane/EtAc (4 :1)) (Rf values: [18F]5=0.75; [18F]6= 0.75) and HPLC 
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Scheme 3.1. Synthesis of [18F]-labelled triazole 5 using [18F]alkyl azide 
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Scheme 3.2. Synthesis of [18F]-labelled triazole 6 using [18F]acetylene 
Modified lys3-bombesin for [18F]-labelling in the presence of monphos as a 
Ligand 
Later we used monophos ligand as a acceleration of reaction to synthesis of Lysine 
amino acide via click reaction to test applicability to 18F-peptide. The synthesis of an alkyne 
containing lysine analogue was initially started with the synthesis of activated ester.The 
product was attained by reacting propiolic acid with N-hydroxysuccinimide in the presence 
of the coupling reagent N,N' dicyclohexylcarbodiimide (DCC). Preparation of methyl ester 
analogue 7 has been done by Lachlan Campbell-Verduyn in Zernike laboratory. 
Methyl-(S)-2-((tert-butoxycarbonyl)amino )-6-(pent-4 ynamido )hexanoate (7). 
TMSCHN2 (0.08 ml, 0.153 mmol) was dissolved in 4 ml of a toluene/methanol mixture 
(5 :1 v/v) under an inert atmosphere of N2 • To this solution was added (5)-2-(tert­
butoxycarbonylamino)-6-pent-4-ynamidohexanoic acid (50.0 mg, 0.153 mmol). The reaction 
was stirred at room temperature for 1.5 h after which it was diluted with diethyl ether (5 
ml) and then with 10% AcOH (5 ml). The organic layers were collected, and the aqueous 
layer was extracted with diethyl ether (2 x 10 ml) and combined with the other organic 
layers. These were dried over Mg5O4 and the solvent was evaporated. The reaction must be 
purified immediately, storing the crude reaction mixture leads to degradation of the product. 
The crude mixture was purified by column chromatography (50: 1 DCM:MeOH) to yield the 
product as a clear oil. Rf=0.40 (50:1 DCM:MeOH). Yield=99%. 1H NMR (400 MHz, CDCl3) :  5 
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6.53 (t, J =8.0 Hz, lH), 5.28 (d, J=8.0 Hz, lH), 4.08-4.09 (m, lH), 3 .59 (s, 3H), 3.11 (t, 
J=8.0 Hz, 2H), 2.35-2.38 (m, 2H), 2.27 (t, J=4.0 Hz, 2H), 2.03-2.04 (m, lH), 1.24-1.67 (m, 
15H); 13C NMR (100.59 MHz, CDCl3) :  i5 173.2, 171.0, 155.5, 83.0, 79.9, 69.3, 53.1, 52.3, 
39.0, 35.2, 32.3, 28.8, 28.3, 22.5, 14.9.  HRMS (EI) calcd for C17H28O5N2Na [M+Na
+] 
363.1890, found 363.1883. 
Compound 7 was reacted with azides 2 and 4 to yield the corresponding triazoles 8 
and 9 (Scheme 3.3). The reactions proceeded relatively quickly to full conversion with 1 
mol % of catalyst. In this manner, faster reaction times were achieved. 
0 C02Me 
�
� NHBoc + 
CuS04·5H20 (1 mol %) NHBoc O 
/
F 
Na Ascorbate (5 mol %) ., � � MonoPhos (1.1 mol %) Me02C � \_.... ,N N-  
7 2 




CuS04·5H20 (1 mol %) 
Na Ascorbate (5 mol %) 
MonoPhos (1.1 mol %) 
H20/DMSO (3:1), 5 h 
MoO,),_,.'-"'� Nh 
9, 66 % 
N 
Q 
Scheme 3.3. CuMC with lysine analogue 7 
(S)-Methyl 2-((tert-butoxycarbonyl)amino)-8-(((1-(4-fluorobutyl)-lH-1,2,3-
triazol-4-yl)methyl)amino )-8-oxooctanoate (8) 
(S)-methyl 2-((tert-butoxycarbonyl)amino)-6-(pent-4-ynamido)hexanoate 7 (67.5 mg, 
0.20 mmol) and fluoroazidobutane 2 (28.0 mg, 0.24 mmol) were dissolved in 10 ml of an 
H2O/DMSO (3 :1) mixture. In a separate vial, CuSO4 · 5H2O (0.50 mg, 2.08 x 10-3 mmol) was 
dissolved in 0.1 ml of water, and sodium ascorbate (1.97 mg, 9.95 x 10-3 mmol) was added 
to this solution. MonoPhos (0.79 mg, 2.20 x 10-3 mmol) was added along with 0.1 ml of 
DMSO. The reagents were stirred together for 10 min and added to the solution of azide 
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and alkyne. The reaction mixture was allowed to stir at room temperature, and the progress 
was monitored by 1H NMR. Upon completion of the reaction mixture was diluted with water 
(10 ml) and extracted with DCM. The organic layers were combined and dried over Mg5O4 
and purified by column chromatography (1:1 DCM:MeOH) to give the product as a white 
solid. Rf=0.20 (100% MeOH). 1H NMR (400 MHz, CDCl3) :  5 7.39 (br s, lH), 6.14 (br s, lH), 
5.23 (br d, J=8.0 Hz, lH), 4.50 (t, J=5.6 Hz, lH), 4.34-4.37 (m, 3H), 4.21-4.22 (m, lH), 
3.70 (s, 3H), 3.14-3.18 (m, 2H), 3.01 (t, J=8.0 Hz, 2H), 1.97-2.04 (m, 2H), 1.23-1.72 (m, 
17H); 13C NMR (100.59 MHz, CDCl3) :  5 173.2, 172.1, 157.0, 123.9, 118.4, 84.2, 79.8, 53.2, 
52.1, 49.6, 40.9, 38.8, 35.6, 31.9, 29.6, 28.9, 28.2, 26.4, 22.3; 19F NMR (200 MHz, CDCl3) :  
46.1-46.5 (m). HRMS (EI) calcd for C21H37O5N5F [M+W] 458.2773, found 458.2768. 
Methyl-(S)-2-((tert-butoxycarbonyl)amino)-6-(3-(1-(4-fluorobenzyl)-lH-1,2,3-
triazol-4-yl)propanamido )hexanoate (9) 
(S)-methyl 2-((tert-butoxycarbonyl)amino)-6-(pent-4-ynamido)hexanoate 7 (20.0 mg, 
0.054 mmol) and 4-fluorobenzyl azide 4 (8.10 mg, 0.054 mmol) were dissolved in 3 ml of 
an H2O/DMSO (3 :1 v/v) mixture. In a separate vial, CuSO4·5H2O (0.13 mg, 5.40 x 10
-4 
mmol) was dissolved in 0.1 ml of water, and to this vial was added sodium ascorbate (0.53 
mg, 2.67 x 10-3 mmol). MonoPhos (0.61 mg, 5.83 x 10-4 mmol) was added along with 0.1 
ml of DMSO. The reagents were stirred together for 10 min and added to the solution of 
azide and alkyne. The reaction mixture was allowed to stir at room temperature, and the 
progress was monitored by thin layer chromatography (100% DCM). Upon completion of 
the reactionthe mixture was diluted with water (10 ml) and extracted with DCM. The 
organic layers were combined, dried over Mg5O4 and purified by column chromatography 
(1:1 DCM:MeOH) to give the product as a white solid. Rf=0.20 (100% MeOH). Yield=66%. 
1H NMR (400 MHz, CDCl3) :  5 7.31 (s, lH), 7.23-7.26 (m, 2H), 7.04 (t, J=8.0 Hz, 2H), 5.94 
(br s, lH), 5.45 (s, 2H), 5.22 (br d, J=8.0 Hz, lH), 4.21-4.27 (m, lH), 3.72 (s, 3H), 3.14-
3.17 (m, 2H), 3.01 (t, ]=8.0 Hz, 2H), 2.52 (m, 2H), 1.32-1.83 (m, 15H); 13C NMR (100.59 
MHz, CDCl3) :  5 173.2, 172.0, 164.4, 161.1, 147.1, 130.7, 129.8 (d, J = l l.3 Hz), 121.4, 116.0 
(d, J=29.4 Hz), 79.9, 53.2, 53.1, 52.2, 38.8, 35.6, 32.1, 29.7, 28.3, 22.7, 21.4; 19F NMR 





Preparation of [18F]8, [18F]9 
[
18F]2 or [18F]4 in MeCN / H2O was added to a solution of sodium ascorbate (0.278 mg, 5 
mol), CuSO4 (0.07 mg, 1 mol), and Methyl-(S)-2-((tert-butoxycarbonyl)amino)-6-(pent-4 
ynamido)hexanoate 7, and Monophos ligand 0.111 mg (0.26 µmol) was added in a solvent 
mixture of DMF/H2O 1ml with a ratio of 1 :4. The resulting light yellow solution was stirred 
vigorously at room temperature for 15 min. The reaction mixture was diluted with water (10 
ml) and preactivated with a C-18 light Sep-Pak cartridge. The product was trapped on the 
cartridge, washed with water (5 ml) and eluted with 5 ml methanol. The products were 
analyzed using analytical RP-HPLC, and conversion of the reaction was monitored by radio­
TLC ( silica gel, Hexane/EtAc (4:1)) (Rt values: [18F]8=0.75; [18F]9= 0.75) and HPLC 
analysis: tR [18F]8 14 min : [18F]9 :  tR= 16 min. (Scheme 4 and 5). 
Results and Discussion 
For exploring both options of the click reaction either an alkyne or azide have been 
radiolabelled with fluorine-18. Nucleophilic fluorination of 1 with anhydrous non-carrier 
added Kryptofix 222 K+[18F]F (acetonitrile, 130 °C, 15 min) provided the azide [18F]2 in 
65% radiochemical yield. The same conditions were used to provide ethynyl[18F] methyl 
benzene 4 in 85% radiochemical yield. 
The phenyl acetylene or benzyl azide and catalyst were used in a large excess to [18F] 2 and 
[
18F]4. In the experiments with CuSO4 catalyst (1 mol %) was generated in situ using 
sodium ascorbate (5%) which was required to prevent oxidation of Cu(I) to Cu(II). This 
catalytic system provided [18F]S and [18F]6 in high radiochemical yields at room temperature 
in 10 min in presence of Cu(I) and monophos as a ligand (figure 3.1). 
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0.5 mg of phenyl acetylene 
+ monophos 
- monophos 
0.1 mg of benzyl azlde 
Figure 3.1. Comparison RCY % of click reaction with and without monophos as a ligand 
for A: [18F]S and B: [18F]6 
The radiolabeled compounds were isolated from the reaction mixture using a C18 Sep­
Pak by extraction with methanol. The radiochemical purity of the products was determined 
by RP-HPLC analysis providing RCP of >99% and specific activities of 95 GBq/µmol. The 
phosphoramidite ligand Monophos providing to be an excellent ligand for the catalytic click 
reaction giving high yields, but in absence of ligand only minor conversion to the triazole 
product [18F]6 was observed. (Figure 1) 
For the synthesis of triazole [18F]S this ligand acceleration effect was much less pronounced 
since the radiochemical yield was already 60 % without the use of Monophos as a ligand 
for copper. (Figure 1) 
Further reaction optimization was performed by varying the amount of acetylene from 0.01 
mg to 0.5 mg. (Scheme 1), (Fig. 2). Reactions with only 0.01 mg acetylene yielded the 18F­
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Figure 3.2. Result of optimization of reaction by varying the amount of phenyl acetylene in 
[1aF]S 
Also the complementary click reaction to [18F]6 was investigated by varying the 
amount of azide from 0.01 mg to 0.05 mg (scheme 3.2; figure 3.3). Again, 1 mol % of 
Cu504 in the presence of 1.1 mol % monophos showed a sufficient catalysis effect within 10 
min. 
1 00 • • 
90 • 
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70 I 60 � 50 • 0 µmol 
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Figure 3 .3. Result of optimization of reaction by varying the amount of benzyl azide in 
[1aF]6 
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Ligand acceleration and exploration of reaction parameters of 18F Click chemistry 
The optimized conditions utilizing Cu(I) and Monophos as a potent catalyst provide an 
important tool to use reduced amounts of peptide precursor, that are expensive in many 
cases. In literature reports usually amounts of > 1 mg peptide have been used and no 
additional catalyst besides Cu(I) was employed. Assuming an average MW of 2000 for 
peptides, 1 mg is 0.5 umol, whereas under the conditions described in this paper 10-fold 
lower amounts of cold precursor have been used. The click reaction is completed in 10 min, 
whereas in comparable system described in the literature reaction times of 15-30 min are 
required. 
The modified lysine alkyne and catalyst were used in a large excess to [18F] 4 and 
[
18F]2. In the experiments with CuSO4 catalyst (1 mol %) was generated in situ using 
sodium ascorbate (5%) which was required to prevent oxidation of Cu(I) to Cu(II). This 
catalytic system provided [18F]8 and [18F]9 Scheme 3.4 and 3.5. in high radiochemical yields 
at room temperature in 15 min in presence of Cu(I) and monophos as a ligand . 
The radiolabeled compounds were isolated from the reaction mixture using a C18 Sep-Pak 
by extraction with methanol. The radiochemical purity of the products was determined by 
RP-HPLC analysis providing RCP of >99% and specific activities of 95 GBq/µmol. 
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Scheme 3.5. CuAAC with lysine analogue 9 
9 
Further reaction optimization was performed by varying the amount of modified lysine 
with alkyne from 1 mg to 12 mg. (Fig. 3.4) Reactions with only 1 mg lysine yielded the 18F­
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Figure 3.4. Result of optimization of reaction by varying the amount of lysine in [18F]8 
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Ligand acceleration and exploration of reaction parameters of 18F Click chemistry 
Also the complementary click reaction to [18F]9 was investigated by varying the 
amount of azide from 1 mg to 12 mg (figure 3 .5). Again, 1 mol % of Cu5O4 in the presence 
of 1.1 mol % monophos showed a sufficient catalysis effect within 10 min. 18F-triazole 
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Figure 3.5.  Result of optimization of reaction by varying the amount of lysine in [18F]9 
Conclusion 
The ligand accelerated Cu(I)-catalyzed, 1,3-dipolar cycloaddition 'click chemistry' 
reaction was applied successfully to the synthesis of small, F-18-labeled molecules, and an 
optimal condition was developed for a one-pot, two-step reaction. After purification by 
semipreparative HPLC fluoroalkynes were obtained in yields ranging from 65% to 85%. 
Conjugation [18F]fluoroalkynes to various amount (> 0.01 mg) of acetylenes or azide with 
via Cul mediated 1,3-dipolar cycloaddition yielded the desired 18F-labeled products in 10 min 
with yields of 54-99% and excellent radiochemical purity (81-99%). The total synthesis 
time was 30 min from the end of bombardment. 
In conclusion, a highly versatile fast ligand-accelerated copper catalyzed click reaction for 






Agard N J, Prescher J A, Bertozzi C R, J. Am . Chem. Soc.,  2004, 126, 15046. 
Arduengo A J, Krafczyk R, Schmutzler R, Craig H A, Goerlich J R, Marshall W J, 
Unverzagt M, Tetrahedron, 1999, 55, 14523 . 
Berrisford D J, Bolm C, Sharpless K B, Angew. Chem. Int. Ed. ,  1995, 1059. 
Campbell-Verduyn L, Elsinga P H, Mirfeizi L, Dierckx R A, Feringa B L Org. Biomol. 
Chem.,  2008, 6, 3461-3463 . 
Campbell-Verduyn L, Mirfeizi L, Elsinga P H, Dierckx R A, Feringa B L Chem. 
Commun. ,  2009, 2139-2141. 
Candelon N D, Lastecoueres A K, Diallo J R, Aranzaes D, Vincent J, Chem . 
Comm., 2008, 741-743. 
Feringa B L, Acc. Chem. Res.,  2000, 33, 346. 
Glaser M, Bioconjugate Chem.,  2007, 18,989. 
Huisgen R, Knorr R, Naturwissenschaften, 1962, 48, 716. 
Kolb H C, Sharpless K B, Drug Discovery Today, 2003, 8, 1128. 
Kolb H C, Finn M G, Sharpless K B, Angew. Chem.,  Int. Ed. ,  2001, 40, 2004. 
Li Z T, Seo S, Ju J, Tetrahedron Lett . ,  2004, 45, 3143. 
P 'erez D, Guiti ' E, Castedo L, J. Org. Chem. ,  1992, 57, 5911. 





18F-FPTC), a novel PET-l igand for 
cerebral beta-adrenoceptors 
L. Mirfeizia, A. A. Rybczynskaa, A. van Waardea, L. Campbell-Verduynh, 
B.L. Feringab, R.A.J.O Dierckxa, P.H .  Elsingaa 
a. Dept. of Nuclear Medicine and Molecular Imaging, University Medical Center 
Groningen, University of Groningen, Groningen, the Netherlands 
b. Stratingh Institute for Chemistry, University of Groningen, Groningen, the 
Netherlands 
Parts of this chapter has been published in Chem. Commun., 2010, 46, 898-900. 
Chapter 4 
Abstract 
Cerebral �-adrenergic receptors (�-ARs) play important roles in normal brain and 
changes of 8-AR expression are associated with several neuropsychiatric illnesses. Given the 
high density of �-AR in several brain regions, quantification of �-AR levels using PET is 
feasible. However, there is a lack of radiotracers with suitable biological properties and 
meeting safety requirements for use in humans. We developed a PET tracer for �-AR by 
18F-fluorination of (R)-1-( (9H-carbazol-4-yl)oxy)-3-4( 4-( (2-(2-(fluoromethoxy)­
ethoxy)methyl)- lH-1,2,3-triazol-1-yl)propan-2-ol (18F-FPTC). 
Methods 18F-FPTC was synthesized by Cu(I)-catalyzed alkyne-azide cycloaddition. 
First, 18F-PEGylated alkyne was prepared by 18F-fluorination of the corresponding tosylate. 
Next 18F-PEGylated alkyne was reacted with an azidoalcohol derivative of 4-hydroxycarbazol 
in the presence of the phosphoramidite Monophos as a ligand and Cu(I) as a catalyst. After 
purification with radio-HPLC, the binding properties of 18F-FPTC were tested in 
�-AR-expressing C6-glioma cells in vitro, and in Wistar rats in vivo, using microPET. 
Results The radiochemical yield of 18F-PEGylated alkyne was 74-89%. The click 
reaction to prepare 18F-FPTC proceeded in 10 min with a conversion efficiency of 96%. The 
total synthesis time was 55 min from the end of bombardment. Specific activities were > 120 
GBq/µmol. Propranolol strongly and dose-dependently inhibited the binding of both 1251-
ICYP and 18F-FPTC to C6 glioma cells, with IC50 values in the 50-60 nM range. However, 
although both FPTC and propranolol inhibited cellular 1251-ICYP binding, FPTC decreased 
1251-ICYP uptake by only 25%, whereas propranolol reduced it by 83%. 18FPTC has the 
appropriate lipophilicity to penetrate the blood brain barrier (logP +2.48). The brain uptake 
reached a maximum within 2 min after injection of 20-25 MBq 18FPTC. SUV values ranged 
from 0.4 to 0.6 and were not reduced by propranolol. Cerebral distribution volume of the 
tracer ( calculated from a Logan plot) was increased rather than decreased after propranolol 
treatment. 
Conclusion 'Click chemistry' was successfully applied to the synthesis of 18F-FPTC 
resulting in high radiochemical yields. 18F-FPTC showed specific binding in vitro, but not in 
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vivo. Based on the logP value and its ability to block 1251-ICYP binding to C6 cells, FPTC may 




�-Adrenoceptors (�-ARs) belong to the family of guanine nucleotide binding regulatory 
protein-coupled receptors (G-protein coupled receptors) (Kobilka 2011). 
Based on ligand binding studies, �-ARs have been classified into three subtypes: �1, �2 
and �3 (Kobilka 2011). �i-ARs are located mainly in heart and kidney, whereas �rARs are 
localized mostly in smooth muscles (bronchial muscle, ciliary muscle of eye and detrusor 
muscle of the bladder), skeletal muscles (Kim 1991), liver and GI tract (Arner 1990, Sano 
1993, Krief 1993). �rARs are found in adipose tissue (Krief 1993). 
�
1
- and �rARs are present in several brain regions, such as frontal cortex, caudate, and 
putamen (Rainbow 1984). �i-ARs are highly expressed in neurons and �2-ARs in glia. The 
receptors are involved in astrogliosis and microglial proliferation. Cerebral �-AR levels were 
shown to be altered in several neurological disorders ( e.g. Parkinson's, Alzheimer's and 
Huntington's disease), and in mood disorders ( e.g. major depressive disorder and 
schizophrenia) (van Waarde 2004, Russo-Neustadt 1997, McEwen 1999). 
Several radioligands for �-AR (e.g. S-11C-carazolol, S-1 1C-CGP12388 and S-11C­
CGP12177) have been validated for imaging of myocardial receptors using positron emission 
tomography (PET) (Law 1993, Berridge 1994, van Waarde 1995, 2004, Elsinga2004, van 
Waarde 2005). Nevertheless, there is a lack of clinically applicable radioligands capable of 
penetrating the blood-brain barrier (BBB) and monitoring changes in cerebral �-AR 
expression in various stages of the disease, or receptor occupancy during treatment (e.g. 
with norepinephrine, serotonin reuptake inhibitors and tricyclic antidepressants). 
Two tracers that have shown good BBB penetration, high affinity and specificity towards 
�-ARs, S-1'-18F-fluorocarazolol and S-1'-18F-fluoroethylcarazolol, displayed mutagenic 
properties and are therefore unsuitable for human use (Doze 2000, 2002). Radiolabeled 
analogs of pindolol (e.g. 1251-ICYP) also display high affinity and specificity towards �-ARs. 
However, their use for imaging of cerebral �-ARs is limited because of low brain uptake and 
low signal-to-noise ratios (Doze 2002). Therefore, to date the development of tracers for �­
ARs in the human brain has been unsuccessful. 
In this study, we report a rapid synthesis method of a 18F-labeled tracer aimed at 
imaging of cerebral �-ARs, using Huisgen's 1,3-dipolar cycloaddition of an alkyne with an 
azide, a reaction known as 'click chemistry'. 
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The 'click reaction' catalyzed by Cu(I) is a well established method for rapid and highly 
efficient synthesis of 1,4-disubstituted-triazoles from a wide variety of substrates (Campbell­
Verduyn 2010). Using this method the hydroxyl propylamine moiety (crucial for binding to �­
ARs) was partially maintained but 18F was introduced as a novel moiety, hopefully not 
causing mutagenicity of the carazolol derivatives. The resulting 18F-fluorinated analog of 
carazolol, carbazol fluoroethoxy methyl triazolyl propanol (18FPTC, 7), was produced by a 
click reaction between a PEGylated 18F-alkyne and a (R)-azidoalcohol derivative of 4-
hydroxycarbazol. We have evaluated this new �-AR tracer both in vitro and in vivo. 
Materials and Methods. 
General 
Chemicals and solvents were obtained from commercial sources and were of analytical 
grade. 1251-ICYP was obtained from Perkin Elmer (Waltham, MA, USA) and R-(±)propranolol 
hydrochloride was purchased from Sigma-Aldrich (St. Louis, MO, USA). For the semi­
preparative HPLC-purification of 18F-FPTC, a Phenomenex Prodigy C18 (250 mm * 10 mm, 5 
µm) HPLC column was used. NMR spectra were acquired on a GE 7 T (400 MHz) 
spectrometer. Chemical shifts are given in ppm relative to the internal TMS signal, coupling 
constants J in Hz. Unless otherwise indicated, all NMR data were collected at room 
temperature in CDCl3 • MS were measured under ESI, MALDI or APCI conditions. Analytical 
thin-layer chromatography (TLC) was carried out on commercial Merck silica gel 60 plates 
(0.25 µm thickness) with fluorescent indicator (F-254). Column chromatography was 
performed with 40-63 µm silica gel. Tetrahydrofuran (THF) was freshly distilled from 
sodium/benzophenone; other solvents were used as received. Unless otherwise specified, all 
reactions were carried out under an atmosphere of dry nitrogen in oven-dried (at least 6 h 
at 140 °C) glassware. 
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Scheme 4.1. Synthesis of racemic carbazol epoxide 2 and azidoalcohol 3 
(R,S)-4-(oxiran-2-ylmethoxy)-9H-carbazole (2) 
9H-Carbazol-4-ol 1 (100.0 mg, 0.55 mmol) was dissolved in 20 ml of isopropanol, 
supplemented with (R,S)-epichlorohydrin (75. 9 mg, 0.82 mmol) and potassium carbonate 
(90.5 mg, 0.65 mmol), and reacted overnight (at 80 °C). After subsequent cooling, NH4CI 
(15 ml) was added to the solution. The resulting mixture was extracted with 
dichloromethane (3 x 15 ml). The organic layers were separated, washed with brine, dried 
over MgSO4 and the solvent was removed by Rotavapor. The product 2 (Scheme 4.1) was 
isolated by column chromatography (EtOAc:pentane, 3 :1); Rt = 0.75 (EtOAc:pentane, 3 :1). 
Yellow solid; yield: 91 mg (70%). 1H NMR (400 MHz, CDCl3) :  5 8.36 (d, J = 8.0 Hz, 1 H), 
8.04 (s, 1 H), 7.25-7.42 (m, 4 H), 7.01 (d, J = 8.0 Hz, 1 H), 6.64 (d, J = 12 Hz, 1 H), 4.44 
(d, J = 16.0 Hz, 1 H), 4.22 (m, 1 H), 3.54 (m, 1 H), 2.98 (m, 1 H), 2.88 (m, 1 H). 13C NMR 
(100.59 MHz, CDCl3) :  155.1, 141.2, 139.0, 126.8, 125.3, 123.4, 122.6, 119.9, 112.9, 110.3, 
104.3, 101.5, 69.0, 50.6, 45.1. The spectroscopic data is in accordance with the literature 
(S.L. Heald 1983). 
1-((9H-carbazol-4-yl)oxy)-3-azidopropan-2-ol (3) 
NaN3 (12.1 mg, 0.19 mmol) was added to a mixture of 4-(oxiran-2-ylmethoxy)-9H­
carbazole 2 (40.5 mg, 0.17 mmol) and CeC'3 ·7H2O (22.2 mg, 0.09 mmol) in 4.0 ml of 
acetonitrile/water (9 :1). The resulting solution was stirred at reflux overnight. The reaction 
70 
18F-FPTC, a novel PET-ligand for cerebral beta-adrenoceptors 
mixture was diluted with dichloromethane and washed with water (5 ml) and brine (2 x 5 
ml). The organic layer was separated dried over MgSO4 and the solvent was removed under 
reduced pressure. The product 3 (Scheme 4.1) was purified by column chromatography 
(EtOAc:pentane, 2 :1); Rf = 0.8. White solid; yield : 41.35 mg (93 %). 1H NMR (400 MHz, 
CDCl3) :  5 8.21 (d, J = 8.0 Hz, 1 H), 8.07 (s, 1 H), 7.26-7.44 (m, 4 H), 7.02 (d, J = 8 .0 Hz, 1 
H), 6.61 (d, J = 8.0 Hz, 1 H), 4.33 (m, 1 H), 4.20 (d, J = 8.0 Hz, 2 H), 3.60 (m, 2 H), 2.78 
(br s, 1 H). 13C NMR (100.59 MHz, CDCl3) :  154.4, 140.8, 138.6, 126.4, 124.9, 122. 5, 121.9, 
119.4, 112.2, 110.1, 104.1, 100.8, 69.4, 69.0, 53.6. The spectroscopic data is in accordance 
with the literature (G. Madhusudhan 2010). 
2-{2-[2-(Prop-2-ynyloxy)ethoxy]ethoxy}ethanol (4) 
Sodium hydride (2.60 g, 65 mmol, 60%) was slowly added to a solution of triethylene 
glycol (15.02 g, 100 mmol) in distilled THF (75 ml) and the mixture stirred for 30 min (all 
carried out at O 0c under nitrogen atmosphere) . Propargyl bromide (5.40 ml, 7.44 g, 50 
mmol) was slowly injected to the reaction flask, thereafter stirred at O 0c for 2 h and at 25 
°C for 20 h. The mixture was poured into water, extracted with CH2Cl2 and the organic 
phase dried over Na2SO4• The crude product was purified by flash chromatography using 
EtOAc:hexane (3 :2) as the eluent, to afford compound 4 (Scheme 4.2). 
Clear yellow oil; yield : 7.1 g (75%). 1H NMR (400 MHz, CDCl3) :  5 4.21 (d, 2 H, J = 2.2 Hz, 
CHCCH2O), 3 .74-3.66 (m, 11 H, OCH2 and OH) 3 .61 (t, 2 H, J = 4.6 Hz, CH2OH), 2.43 (t, 1 
H, J = 2.4 Hz, CHCCH2) ,  13C NMR (125 MHz, CDCl3) :  5 79.68, 74.72, 72.60, 70.76, 70.51, 
70.47, 69.20, 61.89, 58.54. 
2-{2-[2-(Prop-2-ynyloxy)ethoxy]ethoxy}ethyl-methylbenzenesulfonate 
(5) 
p-Toluenesulfonyl chloride (20.82 g, 109.24 mmol) was slowly added to a solution of: 4 
(10.28 g, 54.62 mmol), triethylamine (19.0 ml, 136.5 mmol) and trimethylamine 
hydrochloride (0.522 g, 5.46 mmol) in acetonitrile (140 ml) (at O °C under nitrogen 
atmosphere) .  This mixture was stirred at O °C for 50 min and at room temperature for 30 
min under nitrogen atmosphere, subsequently poured into water, extracted with EtOAc and 
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the organic solution dried over MgSO4• The crude product was purified by flash 
chromatography using EtOAc:hexane (1:3) as eluent to afford compound 5 (Scheme 4.2). 
Clear yellow oil; yield: 16. 19 g (87%). 1H NMR (400 MHz, CDCl3): 5 7.80 (d, 2 H, J = 8.2 Hz, 
ArH), 7.34 (d, 2 H, J = 8.2 Hz, ArH), 4 .19 (d, 2 H, 2.2 Hz, CHCCH2O), 4.16 (t, 2 H, J = 4.7 
Hz, CH2OTs), 3.70-3.67 (m, 4 H, OCH2), 3.65-3.63 (m, 2 H, OCH2), 3.59 (s, 4 H, OCH2), 
2.45 (s, 3 H, ArCH3), 2.43 (t, 1 H, J = 2.3 Hz, CHCCH2),  13C NMR (125 MHz, CDC'3): 5 
144.93, 133. 18, 129.97, 128. 14, 79.77, 74.68, 70.90, 70.72, 70.59, 69.37, 69.24, 68.85, 
58.55, 21 .  79. 
1-( (9H-carbazol-4-yl)oxy)-3-( 4-( ( 2-(2-
(fluoromethoxy)ethoxy)ethoxy)methyl)-1H-1,2,3-triazol-1-yl)propan-2-
01 (7) 
Compound 3 (6.0 mg, 0.021 mmol) and 3-(2-(2-(fluoromethoxy)ethoxy)ethoxy)prop-1-
yne (7.8 mg, 0.043 mmol) were dissolved in 3.0 ml of water: DMSO (4: 1). To this solution 
were added: 5 mol % CuSO4 ·5H2O (1.0 x 10-3 mmol), 25 mol % sodium ascorbate (5.25 x 
10-3 mmol) and 5.5 mol % MonoPhos (1 . 12 x 10-3 mmol). The reaction mixture was allowed 
to stir at room temperature and progress of the reaction was monitored by thin layer 
chromatography. Upon complete consumption of the azidoalcohol, the reaction mixture was 
diluted with water and extracted with DCM. The organic layer was dried over MgSO4 the 
solvent evaporated and the product 7 FPTC (Scheme 4.2) was purified by column 
chromatography (EtOAc:pentane, 2: 1); Rt = 0 . 15 (EtOAc:pentane, 1: 1). 
White solid; yield: 25.0 mg (88 %). 1H NMR (400 MHz, CDC'3): 5 8.23 (d, J = 8.0 Hz, 1 H), 
8.20 (s, 1 H), 7.70 (s, 1 H), 7.41-7.45 (m, 2 H), 7.24-7.27 (m, 2 H), 7.09 (d, J = 8.0 Hz, 1 
H), 6.62 (d, J = 8.0 Hz, 1 H), 4.77-4.80 (m, 1 H), 4.64-4.67 (m, 4 H), 4.58 (t, J = 4.0 Hz, 1 
H), 4.46 (t, J = 4.0 Hz, 1 H), 4.22 (d, J = 4.0 Hz, 2 H), 3.73 (t, J = 8.0 Hz, 1 H), 3.63-3.67 
(m, 8 H), 3.30 (br s, 1 H). 13C NMR (100.59 MHz, CDCl3): 154.3, 147.2, 141.0, 138.7, 
136.1, 135.9, 126.7, 125.2, 122.6, 122. 1, 1 19.8, 1 12.5, 1 10.4, 104.4, 101.2, 70.7, 70.5, 70.4, 
69.6, 69. 1, 68.8, 64.5, 53.4. 19F NMR (200 MHz, CDCl3): 42.6 (m). 
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Aqueous 18F-fluoride was produced by irradiation of 180 water with a Scanditronix MC-
17 cyclotron via the 18O(p,n)18F nuclear reaction. The 18F-fluoride solution was passed 
through a Sep-Pak Light Accell plus QMA anion exchange cartridge (Waters) to recover the 
18O-enriched water. 18F-fluoride was eluted from the cartridge with 1 ml of K2CO3 ( 4.5 
mg/ml) and collected in a vial with 20 mg Kryptofix 2.2.2. To this solution, 1 ml acetonitrile 
was added and the solvents were evaporated at 130 °C. The 18F-KF/ Kryptofix complex was 
dried 3 times by the addition of 0.5 ml acetonitrile, followed by evaporation of the solvent. 
18F-PEGylated alkyne 4 was prepared by 18F-fluorination of the corresponding tosylate 5 (1-
2 mg) in DMSO at 140°C during 15 min. Thereafter, the product was diluted with 20 ml of 
water and passed through a tC18 cartridge (activated with 5 ml EtOH and 10 ml H20). The 
product 4 (scheme 4.2) was eluted from the cartridge with 4 ml of water and purified by 
HPlC (10% EtOH in NaH2PO4, 0.025 M, (pH 7); 4 ml/min; retention time of 16 min). 18F­
FPTC 7 was synthesized by click reaction (reaction time 10 min) of 4 with 3 in the presence 
of the phosphoramidite Monophos (1,1 mol %) as a ligand,(1. lmol %) and CuSO4.5 H2O (1 
mol%), Na-ascorbate (5 mol %) in mixture of DMF: H2O (3 :1) as catalyst, followed by 








140°C, 1 5  min, DMSO 
Scheme 4.2. Synthesis of 18F-FPTC 





CuS04, Na ascorbate 
Monophos 
Samples of 18F-FPTC were dissolved in Phosphate buffered saline (PBS) (1 ml) or rat 
plasma (1 ml) and incubated at 37 °C. After 1 h and 3 h of incubation, respectively, the 
stability of the radiolabeled 18F-FPTC was determined by Radio-TLC (Rf FPTC 0.4; eluent : 
MeOH:CH2Cl2 (2 :8) + 0.1 % Et3N). After elution, the TLC plates were analyzed by phosphor 
storage imaging using a Cyclone Phosphor Storage System (PerkinElmer). The conversion 
rate of 18F-FPTC was calculated by ROI analysis using Opti-Quant software (PerkinElmer) 
and expressed as a percentage of the parent compound lost over the incubation time. 
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Distribution Coefficient (logP) 
To determine the logP of 18F-FPTC, an aliquot of 1 ml of HPlC purified 18F-FPTC 
solution was added to a mixture of n-octanol/PBS (1:1, v/v) at pH 7.4. The tubes were 
vortexed at room temperature for 1 min, followed by 30 min of shaking in a water bath at 
37 °C. Aliquots of 25 and 1000 µl  were drawn from the n-octanol and aqueous phase, 
respectively, and the radioactivity was counted using an automated gamma counter 
(Compugamma 1282 CS, lKB-Wallac, Turku, Finland). The experiments were performed in 
triplicate. 
Cell Culture 
C6 (rat glioma) cell line was purchased from the American Type Culture Collection 
(ATCC) and has been previously shown to express �i- and �rARs (Terasaki 1979, Neve et al 
1986, Zhong 1996). C6 cells were maintained in 5 ml Dulbecco's Modified Eagle Medium 
(DMEM, Invitrogen, Merelbeke, Belgium) supplemented with 4.5 g/ml glucose and 7.5% 
fetal calf serum (FCS, Bodnico, Alkmaar, The Netherlands) in 25 cm3 cell culture flasks. Cells 
were grown in a humidified atmosphere containing 5% CO2 in air and were passaged every 
3-4 days. 
Cellular Uptake of 18F-FPTC in C6 Glioma Cells 
In vitro �i-/�rAR ligand binding affinities and specificities of FPTC were assessed via a 
competitive displacement assay with 1251-ICYP as the �1-/�rAR ligand. For comparison, 
propranolol was used as another competitive inhibitor. Similar binding studies were 
performed with 18F-FPTC as the radioligand. 
Binding studies were performed 48 h after seeding the C6 cells in 12-well plates (when 
confluency had reached 80-90% ). One hour before addition of the radiotracer, various 
concentrations of an unlabelled competitor (propranolol or FPTC) were dispensed to the 
culture medium in the wells. Then, 2 MBq of 1251-ICYP or 4 MBq of 18F-FPTC in <30 µI of 
ethanol:saline mixture (1 :3) were added to each well containing 1 ml of medium. After 1 h 
incubation, the medium was quickly removed and the monolayer of cells was washed 3 
75 
Chapter 4 
times with cold PBS. Cells were then treated with 0.2 ml of trypsin (Invitrogen, Merelbeke, 
Belgium). When the monolayer had detached from the bottom of the well, 1 ml of medium 
containing 7.5% FCS was added to stop the proteolytic action. Cell aggregates were 
resolved by repeated (at least tenfold) pipetting. Radioactivity in the cell suspension (1.2 ml) 
was assessed using a gamma counter and corrected for the number of viable cells. A sample 
of the suspension was mixed with trypan blue solution (1 :1, v/v) and was used for cell 
counting. Cell numbers were determined manually, using a phase contrast microscope 
(Olympus, Tokyo, Japan), a Burker bright-line chamber (depth 0.1 mm; 0.0025 mm2 
squares) and a hand tally counter. All experiments were performed as a quadruplicate study 
at two different occasions. The 50% inhibitory concentration (IC50) values were calculated 
from a nonlinear fit, using GraphPad Prism 5.0 (GraphPad Software, San Diego, California, 
USA). IC50 values are reported as mean ± SD. Experiments were repeated thrice, each with 
triplicate samples. 
Animal Model 
The animal experiments were performed by licensed investigators in compliance with 
the Law on Animal Experiments of the Netherlands. The protocol was approved by the 
Committee on Animal Ethics of the University of Groningen. Male Wistar rats (Hsd/Cpb:WU; 
Harlan/CPB, Zeist, the Netherlands) were maintained at a 12 h light/12 h dark regime and 
were fed standard laboratory chow ad libitum. 
MicroPET Scanning 
Each rat was placed in an induction chamber and subjected to isoflurane anesthesia 
(5% for induction, 2-3% maintenance). Subsequently, body weight of the rat was 
determined and a cannula was placed into one of its femoral arteries. This cannula was later 
used for blood sampling. In blocking studies, rats were pretreated with propranolol (2.5 
mg/kg of body weight), 1 min prior to injection of the radioligand. Two rats were scanned 
simultaneously, using a Siemens/Concorde microPET camera (Focus 220). Each animal was 
carefully positioned in the microPET scanner (brain, heart and lungs in the field of view) and 
injected via the penile vein with 18F-FPTC (25 ±MBq). Data acquisition (a list mode protocol; 
90 min) was started at the moment of tracer injection into the first rat, the second animal 
was injected 16 min later. During the scan, 15 arterial blood samples (volume 0.1-0.15 ml) 
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were drawn, using a standard protocol (at 15, 30, 45, 60, 75, and 90 s, and 2, 3, 5, 7 .5, 10, 
15, 30, 60 and 90 min after injection, respectively). Plasma was separated from these 
samples by short centrifugation (5 min at 13,000 rpm). Radioactivity in plasma samples (25 
µL) was measured using a calibrated gamma counter. 
MicroPET Data Analysis 
List mode data were reframed into a dynamic sequence of 4 * 60 s, 3 *120 s, 4 * 300 
s, 3 * 600 s frames after tracer injection. The data were reconstructed per time frame 
employing an interactive reconstruction algorithm (OSEM2D with Fourier rebinning, 4 
iterations and 16 subsets). The final data sets consisted of 95 slices with a slice thickness of 
0.8 mm and an in plane image matrix of 128 * 128 pixels. Voxel size was 0.5 mm * 0 .5  mm 
* 0.8 mm. The linear resolution at the center of the field-of-view was about 1.5 mm. Data 
sets were fully corrected for decay, random coincidences, scatter, and attenuation. A 
separate transmission scan was acquired for attenuation correction. This scan was 
performed right before the emission scan. 
Three-dimensional regions of interest (3-D ROls) were manually drawn around the brain, as 
described previously. Time-activity curves (TACs) for the ROls were calculated, using Inveon 
Research Workplace software (Siemens, USA). TACs were expressed in mean standardized 
uptake values (SUVs), normalized for body weight and injected dose. The parameter SUV is 
defined as: [tissue activity concentration (MBq/g) x body weight (g) / injected dose (MBq)]. 
Dynamic PET data were analyzed using plasma radioactivity from arterial blood samples as 
an input function and a graphical method according to Logan (2000). Software routines for 
Matlab 7 (The MathWorks), written by Dr. Antoon T.M. Willemsen (University Medical 
Center Groningen), were used for curve fitting. The Logan fit was started at 15 min. The 
cerebral distribution volume (VT) of the tracer was estimated from the Logan plot. Cerebral 




After the scanning period, the anesthetized animals were terminated by extirpation of 
the heart. Blood was collected, and plasma and a cell fraction were obtained from the blood 
sample (5 ml) by centrifugation (5 min at 1000g). Several brain regions and peripheral 
tissues were excised (see Tables 1 and 2). All tissue samples were weighed and counted for 
radioactivity using a gamma counter. The results were expressed as SUV values. 
Results and discussion 
The structure of �-hydroxytriazoles may be an interesting scaffold for designing �-AR 
ligands. Therefore, we investigated whether 18F-FPTC, a �-hydroxytriazole derivative, has 
affinity for �-ARs. Two reaction steps were performed to prepare the azidoalcohol. First, the 
racemic epoxide 2 was synthesized from hydroxycarbazole 1 and epichlorohydrin in the 
presence of potassium carbonate. Second, the epoxide 2 underwent azidolysis promoted by 
CeCl3 · 7H20 to give the desired 1,2-azidoalcohol 3, (Scheme 4.1). 
[
18F]-PEG-alkyne served as a 18F-buidling block and was prepared in radiochemical 
yields ranging from 74 to 89%. Specifically, a PEG-ylated alkyne was chosen to maintain an 
acceptable logP. Conjugation of 18F-PEG-alkyne to (S)-azidoalcohol via Cu(I)-mediated 1,3-
dipolar cycloaddition resulted in rapid reaction (10 min) and high conversion (96%) to the 
final product, 18F-F PTC. 
The radiolabeled compound 7, Scheme 4.2 was obtained from 18F-fluoride in 55 min, in 
35% overall (decay-corrected) radiochemical yield. At the end of synthesis (EOS), the 
specific activity was > 120 GBq/µmol and the radiochemical purity was >96%. 
18F-FPTC has an appropriate lipophilicity to penetrate the blood brain barrier (logP ±2.48). 
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Scheme 4.3. Propranolol and iodocyanopindolol 
In Vitro Competitive Receptor-Binding Assay. 
FPTC dose-dependently inhibited 1251-ICYP and 18F-FPTC binding to CG glioma cells. 
With the highest concentration, propranolol reduced the cellular binding of 1251-ICYP by 
>80% (Fig 4.1). Propranolol blocked 1251-ICYP and 18F-FPTC binding with IC50 values of 49 
and 59 nM respectively, indicating that the hydroxytriazole moiety indeed maintains binding 
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Figure4.1. Competitive Receptor-Binding Assay: Dose-response plot of propranolol 
competition with 1251-ICYP and 18F-FPTC binding to CG cells. Error bars indicate SEM. 




18F-FPTC accumulated in the brain with SUV values of approximately 0.4-0.6. The logP 
value was therefore sufficient for BBB penetration. Radioactivity uptake throughout the 
brain proved to be homogeneous. Pretreatment of animals with propranolol did not 
significantly reduce the uptake of 18F in any brain region compared to controls (Table 4.1). 
In addition, propranolol pretreatment also did not diminish the uptake of 18F in peripheral 
organs like heart, lung, red blood cells, and spleen although these are �-AR rich organs 
(Table 4.2). 
Thus, 18F-FPTC showed a similar in vivo behavior as was reported for 1 1C-toliprolol and 
18F-derivatives of bupranolol and penbutolol (Doze 2002a). Since the regional uptake of 
radioactivity in the brain was homogeneous and propranolol treatment did not reduced 
tracer uptake in target organs, specific in vivo binding of 18F-FPTC was not observed. 
Tissue SUV-Control SUV-Block 
Amygdala/Piriform cortex 0.37± 0.29 0.61± 0.36 
Bulbus olfactorius 0.53± 0.40 0.58± 0.38 
Cerebellum 0.55± 0.44 0.66± 0.40 
Cingulate/Frontopolar cortex 0.56± 0.37 0.72± 0 .44 
Entorhinal cortex 0.54± 0.44 0.61± 0.38 
Frontal cortex 0.61± 0.40 0.39± 0.21 
Hippocamppus 0.47± 0.31 0.56± 0.38 
Medulla 0.51± 0.39 0.46± 0.24 
Par,/Temp,/Occ. Cortex 0.51± 0.43 0.58± 0.37 
Pons 0.53± 0.39 0.66± 0.35 
Striatum 0.46± 0.30 0.62± 0.36 
Rest brain 0.46± 0.34 0.58± 0.35 
Table 4.1. Biodistribution of 18F-FPTC in various brain regions derived from control rats 
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SUV-Control SUV-Block 
0.62 ±0.41 0.64 ±0.34 
0.98 ±1.25 0.49 ±0.18 
0.47 ±0.38 0.77 ±0.44 
0.67 ±0.33 0.63 ±0.25 
0.48 ±0.34 0.74 ±0.33 
0.73 ±0.31 0.78 ±0.26 
1.23 ±0.85 1.65 ±1.035 
1.01 ±0.35 0.91 ±0.21 
0.62 ±0.41 0.60 ±0.35 
0.44 ±0.32 0.66 ±0.34 
1.06 ±0.40 1.34 ±0.81 
1.26 ±0.78 0.23 ±0.16 
0.49 ±0.38 0.60 ±0.30 
0.53 ±0.26 0.67 ±0.23 
0.62 ±0.28 0.72 ±0.15 
0.98 ±0.32 0.74 ±0.15 
0.77 ±0.53 0.86 ±0.61 
0.71 ±0.30 0.89 ±0.28 
0.62 ±0.41 0.64 ±0.34 
Table 4.2. Biodistribution of 18F-FPTC in rat tissues (expressed as Standard Uptake Values). 




Kinetics of Radioactivity in Brain. 
Cerebral kinetics of radioactivity after injection of 18F-FPTC is presented in Figure 4.2. 
Maximal uptake was already observed in the first few frames (i.e., < 5 min after tracer 
injection) and was followed by an exponential washout. After pretreatment of animals with 
propranolol (20 mg/kg), the brain uptake of 18F-FPTC appeared to be increased, although 
the difference with control animals was not statistically significant. 





-- Control ... Blocking 
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Time after injection [min] 
Figure 4.2. Cerebral kinetics of 18F-FPTC with control animals and blocking animals treated 
with propranolol with saline, data are SUV-PET values for the entire brain, expressed as 
mean ± SEM. 
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Kinetics of Radioactivity in Plasma 
Plasma kinetics of radioactivity after injection of 18F-FPTC is presented in Figure 4.3. 
Drug treatment did not significantly affect the clearance of 18F-F PTC from rat plasma, 
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Figure 4.3. Clearance of radioactivity from blood plasma of control animal ( n=6) after 
injection of 18F-FPTC tracers and animals pretreated with propranolol (n=6). Data are SUV 
values, expressed as mean ± SEM. 
Cerebral Distribition Volumes 
The cerebral distribution volume of the tracer (VT), calculated from Logan plots, was 
significantly increased after treatment of animals with propranolol (from 0.420 ± 0.070 to 




this phenomenon. First, propranolol may be metabolized by the same hepatic enzyme 
system as 18F-FPTC and, therefore, propranolol treatment may increase the fraction of 
radioactivity in plasma representing parent compound. Second, both FPTC and propranolol 
may be weak substrates for ABC transporters in the blood-brain barrier, such as P­
glycoprotein. Many 13-blockers are substrates for P-glycoprotein (Neuhoff et al. 2000). The 
administration of an excess of propranolol may saturate this efflux system, resulting in 
greater entry of the tracer 18F-FPTC into the brain. Since the brain uptake of 18F was 
homogeneous and tracer uptake in peripheral target organs with high beta-adrenoceptor 
density (lungs, heart, spleen) was not affected by propranolol, indicating lack of specific in 
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18F-FPTC, a novel PET-ligand for cerebral beta-adrenoceptors 
We have demonstrated that it is possible to prepare 18F-FPTC in good radiochemical 
yield. Based on its appropriate logP value and its specific in vitro binding to CG cells, 18F­
FPTC could have been suitable for PET imaging of cerebral �-ARs. However biodistribution 
and microPET data indicated that these criteria were insufficient to ensure visualization of �­
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Chapter 5 
Abstract 
The goal of our study was the synthesis of a new 18F-labeled bombesin derivative by 
click chemistry for specific targeting of Gastrin-Releasing Peptide (GRP) receptors in human 
prostate cancer cells. Bombesin is a 14 amino acid peptide sequence which serves as a 
tumor marker for various cancers. Amino acids 7-14 are considered to be the sequence 
responsible for binding to the GRP-receptor. Click chemistry, in particular the copper­
mediated 1,3-dipolar [3+2] cycloaddition between azides and alkynes, has entered the field 
of radiopharmaceutical sciences. We used a 1,3-dipolar cycloaddition to label bombesin 
modified at the Lys3-position with a triple bond. 
The [Lys3]-Bombesin (BN3) analogue [18F]-Bombesin ([18F]-TBN3) was designed and 
synthesized for the targeting of gastrin-releasing peptide receptors in prostate cancer cells. 
It incorporates a terminal alkyne at the Lys[3] residue of the 14 amino acid peptide 
sequence, where [18F] can be readily introduced. The in vitro binding affinity to GRPR, cell 
uptake, internalization and efflux kinetics of the radiolabeled bombesin analogue were 
investigated in the GRPR-expressing human prostate cancer cell line PC-3. The tracer 
proved to have good in vitro properties. Biodistribution and the GRPR-targeting potential 
were evaluated in PC-3 tumor-bearing athymic nude mice. Tumor uptake and in vivo 
pharmacokinetics in PC-3 tumor-bearing mice were not in agreement with the in vitro 
results. The GRPR targeting ability of the [18F]- BN3 was proven in vitro but not in vivo. 
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Introduction 
The gastrin-releasing peptide receptor (GRP-r) is a seven trans membrane G-protein 
coupled receptor that is overexpressed in primary breast, prostate, colon cancer and lymph 
node metastases (Reubi 2003). Bombesin (BN) is a peptide that binds with high affinity to 
GRP-r. Several bombesine derivatives have been reported as a radiopeptide with high 
stability in human serum, specific cell receptor binding and rapid internalization (Ananias 
2008, Baidoo 1998, Ferro-Flores 2006). Bio-distribution data in mice showed rapid blood 
clearance, with predominant renal excretion and specific binding towards GRP receptor­
positive tissues such as pancreas and prostate tumors (Ferro-Flores 2006, Santos-Cuevas 
2009). Most of the bombesin derivatives are SPECT radioligands. 
The goal of our study was the synthesis of PET-based bombesin derivatives that can be 
easily prepared by click chemistry with high tumor uptake and optimal pharmacokinetics for 
specific targeting of Gastrin-Releasing Peptide (GRP) receptors in human prostate cancer 
cells. Bombesin is a 14 amino acid peptide sequence which serves as a tumor marker for 
various cancers. Amino acids 7-14 are considered to be the sequence responsible for 
binding to the GRP-receptor. There are synthetic challenges associated with the introduction 
of [18F] when compared with the ease of chelation techniques used for metallic 
radionuclides. The synthetic time frame of [18F] (t112~110 min) is also much reduced as 
compared to metallic radionuclides such as [64Cu] (t112~12 h). A further drawback to the use 
of [18F] is the necessity for multi-step synthetic procedures to synthesize current prosthetic 
groups such as succinimidyl-[18F]-4-fluorobenzoate ([18F]SFB) or [18F]-4-fluorobenzaldehyde 
which are commonly used to label bombesin. (Chang 2005) 
An ideal prosthetic group is one that can be easily synthesized, in which the 
radionuclide is introduced in the last step of the synthesis, and which requires only the 
mildest of conditions to attach it to the biomolecule of interest. 
Many groups have begun to exploit the bioorthogonality of the copper-catalyzed azide­
alkyne cycloaddition (CuAAC) to allow for straightforward labeling of sugar, protein and 
peptide targets with [18F] and other radionuclides by introducing a 'click' handle into the 
target molecules. An advantage of introducing a 'click' handle such as an alkyne into 
bombesin is the ability to easily tune the properties of the analogue by designing various 
azides of different sizes, linker lengths or hydrophobicities. Since the 'click' reaction is known 
to be very robust and to withstand a very wide substrate scope, changing the azide 
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prosthetic group to achieve new tracers should not require much optimization of the 
conditions for the labeling protocol. 
We use 1,3-dipolar cycloaddition to label the peptide modified at the lys3-position 
derivatized with a triple bond providing a functional group to perform click chemistry. The 
"click chemistry" method has been useful in coupling two molecules, in particular azide and 
alkyne to get a 1,2,3-triazole via a so called the Huisgen's reaction which occurs through 
1,3-dipolar cycloaddition. 
Materials and Methods 
All reagents and solvents were obtained from Fluka and Sigma/ Aldrich and used without 
further purification. 
Bromo azido butane 
The synthesis of bromoazidobutane was carried out by adding NaN3 (1.5eg) to a stirred 
solution of the corresponding bromochlorobutane (1.0 eq) in a 50 ml water/acetone 
mixture (1 :4).  The resulting suspension was stirred at room temperature for 24 hours. 
Dichloromethane was added to the mixture and the organic layer was separated. The 
aqueous layer was extracted with 3 x 10 ml aliquots of dichloromethane and the combined 
organic layers were dried over MgSO4• The solvent was removed under reduced pressure, 
and the azide was sufficiently pure to use without further work up (Scheme 5.1). 
Schem 5.1. Bromo Azido Butane 
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Production and workup of [18F]fluoride 
[
18F]fluoride was obtained by proton (17 MeV) bombardment of an [18O]enriched water 
target via the 18O(p,n)18F reaction. The radioactive material was trapped by passing the 
target water through a preactivated Sep-Pak light QMA cartridge (Waters). 1 ml H2O 
solution of the K2CO3 ( 4.5 mg) and Kryptofix 2.2.2. (20 mg) was used to elute the 
[
18F]fluoride from the cartridge into a conical glass vial. This eluate was evaporated to 
dryness by three consecutive azeotropic distillations after addition of acetonitrile (3 x 500 
µL) under a gentle stream of nitrogen gas (130 °C). 
Br� tsp N3 ---. 18�N3 
Scheme 5.2. Synthesis of [18F]Fluoroazidobutane 
[18F]-Fluoroazidobutane. The dried [18F]-fluoride was then added to 3.0 mg of 
bromoazidobutane (17 µmol) in 0.5 ml dry DMSO, and the mixture was heated at 140 °C 
for 10 min (Scheme 5.2). The labeled product was absorbed on a C18-light Sep-Pak 
cartridge followed by washing with 10 ml H2O and eluted with 5 ml pure methanol. The 
Sep-Pak eluate containing [18F]-fluoroazidobutane was then purified and separated from its 
precursor using semi-preparative HPLC on a semi-preparative C18-reversed phase column 
(mobile phase 60/40 MeCN/H2O, retention time=10 min). In addition, conversion of the 
reaction was monitored by radio-TLC (silica gel, hexane/EtOAc (4:1)) (Rf of product=0.40), 




Propargyl-[Lys3]-bombesin (Lys3-BN3) An alkyne-containing lysine amino acid 
was synthesized by reaction of lysine with the activated succinimide ester of propionic acid 
and incorporated via standard solid phase peptide synthesis into bombesin. 
Peptide synthesis was performed on a 0.1 mmol scale. The Fmoc solid phase method 
was performed on a Rink amide resin (bead size 100-200 mesh, loading 0.7 mmol/g). After 
completion of the synthesis, the resin was filtered off, and washed first with DCM (1 x 10 
ml) and then diethyl ether (3 x 10 ml). The resin was transferred to a sample vial, and to 
this vial was added a cleaving solution, a mixture of trifluoroacetic acid (TFA)/triisopropyl 
silane (TIS)/1,3-ethanedithiol (EDT)/thioanisole /H20 (85/1/4/5/5). The peptide was cleaved 
from the resin, and all of the remaining side chain protecting groups were cleaved off by 
gently stirring the resin in this solution at room temperature for 5 h. The solution containing 
the peptide was filtered and concentrated. The peptide was precipitated using cold diethyl 
ether and centrifuged. The supernatant was decanted and the solid was washed with cold 
diethyl ether (20 ml), centrifuged, and the supernatant decanted. This was repeated a 
further two times. The solid was allowed to dry and then dissolved in water (with 1 % formic 
acid) and lyophilized. Purification of the peptide was achieved by RP-HPlC (Gradient A). 
Retention time=32 min. HRMS (EI) calcd for C26H2905N2 [M+W]1671.9194, found 
1671.9900. (Scheme 5.3) 
Scheme 5.3. [lys3]-bombesin 
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Fluoro triazolyl lysine 3bombesin (FTBN3) Propargyl-[Lys3]-bombesin (1.00 mg, 5.98 
x 10-4 mmol) and 4-fluorobutaneazide (0.14 mg, 9.2 x 10-4 mmol) were dissolved in a 
H2O/DMSO mixture (3 :1, 0.8 ml). In a separate vial, CuSO4 · 5H2O (1.5 µg, 5.98 x 10-
5 
mmol) was dissolved in 0.1 ml of water, to this was added sodium ascorbate (5.9 µg, 3.00 
x 10-5 mmol). MonoPhos (2.51 µg, 6.98 x 10-5 mmol) was added along with 0.1 ml of 
DMSO. The reagents were stirred together for 10 min and added to the solution of azide 
and peptide. The reaction was monitored by RP-HPLC. Upon completion, the reaction 
mixture was lyophilized. The crude product was purified by RP-HPLC (Gradient A). HRMS 
(EI) calcd for C83H121O19N25FS [M+W] calc 1821.8901, found 1821.8932. Retention 
time=36.0 min. (Scheme 5.4) 
Schem 5.4. Fluoro Triazolyl Lysine 3 Bombesin (FTBN3) 
[ 18F]-TBN3. [18F]-fluoroazidobutane in MeCN/H2O and propargyl-BN3 were dissolved in 
a mixture of water and DMF (3 :1 v/v). In a separate vial, CuSO4 ·5H2O (5 mol %) was 
dissolved in 0.1 ml of water, and to this was added sodium ascorbate (25 mol %). 
MonoPhos (6 mol %) was added along with 0.1 ml of DMF. The reagents were stirred 
together for 10 min and added to the solution of azide and peptide. The reaction was 
monitored by HPLC and radio-TLC until full conversion was reached. [18F]-TBN3 was purified 
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by RP-HPLC. Retention time=18 min, and analyses was with radio-TLC (silica gel, 
hexane/EtOAc (4:1)) (Rt=0.20). Radiochemical yield=59%. Specific activity of final product 
was around 90 GBq/µmol. 
Analytical as well as semipreparative reversed-phase high-performance liquid 
chromatography (RP-HPLC) was performed. Isolation of radiolabeled peptides was 
performed using a RP-C18 column (4.6 mm x 250 mm, 10 µm). The flow was set at 2.5 
ml/min using a gradient system starting from 90% solvent A (0.01 M phosphate buffer, 
pH=6.0) and 10% solvent B (acetonitrile) (0-2 min) and ramped to 45% 
solvent A and 55% solvent B at 35 min. The analytical HPLC was performed using the same 
gradient system but with a reversed-phase Grace Smart RP-C18 column (4.6 mm x 250 
mm, 5 µm) and a flow of 1 ml/min. (Scheme 5.5) 
Scheme S.S. [18F]-Fluoro Triazol Lysine 3 Bombesin ( [18F]-TBN3) 
Octanol/Water Partition Coefficient Study 
Water/ Octanol partition coefficients were determined at pH=7.4. Aliquots of 5 µL 
containing 500 kBq of the radiolabeled compound in PBS were added to a vial containing 1.2 
ml 1-octanol and PBS (1:1). After vortexing for 1 min, the vial was centrifuged for 5 min at 
10 000 rpm to ensure complete separation of layers. Then, 40 µL of each layer was taken in 
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a preweighed vial and measured in the y-counter. Counts per unit weight of sample were 
calculated. The experiments were performed in triplicate. 
Cell culture 
The GRPR-positive PC-3 human prostate cancer cell line (ATCC, Manassas, Virginia, 
USA) was cultured at 37°C in a humidified 5% CO2 atmosphere. The cells were cultured in 
RPMI 1640 (Lonza, Verviers, France) supplemented with 10% fetal calf serum (Thermo 
Fisher Scientific Inc., Logan, Utah, USA). They were subcultured twice a week after 
detaching with trypsin-EDTA. 
In Vitro Stability 
The tracer was dissolved in 1 ml saline (1 mg/ml). The resulted solutions were 
incubated at room temperature and samples were analyzed by RP-HPLC with radiometric 
detection. Metabolic stability was investigated in human serum. Human serum from healthy 
donors were incubated at 37°C with [18F]-TBN3 for different time periods. After incubation, 
250 µL sample was precipitated with 750 µL acetonitrile/ethanol (Vaceton itrile/Vethanol = 1 : 1) and 
then centrifuged (3 min, 3000 rpm), the supernatants passed through a filter followed by 
analysis by RP-HPLC. 
In Vitro Competitive Receptor-Binding Assay 
In vitro GRPR binding affinities and specificities 125I-Tyr4-BN(l-14) (Perkin Elmer, 
Oosterhout, The Netherlands) and [18F]TBN3 were assessed via a competitive displacement 
assay with BN(l-14). Experiments were performed at 37 °C with PC-3 human prostate 
cancer cells (Chen 2004). The 50% inhibitory concentration bombesin (1-14) (IC50= 3 .5  ± 
0.2 nM) (n=3, mean ± SD), values were calculated by fitting the data with nonlinear 
regression using GraphPad Prism 5.0 (GraphPad Software, San Diego, California, USA). 
Experiments were performed with triplicate samples. IC50 values are reported as an average 




Internalization studies and stability of tracer 
The tracer was dissolved in 1 ml saline. The resulted solutions were incubated at room 
temperature and reaction was followed by RP-HPLC with radiometric detection. 
The internalization studies were performed according to the method described in the 
literature (Chen 2004), although slightly modified. In short, PC-3 cells cultured in 6-well 
plates were incubated in triplicate with [18F]-TBN (0.0037 MBq/well) for 2 h at 4°C, 
afterwards washed twice with ice-cold PBS to remove unbound radioactivity and then 
incubated in the pre-warmed culture medium at 37°C for 0, 5, 15, 30, 45, 60, 90 and 120 
min to allow for internalization. To remove cell-surface bound radiotracer, the cells were 
washed twice for 3 min with acid (50 mM glycine-HCl/100 mM NaCl, pH 2.8) .  Next, the cells 
were lysed by incubation with 1 M aq. NaOH at 37 °C, and the resulting lysate in each well 
was aspirated to determine the internalized radioactivity in a y-counter (Compugamma 
CS1282, LKB-Wallac, Turku, Finland). Results were expressed as the percentage of the total 
radioactivity (internalized activity/(surface-bound activity plus internalized activity)). 
Efflux studies 
The efflux studies were also performed according to the method described in literature 
(Chen et al., 2004), although the procedure was slightly modified. In short, PC-3 cells 
cultured in 6-well plates were incubated with [18F]TBN (0.0037 MBq/well) for 1 h at 37°C to 
allow for maximal internalization, subsequently washed twice with ice-cold PBS to remove 
unbound radioactivity and then incubated in the pre-warmed culture medium at 37°C for 0, 
15, 30, 45, 60, 90, 120 min in triplicate. To remove cell-surface bound radiotracer, the cells 
were washed twice for 3 min with acid (50 mM glycine-HCl/100 mM NaCl, pH 2.8). Next, 
the cells were lysed by incubation with 1 M aq. NaOH at 37°C, and the resulting lysate in 
each well was aspirated to determine the remaining radioactivity in a y-counter 
(Compugamma CS1282, LKB-Wallac, Turku, Finland). Results are expressed as the 
percentage of maximal intracellular radioactivity (remaining activity at specific time-point 
divided by activity at time-point 0). 
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Animal model 
The PC-3 tumor model was generated by subcutaneous injection of 2 x 106 PC-3 cells 
suspended in 0.1 ml of saline into the right front flank of male athymic nude mice (Harlan, 
Zeist, The Netherlands). The mice were used for biodistribution experiments and microPET 
imaging when the tumor volume reached a mean diameter of ~0.8-1.0 cm. (3-4 weeks after 
inoculation). All animal experiments were performed in accordance with the regulations of 
Dutch law on animal welfare, and the institutional ethics committee for animal procedures 
approved the protocol. 
Biodistribution experiments 
Twelve PC-3 tumor-bearing mice were randomly divided into two groups, each of which 
had three animals. Isoflurane inhalation was used as method of anaesthesia. [18F]TBN 
(10±2 MBq/mouse) dissolved in 0.1 ml of saline was injected intravenously via the penis 
vein. A 0-60 min dynamic scan followed by biodistribution and a 120 min static scan 
followed by biodistribution were carried out. A blocking group followed the same protocol. 
The mice were anaesthetized and sacrificed by cervical dislocation. Immediately after 
sacrificing the animals, blood was withdrawn from the eye through a capillary tube and 
organs of interest (heart, liver, spleen, lung, kidney, small intestine, large intestine, 
stomach, bone, muscle, tumour) were collected and weighed. Radioactivity was determined 
in a y-counter (Compugamma CS1282, LKB-Wallac, Turku, Finland). 
To determine specificity of the in vivo uptake, another group of mice received an 
intravenous injection of 250 µg of unlabeled E-aminocaproic, Aca-BN(7-14) at 30 minutes 
prior to injection of [18F]TBN (10±2 MBq /mouse). Mice were sacrificed 1 h after injection of 
the radiotracer and processed as described above. 
Organ uptake was calculated as a percentage of the injected dose per gram of tissue mass 
(%ID/g). Biodistribution data was reported as an average plus the standard deviation based 
on the results from four animals at each time point. Significant blocking was calculated with 
the student's t-test. P-values were considered significant when p�0.05. T/NT ratios were 
reported as an average at each time point (without the blocking group). 
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MicroPET /CT imaging 
The imaging study was performed in PC-3 tumor-bearing mice, of which 6 were used 
for the blocking experiment. Each PC-3 tumor-bearing mouse was injected via the penis 
vein with [18F]TBN (10±2 MBq/mouse) in 0.1 ml saline under isoflurane anesthesia. Animals 
were placed prone in the µ-PET using a Focus 200 rodent scanner (CTI Siemens, Munich, 
Germany). 
Dynamic data was acquired immediately after injection of the radiotracer for 60 
minutes, 6 frames, 10 minutes per frame. Two hours after injection of the radiotracer, the 
mice were sacrificed, placed horizontal in the µ-PET and a 60min-static scan was performed 
at 2 h post injection after sacrificing the animals. For the blocking experiment, each of the 
mice was administered intravenously (penis vein) with an excess Aca-BN(7-14) (250 µg 
dissolved in 0.2 ml of saline) 30 min prior to administration of 18FTBN (10±2 MBq/mouse. 
Images were acquired using the same procedure as described above. Images were 
reconstructed by using µ-PET. Inveon Research Workplace Software (Siemens Inveon 
Software, Erlangen, Germany). 
Metabolic Stability 
Male mice bearing PC-3 tumors were injected intravenously with [18F]TBN tracer 
(10±2 MBq/mouse). Tracer uptake is expressed as SUV. The animals were sacrificed and 
dissected at 5 min and 20 min after injection. Blood, urine, liver, kidneys, and tumor were 
collected. Blood was immediately centrifuged for 5 min at 13,200 rpm. Organs were 
homogenized using an IKA Ultra-Turrax TS (IKAWorks Inc.), suspended in 1 ml of PBS, and 
centrifuged for 5 min at 13,200 rpm. After removal of the supernatants, the pellets were 
washed with 500 ml of PBS. For each sample, supernatants of both centrifugation steps 
were combined and passed through Sep-Pak C18 cartridges. The urine sample was directly 
diluted with 1 ml of PBS and passed through Sep-Pak C18 cartridge. The cartridges were 
washed with 2 ml of H20 ·and eluted with 2 ml of acetonitrile containing 0.1 % TFA. The 
combined aqueous and organic solutions were concentrated to about 1 ml by rotary 
evaporation, passed through a 0.22-mm Millipore filter. Tumors and plasma were weighted 
and the amount of radioactivity was determined with the gamma counter. The soluble 
fraction of tumors and plasma samples was analyzed by Radio-TLC (Rf 
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[1
8F]Fluoroazidobutane=0.89, Rf [18F]TBN=0.57) eluent:MeCN/H2O 3:7). After elution, 
radioactivity on TLC plates was analyzed by storage system (PerkinElmer) and the 
percentage of conversion of [18F]TBN as a function of the tracer distribution time was 
calculated by ROI analysis using OptiQuant software. 
Results and discussion 
Synthesis and radiolabeling 
[18F]fluoro azido butane was prepared in yields ranging from 78 to 81 %. Conjugation of 
[1
8F]fluoro azido butane to 0.1 mg of propionyl-Lys3-Bombesin (1-14) using via Cu(I) 
mediated 1,3-dipolar cycloaddition yielded the desired [18F]-labeled peptide in 15 min with a 
radiochemical yield of 93%. The total synthesis time was 60 min from the end of 
bombardment; the specific activity was around 90 GBq/µmol. 
Increasing the amount of 3-propronyl-Lysine-Bombesine(l-14) from 0.05 to 0.1 mg resulted 
in increase of RCY of the triazole product from 70 to 93%. With respect to 3-Fluorobutyl 
triazolyl -lysine-Bombesin (1-14) (18FTBN), lmol % of Cu5O4 showed a sufficient catalytic 
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Scheme 5.6. Synthesis of [18F]-TBN 
In Vitro Competitive Receptor-Binding Assay 
Using [125I]-Tyr4-BN(1-14) and [18F]-TBN as the GRPR-specific radioligand, the binding 
affinities of were assessed via a competitive displacement assay using BN(l-14). Results 
were plotted in sigmoid curves for the displacement of [125I]-Tyr4-BN(1-14) and [18F]-TBN 
as a function of increasing concentration of BN(l-14). The IC50 values were determined at 
16.3 nM, 20 nM for BN(1-14)with [125l]-[Tyr4]-BN and [18F]-TBN respectively (Figure 5. 1). 
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Figure 5.1. Competitive binding assay on PC-3 cells with [125I]-[Tyr4]-BN and [18F]-TBN 
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Figure 5.2. In vitro stability of 18F-TBN in PBS 
The stability of [18F]-TBN in PBS was determined at 37 °C. After 90 min of incubation, 
HPLC analysis showed that 98% of the tracer was still intact. The stability of [18F]-TBN in 
PBS and human plasma were also determined at 37 °C. After 90 min of incubation 98% ( 
Radio-TLC) of radioactivity still corresponding to the intact tracer. This indicates that the 
tracer is highly stable in vitro (figure 5.2). 
Internalization and efflux studies 
The results of the internalization of [18F]-TBN into PC-3 cells are shown in figure 5.3. 
Internalization occurred fast in the first 15 min and reached a plateau of 84% after 30 
minutes remaining steady for 120 minutes during the experiment. 
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Figure 5.3. Internalization of [18F]-TBN into PC-3 cells (n = 3, mean ± SD). Cell-associated 
data are expressed as % radioactivity/million cells 
For a good PET tracer, not only tracer uptake, but also its retention is important. The 
results of the efflux study are depicted in figure 5.4. A moderate efflux rate in the first 60 
min is shown with only 32% of radioactivity externalized by the PC-3 cells. After 90 min a 
relatively stable situation is created with just over 50% of added radioactivity remaining in 
the cells for the remainder of the experiment. 
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Figure 5.4. Efflux kinetics of 18F-FTBN in PC-3 cell line (n = 3, mean ± SD). Cell-associated 
data are expressed as % radioactivity/million cells 
Biodistribution experiments 
Biodistribution of 18F-FTBN was evaluated in PC-3 tumor xenografts bearing athymic 
nude mice. Biodistribution data are shown in table 5.1. Fast clearance of activity from the 
blood and high non-specific uptake in kidney was observed, suggesting that radioactivity is 
rapidly cleared mainly via the renal-urinary system. Low uptake of radioactivity in bone, 
muscle and the rapid clearance from blood resulted in favourable high T/NT ratios. Low 
uptake was detected in the GRPR-rich pancreas during the experiment, Uptake in tumor, 
stomach, small and large intestine was not significantly reduced in the study of GRPR 
blockade. 
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S min 20 min 
Organ %1D/g T/NT %1D/g 
Bone 0.46±0.09 5.58 1.67±1.22 
Largelnt. 0.90±0.56 2.51 0.83±0.56 
Small 
Int. 1.41±1.21 1.66 2.32±0.91 
Heart 0.67±0.71 7.02 0.32±0.27 
Kidney 4.21±5.90 1.78 2.62±1.01 
Liver 2.60±2.20 0.82 1.01±0.59 
Lung 2.93±3.44 3.11 0.60±0.27 
Muscle 0.50±0.44 19.27 0.25±0.22 
Pancreas 1.01±1.02 4.12 0.63±0.28 
Blood 1.16±0.58 3.29 0.46±0.33 
Spleen 0.50±0.54 7.60 0.35±0.22 
Stomach 0.57±0.52 4.45 0.59±0.16 
Tumor 2.81±4.05 1.00 0.39±0.22 
lh 2h 
T/NT %1D/g T/NT %1D/g 
0.30 0.62±0.16 0.79 0.44±0.22 
0.96 0.52±0.07 1.01 0.60±0.27 
0.23 1.63±0.76 0.30 1.53±1.27 
2.19 0.47±0.17 1.03 0.28±0,30 
0.18 1.78±0.50 0.30 2.07±1.46 
0.59 1.17±0.26 0.43 0.88±0.67 
0.79 0.61±0.23 0.77 0.45±0.40 
2.81 0.39±0.10 1.28 0.26:t:0.22 
0.83 0.60±0.17 0.82 1.38±1.49 
1.51 0.54±0.18 0.88 0.37±0.41 
1.63 0.43±0.14 1.11 0.31±0.25 
0.76 0.50±0.26 0.99 0.55:t:0.24 






























Table 5.1. Biodistribution and Tumor-to- Normal- Tissue Ratios of 18FTBN after 
Intravenous Injection in PC3 prostate tumor in mouse tissues ( expressed as Standard 
Uptake Values). Value are expressed as %ID/g, mean ± standard deviation (n=3 at each 




To investigate whether the radioactivity accumulation in the tumors was affected by 
metabolism of 18F-FTBN, metabolite analysis of PC3 tumors was performed. 
Plasma analysis of the mice injected with 18F-FTBN revealed that 90% of the activity 
was present as compite at 60 min, indicating high in vivo stability. Figure 5.5 indicate that 
80 % of 18F-FTBN in PC3 tumors was metabolized to more polar metabolites. 
Metabolite analysis of the tumors suggests that the enhanced radioactivity in PC3 
tumors is due to conversion to 18F-FTBN in intracellular domain. Plasma analysis revealed 
that 18F-FTBN is highly stable in vivo during injection. 
20 





Figure S.S. 18F-FTBN metabolite analysis by Radio-TLC of soluble fraction of PC3 tumors. 
PET Imaging 
Small animal PET was performed in mice inoculated with PC3 tumor cells. Unfortunately 
using PET imaging with 18F-FTBN tumor could not be visualized. Only high uptake was 
observed in biodistribution experiments. 
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Conclusion 
In this study, it has been demonstrated that it is possible to use the CuAAC to label 
bombesin with [18F] in a rapid and high yielding fashion using an alkyne modified bombesin 
and an azido prosthetic group. This approach fulfills many of the requirements that we set 
as ideal characteristics for a prosthetic group. The [18F] is introduced in the last step of the 
synthesis, the labeling proceeds at room temperature in aqueous solution and can reach full 
conversion in 15 min. Most importantly, the system is modular so that a wide range of 
azides can be readily synthesized, altering the properties of the resulting peptide. We 
demonstrated that labeling with [18F]-fluoroazidobutane results in the formation of a tracer 
[18F]-TBN which retains its high affinity for GRP receptors in vitro. Tumor uptake and in vivo 
pharmacokinetics in PC-3 tumor-bearing mice were not in agreement with the in vitro 
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Abstract 
In the last few years click chemistry reactions, and in particular copper-catalyzed 
cycloadditions have been used extensively for the preparation of new bioconjugated 
molecules such as 18F-radiolabelled radiopharmaceuticals for positron emission tomography 
{PET). This study is focused on the synthesis of the Siemens imaging biomarker 18F-RGD-K5. 
This cyclic peptide contains an amino acid sequence which is a well known binding motif for 
integrin av�3 involved in cellular adhesion to the extracellular matrix. We developed an 
improved "click" chemistry method using Cu(l)-Monophos as catalyst to conjugate 
[
18F]fluoropentyne to the RGD-azide precursor yielding 18F-RGD-K5. A comparison is made 
with the registered Siemens method with respect to synthesis, purification and quality 
control. [18F]RGD-K5 was obtained after 75 min overall synthesis time with an overall 
radiochemical yield of 35% (EOB). The radiochemical purity was > 98 % and the specific 
radioactivity was 100-200 GBq/µmol at the EOS. 
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Introduction 
Integrins are heterodimeric (a-f3) transmembrane proteins expressed at the cell surface 
that are involved in cellular adhesion to the extracellular matrix [Plow 2000, Gottschalk 
2002]. They stimulate vascular endothelial cell migration and invasion, regulate their 
growth, survival and differentiation and they serve as receptors for a variety of extracellular 
matrix proteins including vitronectin, fibronectin, fibrinogen and osteopontin. They are 
involved in many biological processes such as angiogenesis, thrombosis, inflammation, 
osteoporosis and cancer, playing a key role in many severe human diseases [Hynes 1992, 
2002a, Brooks, 1994]. So far, 18 a and 8 f3 subunits of integrins have been identified : they 
form 24 heterodimers, each with distinct ligand binding properties. Among the integrin 
superfamily, avf33 and a5f31 integrins, targeted by the RGD sequence, play a pivotal role in 
the formation of new blood vessels in tissues (angiogenesis) [Tamkun, 1986, Hynes 2002b, 
Hwang 2004, Ruoslahti 1987]. avf33 and a5f31 integrins are overexpressed on activated 
endothelial cells during physiological and pathological angiogenesis [Ruegg 2003]. 
Since avf33 integrin is expressed on tumor cells of various types (melanoma, 
glioblastoma, ovarian and breast cancer) where it is involved in the processes that govern 
metastasis, it represents an attractive target for cancer therapy and has stimulated ongoing 
research to define high affinity ligands [Pierschbacher 1984, Meyer 2006]. 
RGD containing integrin ligands have a large number of medical applications ranging 
from noninvasive visualization of integrin expression in vivo to the synthesis of 
functionalized biomaterials. Over the past decade, a variety of radiolabeled cyclic peptide 
antagonists with structures based on the RGD sequence have been evaluated as integrin 
avf3rtargeted radiotracers [Liu 2006 and 2009]. The PET tracers [18F]Galacto-RGD, [18F]­
AH111585 and [18F]RGD-KS are currently under clinical investigation for visualization of 
integrin avf33 expression in cancer patients [Beer 2006, Cho 2009, Doss 2009, Haubner 
2005, Kenny 2008, McParland 2008]. 
Due to its favourable f3-energy and half-life, fluorine-18 is the most frequently used 
radionuclide in PET. However, rapid and direct non carrier-added 18F-labeling of complex 
biomolecules such as peptides is not straight forward. The main approach to label peptides 
with 18F is via fluorination of prosthetic groups which are then conjugated to the 
biomolecule [Okarvi 2001, Wester 2007]. [18F]Galacto-RGD, a glycosylated cyclic 
pentapeptide, is labeled via 18F-acylation with 4-nitrophenyl-2-[18F]fluoropropionate 
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[Haubner 2004]. The acylation methodology is however complex and time consuming. 
Synthesis of [1BF]Galacto-RGD via this prosthetic group method, requires a total synthesis 
time of about 200 min of which the production of the 1BF-prosthetic group takes about 130 
min [Haubner 2004]. Another strategy, which has been applied for the synthesis of [1BF]­
AH111585, involves chemoselective oxime formation between the aminooxy functionality of 
the peptide and the carbonyl group of the lBF_labeled aldehyde prosthetic group 4-
[1BF]fluorobenzaldehyde [Glaser 2008, Poethko 2004]. Introduction of fluorine-18 can also 
be achieved by chelation of aluminium fluoride [McBride, 2010]. 
Recently, the copper(I)-catalysed Huisgen 1,3-dipolar cycloaddition reaction (CuAAC) 
between terminal alkynes and azides resulting in 1,4-disubstituted 1,2,3-triazoles 
[Rostovtsev 2002, Torn0e 2002] has found its way in radiopharmaceutical chemistry 
[Glaser, 2009]. The main advantages of this 'click chemistry' approach are selectivity, 
reliability and short reaction times while only mild reaction conditions are required [Bock, 
2006, Kolb 2006]. The 1BF-labeling of peptides has been the area that has benefited the 
most from click chemistry [Glaser, 2007, Marik 2006]. The additional advantage of this 
chemistry is that there is no need of protective groups when labeling peptides. Both alkynes 
[Marik 2006] and azides [Glaser 2007] have been radiolabeled with fluorine-18 to produce 
1BF-peptides. 
As a result of a collaboration between the PET-centers in Leuven (Belgium), Groningen 
(The Netherlands) and Siemens (MIBR, Los Angeles, USA), we report an improved and 
simplified procedure to prepare [1BF]RGD-KS using a Cu-catalyst based on phosphoramidite 
ligand [Campbell-Verduyn 2009] . This paper describes in detail the optimized 
radiosynthesis (Scheme 6.1) and QC procedure of [1BF]RGD-KS, and compares it with the 
registered method by Siemens. The efficient radiosynthesis procedure can generally be 
applied for other click reactions using [1BF]fluoroalkynes as prosthetic group. 
Matherials and Methods 
General 
Reagents and solvents were obtained from commercial suppliers (Aldrich, Fluka, Sigma, 
and Merck) and used without further purification. RGD-KS azide and 19F-RGD-KS were 
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prepared by Siemens. For radiolabeled compounds, radioactivity detection on TLC was 
performed with Cyclone phosphor storage screens (multisensitive, PerkinElmer). These 
screens were exposed to the TLC strips and subsequently read out using a Cyclone 
phosphor storage imager (PerkinElmer) and analyzed with OptiQuant software. HPLC 
analysis was performed in Groningen with an Elite LaChrom VWR Hitachi L-2130 pump 
system (Darmstadt, Germany) connected to a UV-spectrometer (Elite LaChrom VWR Hitachi 
L-2400 UV detector) and a Bicron frisk-tech radiation detector. In Leuven, HPLC analysis 
was performed on a LaChrom Elite Hitachi HPLC system (Darmstadt, Germany) connected to 
a UV spectrometer (Waters 2487 Dual y absorbance detector). For the analysis of 
radiolabeled compounds, the HPLC eluate after passage through the UV detector was led 
over a 3 in. NaI(TI) scintillation detector (Wallac, Turku, Finland) connected to a multi 
channel analyzer (Gabi box, Raytest, Straubenhardt Germany). The output signal was 
recorded and analyzed using a GINA Star data acquisition system (Raytest, Straubenhardt, 
Germany). 
Radiolabeling 
Production of [18F]fluoride 
Aqueous [18F]fluoride was produced via the 18O(p,n)18F nuclear reaction by irradiation of 
97 % enriched [18O]water (2-4 ml; Rotem HYOX18, Rotem Industries, Beer Sheva, Israel). 
The [18F]fluoride solution was passed through a Sep-Pak Light Accell Plus QMA anion 
exchange cartridge (Waters) to trap the [18F]fluoride and recover the 18O-enriched water. 
The [18F]fluoride was eluted from the cartridge with 1 ml of K2CO3 solution (4.5 mg/ml) 
into a conical glass reaction vial containing 20 mg Kryptofix 2.2.2. To this solution, 1 ml 
acetonitrile was added and the solvents were evaporated at 130 °C. The [18F]KF/Kryptofix 
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Scheme 6.1. A) Production of 5-[18F]fluoro-1-pentyne: nucleophilic substitution between 
pentynyl tosylate and anhydrous [18F]fluoride in ortho-dichlorobenzene (o-DCB). B) 
MonoPhos Cu(I)-catalysed Huisgen cycloaddition of [18F]fluoropentyne with the RGD-K5 
azide precursor resulting in the 1,4-disubstituted triazole [18F]RGD-K5. 
A solution of pent-4-ynyl-4-methylbenzenesulfonate (20-25 mg, 84-105 µmol) in 0.8-1 
ml anhydrous 1,2- dichlorobenzene was added to the Kryptofix 2.2.2 K18F residue and the 
mixture was heated for 10 min at 110 °C to provide [18F]fluoropentyne which was 
simultaneously distilled with a gentle flow of helium to a second reactor containing the click 
reaction mixture. The click reaction mixture contained 0.1 mg RGD-K5 azide precursor( 2-
( (2S,5R,85, 11S)-8-( 4-( (35,4S,5R,6R)-6-( (2-azidoacetamido )methyl)-3,4,5-
trihydroxytetrahydro-2H-pyran-2-carboxamido )butyl)-5-benzyl-11-(3-guanidinopropyl)-
3 ,6, 9, 12, 15-pentaoxo-1,4, 7, 10, 13-pentaazacyclopentadecan-2-yl)acetic acid; TFA salt) in 
the presence of 0.2 mg phosphoramidite Monophos, 1 mol% (0.05 mg) CuSO4.5H2O 
(reduced to Cu(I) with 5 mol% (0.25 mg) sodium ascorbate), in either 0.25 ml EtOH and 
0.25 ml CH3CN (Groningen) or 0.084 ml EtOH, 0.125 ml CH3CN and 0.042 ml water 
(leuven) (Table 2). The subsequent conversion to radiolabeled [18F]RGD-KS was followed 
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by radio-TLC (Rf [18F]RGD-K5 = 0.4 (eluent: MeOH/H2O 2:1)). After reacting at room 
temperature for 10 min, the crude [18F]RGD-K5 was diluted with 1.5 ml of 0.025 M 
Na2HPO4 pH 7 and purified by semi-preparative RP-HPLC using an XBridge C18 column (5 
µm, 4.6 mm x 150 mm column, Waters) eluted with 0.025M Na2HPO4 pH 7.0 and EtOH 
88/12 at a flow rate of lml/min (Leuven) or by semi-preparative RP-HPLC using an XBridge 
C18 column (5 µm, 10 mm x 150 mm column, Waters) eluted with 0.025M Na2HPO4 pH 7.0 
and EtOH 86/14 at a flow rate of 4 ml/min (Groningen). UV detection of the HPLC eluate 
was performed at 254 nm. [18F]RGD-K5 was collected after 20-25 min (Figure 6.2). On 
average, about 11 GBq (n=24, ranging from 3.7 to 19.5 GBq) of purified [18F]RGD-K5 was 
collected in a 1.3-2.6 ml volume (mobile phase). This HPLC-purified fraction was diluted 
with preparative HPLC mobile phase and passed through an apyrogenic 0.22 µm membrane 
filter (Millex®-GV, Millipore, Ireland). A final solution of 370 MBq/mL was obtained by 
further dilution with saline which was passed through the same membrane filter. 
Quality control procedures 
Quality control procedures for [18F]RGD-K5 are based upon the current requirements for 
radiopharmaceuticals laid out in the European Pharmacopoeia [Ph.Eur. 6.0-
Radiopharmaceutical Preparations]. 
The radiochemical identity of [18F]RGD-K5 is checked using an analytical HPLC system 
consisting of an XBridge C18 column (3.5 µm, 3 mm x 100 mm; Waters) eluted with 0.025 
M Na2HPO4 (pH 7) and CH3CN (90: 10 v/v) at a flow rate of 0.8 ml/min. UV detection of the 
HPLC eluate is performed at 210 nm (Figure 6.3). 
In Groningen QC was performed on a Phenomenex Prodigy C18 column (5 µm, 4.6 mm 
x 150 mm column, Waters with CH3CN and water (40:60 v/v) in the presence of 0.1 % TFA 
as eluent at a flow rate of 3ml/min. The radiochemical identity of [18F]RGD-KS is confirmed 
using authentic RGD-K5 as an external reference material. After injection and analysis of a 
solution of the reference material RGD-K5, a blank injection of preparative HPLC mobile 
phase is performed. The retention time of [18F]RGD-K5 should be the same ( ± 10 % ) as the 
retention time observed for the RGD-K5 reference standard. The radiochemical purity and 




products should be � 5%. Rather than setting a lower limit for specific activity, the 
maximum mass of RGD-KS which is administered to a patient is limited to < 96 µg and the 
mass of the RGD-KS azide precursor should be < 5 µg per administered dose, these limits 
were defined in relation to toxicity tests findings performed by Siemens. Residual solvent 
analysis is performed using GC (direct injection). For the residual class 2 solvent acetonitrile 
a limit of 4.1 mg per patient dose is set as described in the European Pharmacopoeia. 1,2-
Dichlorobenzene is not described in the European Pharmacopoeia but has a no observed 
adverse effect level (NAOEL) of 120 mg/kg/day [http://www.epa.gov/iris/subst/0408.htm] 
in rats which is considerably higher than for chlorobenzene (27 mg/kg/day) 
[http://www.epa.gov/iris/subst/0399.htm]. For chlorobenzene the European Pharmacopoeia 
sets a limit of 3.1 mg per day. 
In order to have a safety margin we have therefore set a limit of 1 mg of o-DCB per 
injected dose. To be safely administered to the patient, the amount of residual ethanol 
should be < 10% v/v. The drug product pH should be in the range 5-8. Testing of the 
integrity of the filter that is used for sterile filtration is done by bubble point determination. 
The bubble point pressure for the particular filter used should be � 3.45 bar. Determination 
of the radionuclide identity and endotoxin and sterility testing are performed post batch 
release. Since CuSO4 is being used in the manufacturing process of the radioligand, the 
finished drug product should be tested for residual levels of the metal reagent. 
Result and discussion 
Using our optimized click reaction condition we improved and simplified the original 
registered Siemens production method. Scheme 1 shows the two-steps radiosynthetic route 
to yield [18F]RGD-K5. In a first step the labeling synthon 5-[18F]fluoro-1-pentyne was 
prepared via nucleophilic fluorination of pentynyltosylate with anhydrous [18F]KF-cryptate at 
110 °C in o-DCB. The 18F-labelled pentyne (Bp= 76 °C) was isolated from the tosyl 
precursor and unreacted 18F via distillation and was, without further purification, trapped in 
a receiving vial containing the RGD-KS azide precursor. Effluent gasses that escaped from 
the receiving vial were collected in a balloon. We choose a high boiling point solvent (o­
DCB, 179 °C) instead of acetonitrile (82 °C) to prevent co-distillation of the solvent. 
Acetonitrile co-distilling to the click reaction mixture was found to decrease the yield of the 
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click reaction and the efficiency of the HPLC purification. The distilled [18F]fluoropentyne 
was efficiently trapped at room temperature in the click reactor (90 %) avoiding the need to 
use a cold trap. Radiometric detection showed that the amount of [18F]fluoropentyne in the 
receiving vial saturated after about 10 min. 
The phosphoramidite ligand Monophos showed to be an excellent ligand for 
complexation of Cu(I) in order to catalyze the click reaction [Campbell-Verduyn, 2009]. 
Monophos was far superior to the previously reported ligand TBTA [Chan, 2004] . In absence 
of the ligand only minor conversion to the triazole product [18F]F-RGD-KS was observed. 
Further reaction optimization was performed by varying the amount of RGD-KS azide from 
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Figure 6.1. Radiochemical conversion of the click reaction as a function of time and 




Reactions with only 0. 1 mg RGD-K5 azide yielded 18F-RGD-K5 in excellent 
radiochemical yield. So far 1 mol % of CuSO4 in the presence of 1. 1 mol % Monophos 
showed sufficient catalytic effect within 15 min. These optimized conditions utilizing Cu(I) 
and Monophos as a potent catalyst provide an important tool to use reduced amounts of 
peptide precursor, that is expensive in many cases. Usually amounts of > 1 mg peptide are 
used and no additional catalyst beside Cu(I) is employed. As a result of the dramatic 
acceleration of the click reaction by Monophos it was possible to substantially reduce the 
amounts of reactants such as sodium ascorbate, CuSO4, catalytically active and amount of 
azide (Table 6. 1). 
Material and method Optimized protocol SIEMENS protocol 
Synthesis of 24 mg pentynyl tosylate in 1 24 mg pentynyl tosylate in 1 ml 
[
18F]fluoropentyne ml dichlorobenzene MeCN 
RGD-K5 azide 0. 1 mg 4 mg 
Na-ascorbate 0.25 mg 40 mg 
CuSO4 0.05 mg in 0.25 ml H2O 15 mg in 0.25 ml MeCN 
Ligand 0.2 mg MonoPhos in 0. 1 ml 15 mg TBTA 
DMSO 
Purification by HPlC: isocratic gradient 
Mobile phase Phosphate buffer 0.025M pH MeCN : H2O 50/50 v/v+ 0.01 % TFA 
7 I EtOH 86/14 v/v 
(Groningen) or 88/12 v/v 
(leuven) 
Formulation by C-18 None Dilute HPlC fraction with 100 ml 
seppak classic of water 
Elute with 1 ml ethanol 
Table 6.1 .  Main differences between the optimized [18F]RGD-K5 production procedure as 
described in this article and the original Siemens protocol 
120 
Synthesis of 18F-RGD-KS by catalyzed [3+2] cycloaddition for imaging integrin av�3 
The crude click reaction mixture was purified using semi-preparative HPLC. Before 
injection, the mixture was diluted with phosphate buffer pH 7 to adjust the pH to that of the 
mobile phase resulting in sharper peaks. We evaluated different sizes and types of columns 
and found that the Waters XBridge C18 (5 µm, 4.6 x 150 mm) gave sharper peaks and 
provided the best separation between the azide precursor and [18F]RGD-K5 (resolution 
2.18). For the preparative HPLC purification we preferred an isocratic method with a mobile 
phase consisting of a phosphate buffer in combination with ethanol. 
Using a mobile phase with ethanol as organic modifier eliminates post HPLC SepPak 
formulation resulting in a reduced synthesis time and a more simple and reliable tracer 
production [Serdons 2008]. Using the XBridge column in combination with a mobile phase 
consisting of 12 % ethanol in 0.025 M phosphate buffer pH 7, the unreacted azide precursor 
eluted at 20 min and [18F]RGD-K5 at 25 min. 
· The RGD-K5 azide precursor and the reference compound RGD-K5 have their maximal 
UV absorption at 210 nm. The reference compound also absorbs at 254 nm, the azide 
precursor does not. Since for the preparative purification UV detection was performed at 
254 nm, the trace of unreacted precursor is not visible in the UV channel of the preparative 
HPLC chromatogram of the crude radiolabeling mixture (Figure 6.2). Within the isocratic 
conditions unreacted [18F]fluoropentyne is retained on the column and only elutes upon 
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Figure 6.2. Semi-preparative HPLC chromatogram of the purification of [18F]RGD-K5. Upper 
channel : radiometric detection . Lower channel : UV detection at 254 nm. [18F]RGD-K5 elutes 
at 22 min. Unreacted [18F]fluoropentyne elutes during rinsing of the column. 
The radiolabeled compound [18F]RGD-K5 was obtained in 35% radiochemical yield 
based on [18F]fluoride starting radioactivity (decay-corrected) in 75 min. 
Analysis of the radiochemical identity, radiochemical and chemical purity and determination 
of specific radioactivity was performed on an analytical HPLC system consisting of a XBridge 
C18 column (3.5µm, 3 x 100 mm) eluted with a mobile phase consisting of 10 % acetonitrile 
in 0.025 M phosphate buffer pH 7. At 210 nm using a flow rate of 0.8 ml/min, [18F]RGD-K5 
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elutes at 11 min. The radiochemical purity was higher than 98% and the specific 
radioactivity of [18F]RGD-KS was determined to be in the range of 100-200 GBq/µmol. For 
all productions, QC HPLC analysis (Figure 6.3) showed that the amount of RGD-KS azide 
precursor (Rt= 6 min) in the final solution was lower than the detection limit (LOD 0.2 ng), 
confirming the efficient separation between the azide precursor and [18F]RGD-KS with the 
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Figure 6.3. Quality control of [18F]RGD-KS. Upper channel: UV detection at 210 nm. No 
trace of RGD-KS azide precursor is observed at the expected retention time of 6-7 min. 
Lower channel: radiometric detection. ( Performed by Leuven-Belgium)HPLC system 
consisting of an XBridge C18 column (3.5 µm, 3 mm x 100 mm; Waters) eluted with 0.025 
M Na2HPO4 (pH 7) and CH3CN (90: 10 v/v) at a flow rate of 0.8 ml/min. 
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For all productions, the amount of RGD-K5 in the final drug product was < 96 µg. The 
concentration of copper was determined for 5 batches of RGD-K5 using inductively coupled 
plasma mass spectrometry (ICP-MS) and was found to be 53±22 µg/L which corresponds to 
1/l0th of the concentration of naturally copper in plasma (50-150 µg/dl) (Merck Manual). If 
the total batch would be injected into a single subject this would result in the administration 
of < 0.5 µg which corresponds to less than 1/l000th of the daily recommended dose (1.2 
mg/day), indicating that there is a large safety margin with regard to the copper content in 
the [18F]RGD-K5 productions. Residual Kryptofix-[2.2.2] analysis was not performed as it 
was validated that Kryptofix does not co-distil with [18F]fluoropentyne from the first reaction 
vial. The amount of acetonitrile and o-DCB in the final formulation were below the detection 
limit (LOD 0.0001 %). Ethanol was present ( < 8 %) to increase radiochemical stability and 
to minimize the tracer being retained on the walls of the sterile filter, the vial and the 
syringes used to administer the drug product to the patient (Serdons 2008). 
Radionuclide purity, sterility and endotoxin testing were performed post batch release. 
The radionuclide identity was determined using a two-time point radioactivity measurement 
in a dose-calibrator. 
For all batches, the calculated half-life was in the range 105-115 min which is 
according to Ph.Eur. guidelines [Ph.Eur. 6.0-Radiopharmaceutical Preparations]. Bacterial 
endotoxin determination of the [18F]RGD-K5 batches was done using the Limulus amebocyte 
lysate (LAL) test according to the Ph.Eur. guidelines [Ph.Eur. 6.0-Chapter 2.6.14: Bacterial 
Endotoxines]. For all batch productions the endotoxin content was < 1 IU/ml (limit set at 
10 IU/ml). If the total batch volume (max 20 ml) would be injected to one volunteer the 
amount of injected IU would be well below the 175 IU per dose limit for 
radiopharmaceuticals specified in the Ph.Eur [Ph.Eur. 6.0-Chapter 2.6.14: Bacterial 
Endotoxines]. Sterility testing was done according to Ph.Eur. 6.0 and no growth of 
microorganisms was detected after 14 days incubation at 37 °C in any of the batches. 
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Conclusion 
18F-RGD-KS was synthesized with high specific activity and high radiochemical yield 
using click chemistry. The beneficial effects of click chemistry for the synthesis of 
biomolecules containing the RGD system will ensure the growth of this area in the future. 
The monophos ligand accelerated Cu(I)-catalyzed 1,3-dipolar cycloaddition reaction was 
applied successfully. The QC system has been validated and allows the tracer to be used in 
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Chapter 7 
Abstract 
Background: Given the fact that angiogenesis plays an important role in atherosclerotic 
plaque vulnerability, molecular imaging of angiogenesis can be used for determination of 
rupture-prone atherosclerotic plaques. av�3 integrin is a key player in the process of 
angiogenesis. Targetted imaging of av�3 integrin has been shown to be possible in previous 
studies on tumor models, using radiolabeled arginine-glycine-aspartate- (RGD-KS). 
Our aim was to investigate feasibility of ex vivo detection of av�3 integrin in human carotid 
endarterectomy (CEA) specimens. 
Methods CEA specimens, immediately after excision, were incubated in 5 Mbq 18F­
RGD-KS for one hour followed by one hour emission microPET scan. The results were 
quantified in 4mm wide segments as percent incubation dose per gram (%lnc/g). A 
segmental-to-total ratio was calculated by dividing segmental %Inc/g by total specimen's 
%Inc/g. Presence of av�3 integrin and endothelial cells in each segment was confirmed by 
immunohistochemical staining for CD31 and av�3 integrin, respectively. 
Results [18F]-RGD-KS uptake was heterogeneous in CEA specimens and was localized 
within the vessel wall. Significant correlations was observed between segmental-to-total 
ratio with av�3 integrin staining score (r = 0.58, p = 0.038) and CD31 staining score (p = 
0.67, P < 0.002). 
Conclusion This study, for the first time showed the feasibility of integrin imaging in 




Intraplaque hemorrhage as a consequence of intraplaque pathology has been linked to 
vulnerability of atherosclerotic plaques to rupture and further cardiovascular complications 
(Virmani , 2005). Given the fact that most of cardiovascular events (including heart attacks 
and strokes) occur in non-stenotic atherosclerotic plaques (Naghavi , 2003), raise attention 
for development of non-invasive methods for detection of rupture-prone plaques to provide 
an individualized means for clinicians to risk stratify patients at higher risk for cardiovascular 
events. 
Molecular imaging of angiogenesis targets variable players in the process of 
angiogenesis. Vascular endothelial growth factor (VEGF) (Nagengast , 2007), VEGF-receptor 
(Cai , 2006), and integrins (Schnell , 2009) have been targeted by molecular imaging 
probes. Imaging studies have shown promising results in detection of angiogenesis in 
oncology research. Among integrin proteins, specifically av�3 integrin, a cell surface 
receptor, plays a crucial role in process of angiogenesis by mediating adhesion of cells to 
extracellular matrix and migration of endothelial cells (Morrison, 2010). Because of its 
critical role, av�3 integrin imaging has been focus of many studies. 
RGD containing integrin ligands have a large number of medical applications ranging 
from noninvasive visualization of integrin expression in vivo to the synthesis of 
functionalized biomaterials. Over the past decade, a variety of radiolabeled cyclic peptide 
antagonists with structures based on the RGD sequence have been evaluated as integrin 
av�rtargeted radiotracers [Liu, 2006, 2009]. The PET tracers [18F]Galacto-RGD, [18F]­
AH111585 and [18F]RGD-KS are currently under clinical investigation for visualization of 
integrin av�3 expression in cancer patients [Beer, 2006; Cho, 2009; Doss, 2009; Haubner, 
2005; Kenny, 2008; McParland, 2008]. 
High binding affinity of arginine-glycine-aspartate (RGD) peptide sequence for 0v�3 
integrin has resulted development of multiple tracer for detection of av�3 integrin as a 
marker for angiogenesis (Liu, 2006). It has been shown that small animal positron emission 
tomography (PET) imaging of av�3 integrin is possible in highly av�3 integrin-expressing 
mouse tumors and mouse models of human tumor xenografts with a high tumor-to­
background ratio and specificity ( Haubner, 2001). The role of a single photon emission 
computed tomography (SPECT) RGD-based probe in detection of inflammation in mouse 
models of vascular remodeling has been demonstrated recently ( Razavian, 2011).Moreover 
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the link between 18F-galacto-RGD uptake and inflammation has been recently demonstrated 
in mouse models of atherosclerosis (Laitinen, 2009). In another study, feasibility of RGD­
based imaging was showed in predicting scar formation in patients with myocardial 
infarction (Verjans, 2010). 
In this study, for the first time we investigated whether it is feasible to detect av�3 
integrin in human carotid endarterectomy (CEA) specimens using an ex vivo imaging 
method recently developed by our group (Masteling, 2011). This method allows using high 
resolution microPET system to illustrate heterogeneous tracer uptake within atherosclerotic 
plaque and correlating tracer uptake with pathologic finding of plaques in different regions. 
For this study we used a recently developed 18F-labeled RGD compound which is produced 
using click chemistry method. 
Methods and Methods 
Study design and specimens 
This study was designed according to previous work of our group on incubation of CEA 
specimens immediately after excision in a solution containing tracer followed by ex vivo 
high-resolution micro PET scan to visualize tracer uptake with great detail (Masteling, 2011). 
The study was approved by the institutional ethics review board of the University Medical 
Center Groningen, Groningen, the Netherlands. CEA specimens were included from 20 
patients who underwent CEA because of significant symptomatic carotid artery stenosis in 
between January 2011 and June 2012. The samples contained the carotid bifurcation, the 
distal segment of common carotid artery, and proximal segments of both the internal and 
external carotid artery. In order to determine receptor-specific tracer uptake, in three CEA 
specimens co-incubation of samples with cold compounds (blocking) was performed and 
specimens were scanned. 
Materials 
Reagents and solvents were obtained from commercial suppliers (Aldrich, Fluka, Sigma, 
and Merck) and used without further purification. RGD-KS azide and 19F-RGD-KS were 
132 
RGD-Plaque 
prepared by Siemens Molecular Imaging Biomarker Research (Culver City USA). For 
radiolabeled compounds, radioactivity detection on TLC was performed with Cyclone 
phosphor storage screens (multisensitive, Perkin Elmer). These screens were exposed to the 
TLC strips and subsequently read out using a Cyclone phosphor storage imager 
(PerkinElmer) and analyzed with OptiQuant software. HPLC analysis was performed with an 
Elite LaChrom VWR Hitachi L-2130 pump system (Darmstadt, Germany) connected to a UV­
spectrometer (Elite LaChrom VWR Hitachi L-2400 UV detector) and a Bicron frisk-tech 
radiation detector. For the analysis of radiolabeled compounds, the HPLC eluate after 
passage through the UV detector was led over a 3 inch NaI(TI) scintillation detector (Wallac, 
Turku, Finland) connected to a multi channel analyzer (Gabi box, Raytest, Straubenhardt 
Germany). The output signal was recorded and analyzed using a GINA Star data acquisition 
system (Raytest, Straubenhardt, Germany). 
Synthesis of [18F]RGD KS 
Production of [18F]fluoride Aqueous [18F]fluoride was produced via the 18O(p,n)18F 
nuclear reaction by irradiation of 97 % enriched [18O]water (2-4 ml; Rotem HYOX18, Rotem 
Industries, Beer Sheva, Israel). The [18F]fluoride solution was passed through a Sep-Pak 
Light Accell Plus QMA anion exchange cartridge (Waters) to trap the [18F]fluoride and 
recover the [18O]-enriched water. The [18F]fluoride was eluted from the cartridge with 1 ml 
of K2CO3 solution ( 4.5 mg/ml) into a conical glass reaction vial containing 20 mg Kryptofix 
2.2.2. To this solution, 1 ml acetonitrile was added and the solvents were evaporated at 
130°C. The [18F]KF/Kryptofix complex was dried 3 times by the addition of 0.5 ml 
acetonitrile, followed by evaporation of the solvent. 
Production of 5-[18F]fluoro-1-pentyne and [18F]RGD-KS A solution of pent-4-
ynyl-4-methylbenzenesulfonate (20-25 mg, 84-105 µmol) in 0.8-1 ml anhydrous 1,2-
dichlorobenzene was added to the Kryptofix 2.2.2 K[18F]F residue and the mixture was 
heated for 10 min at 110 °C to provide [18F]fluoropentyne which was simultaneously distilled 
with a gentle flow of helium to a second reactor containing the click reaction mixture. The 






pentaazacyclopentadecan-2-yl)acetic acid; TFA salt) in the presence of 0.2 mg 
phosphoramidite Monophos, 1 mol% (0.05 mg) Cu5O4.5H2O (reduced to Cu(I) with 5 mol% 
(0.25 mg) sodium ascorbate), in either 0.25 ml EtOH and 0.25ml CH3CN. The subsequent 
conversion to radiolabeled [18F]RGD-K5 was followed by radio-TLC (Rf [18F]RGD-K5 = 0.4 
(eluent: MeOH/H2O 2:1)). 
After reacting at room temperature for 10 min, the crude [18F]RGD-K5 was diluted with 
1.5 ml of 0.025 M Na2HPO4 pH 7 and purified by semi-preparative RP-HPLC using an 
XBridge C18 column (5 µm, 4.6 mm x 150 mm column, Waters) eluted with 0.025M 
Na2HPO4 pH 7 .0 and by semi-preparative RP-HPLC using an XBridge C18 column (5 µm, 10 
mm x 150 mm column ,Waters) eluted with 0.025M Na2HPO4 pH 7.0 and EtOH 86/14 at a 
flow rate of 4 ml/min. UV detection of the HPLC eluate was performed at 254 nm. 
[1
8F]RGD-K5 was collected after 20-25 min (Figure 7.1). Purified [18F]RGD-K5 was collected 
in a 1.3-2.6 ml volume (mobile phase). This HPLC-purified fraction was diluted with 
preparative HPLC mobile phase and passed through an apyrogenic 0.22 µm membrane filter 
(Millex®-GV, Millipore, Ireland). A final solution of 370 MBq/mL was obtained by further 
dilution with saline which was passed through the same membrane filter. 
Quality control procedures 
Quality control procedures for [18F]RGD-K5 are based upon the current requirements for 
radiopharmaceuticals laid out in the European Pharmacopoeia [Ph.Eur. 6.0-
Radiopharmaceutica I Preparations]. 
QC system was performed on a Phenomenex Prodigy C18 column XBridge C18 column 
(5 µm, 4 .6 mm x 150 mm column ,Waters with CH3CN and water (40:60 v/v) in the 
presence of 0.1 % TFA as eluent at a flow rate of 3mL/min. The radiochemical identity of 
[
18F]RGD-K5 was confirmed using authentic RGD-K5 as an external reference material. 
After injection and analysis of a solution of the reference material RGD-K5, a blank injection 
of preparative HPLC mobile phase is performed. The retention time of [18F]RGD-K5 should 
be the same (± 10 %) as the retention time observed for the RGD-K5 reference standard. 
The radiochemical purity and specific activity was analyzed using the same HPLC system. 
The total of radiolabeled side products were � 5%. Residual solvent analysis is performed 
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using GC (direct injection). Quality control analyses were developed in collaboration with 
Leuven University, more detail is mentioned in chapter 6. 
Micro PET procedure 
For the preparation of incubation buffer, [18F]-RGD-K5 (5.1 MBq ± 0.2, xx µg) was 
diluted in 15 ml phosphate-buffered saline (PBS). Immediately after surgery, the specimens 
were transported to the lab and incubated in the incubation buffer at room temperature. 
After one hour the plaques were flushed 3-5 times with PBS and fixed in a humid box to 
prevent dehydration, positioned and fixed on microPET bed. All specimens were scanned 
using a microPET focus 220 camera (Siemens Preclinical Solutions, Knoxville, TN, USA, Inc.) 
for 60 minutes. Thereafter, a microCT scan was performed using a microCAT II system 
(Siemens Preclinical Solutions, Knoxville, TN, USA) as the stereotactic position was 
maintained. MicroPET images were corrected for scatter and reconstructed applying an 
interactive reconstruction algorithm (OSEM 2D). 
Immunohistochemistry 
Specimens were were serially cross-sectioned in 4 mm slices and numbered from 
proximal to distal. Formalin-fixed paraffin-embedded 5 µm-cut slides were made and were 
stained for Ov�3 integrin and CD31 to show endothelial cells as a marker for new vessels. 
The level of staining was scored from 0-3, by assessment of the percentage of stained 
cells and the staining intensity. 
Data Analysis and Statistics 
Tracer uptake in microPET images was corrected for radioactive decay. MicroPET and 
microCT images were registered using AMIDE software (version 0.9.1, Stanford University) 
and a whole specimen 3-dimensional region of interest (ROI) was drawn manually in 
microCT images and was applied to microPET images. The mean percent incubation dose 




drawn manually in accordance to the cut segments for immunohistochemical analysis to 
compare tracer accumulation with immunohistochemistry. In each segment a %Inc/gsegmental 
was measured and ratio of %Inc/gsegmenta l to %Inc/gtotal (segmental-to-total) was calculated 
for each segment. 
Quantitative results were shown as mean ± SD. Segmental-to-total ratio of 18F-RGDk5 
uptake in each segment was compared with av�3 integrin and CD31 staining and correlation 
between variables were tested by use of Spearman correlation coefficients (p), we set the 
significance level (P) at 0.05. 
Results 
Feasibility and Specific Uptake 
A total of 16 specimens were scanned (average weight 1.1 g). The mean length of the 
specimens was 2.1 ± 0.6 cm. The CEA specimens were transported from the operation 
room to the lab within 15 minutes after surgical excision. In all CEA specimens clear in 
specimens was seen (Figure 7.1). [18F]-RGD uptake was heterogeneous in CEA specimens 
and was localized within the vessel wall (Figure 7.1A). A 3-dimensional 70% maximum 
uptake value isocontour region of interest was drawn to determine the hotspot inside the 
specimen. Mean %Inc/g in hotspot was 1.30% ± 0.34 (ranging from 0.65% to 1.93, and 
the mean %Inc/g in total specimen was 0.45% ± 0.19 (ranging from 0.14% to 0.77%). 
Average hotspot-to-total uptake ratio was 3.19 ± 0.91. 
A blocking experiments were performed by incubation of CEA plaques in 550 times 
excess unlabeled compound (Cold RGD-K5) followed by incubation in 18F-RGD. Using the 
same protocol, one hour after incubation an emission scan was performed and mean 
%Inc/g was calculated to show the effects of blocking on the tracer uptake. The results 
showed a significant decrease (6 times less accumulation) of the tracer in CEA specimens 




In 13 slices av�3 integrin staining was performed. A very heterogeneous integrin 
expression was observed in samples. Immunohistochemical Ov�3 integrin staining was 
scored according to a semi-quantitative three-score scaling method based on staining 
intensity and amount of stained area. Comparing staining 5 scores and segmental-to-total 
ratio showed a moderate but significant correlation as indicated by 
the Spearman's correlation coefficient (r = 0.58, p = 0.038). 
In 18 slices of the CEA specimens CD31 staining was performed (Figure 7.2). The level 
of CD31 staining was scored from 0-3, by assessment of the percentage of stained cells and 
the staining intensity. Semi-quantitative measures of segmental-to-total ratio and CD31 
staining score is shown in table 7.1. The correlation between CD31 staining score and 
Segmental-to-total ratio was significant (p = 0.67, P < 0.002). 
Discussion 
Angiogenesis occurs in atherosclerotic plaques due to increase in size and hypoxia leads 
to formation of immature blood vessels which in turn exacerbate inflammation and 
intraplaque hemorrhage (Ribatti, 2008). These result in plaque instability and vulnerability to 
rupture. As such, clinical detection of angiogenesis in vessel walls can be used for the 
assessment of plaque vulnerability. Integrins play important role in the course of 
angiogenesis and among integrin proteins av�3 integrin, a cell surface receptor, plays a 
crucial role by mediating adhesion of cells to extracellular matrix and migration of 
endothelial cells (Morrison, 2010). Because of its critical role, av�3 integrin imaging has been 
focus of many studies. The RGD peptide sequence has shown high binding affinity for av�3 
integrin and has been labeled with 18F for molecular imaging of integrin in vivo. 
In order to perform ex vivo study on CEA specimens with 18F-RGD-KS, we performed 
quality control on 18F-RGD to check whether the tracer is stable in vitro/ex vivo. For quality 
control, we resembled incubation condition with diluting 18F-RGD-K5 in 15 ml PBS and 




showed that the amount of RGD-KS azide precursor (Rt= 6 min) in the final solution was 
lower than the detection limit (LOD 0.2 ng), confirming the efficient separation between the 
azide precursor and [18F]RGD-KS with the applied preparative HPLC system. In the next step 
we performed ex vivo imaging study on human CEA specimens. This research was designed 
according to a method developed by the department of Nuclear Medicine of UMCG for ex 
vivo depiction of carotid atherosclerotic plaques using a microPET camera system with a 
high spatial resolution (Masteling, 201 1). The resolution of approximately 1 mm offers a 
unique opportunity to visualize atherosclerotic plaque in great detail to provide information 
on underlying processes within atherosclerotic plaque. 
In a previous study, by our group, it was shown that ex vivo imaging of CEA specimens 
after incubation in a solution containing 18FDG is feasible. The results of imaging 
significantly correlated with CD68 positive cells as surrogate markers of macrophages. 
In this study we showed that [18F]-RGD-KS microPET imaging of CEA specimens is 
feasible. The uptake was heterogeneous along CEA specimens and differed plaque by 
plaque. The difference of uptake in different plaques raises the possibility that a proportion 
of surgically excised atherosclerotic plaques would have imposed lower risk of rupture 
according to [18F]-RGD KSimaging. Future studies should be designed to investigate 
implications of high [18F]-RGD KSuptake on the outcome of atherosclerotic plaques. 
Additionally, the correlation between [18F]-RGD-KS uptake with integrin levels and 
inflammation remain to be determined. 
A satisfactory hotspot-to-average ratio was observed in [ 18F]-RGD-KS microPET images 
of CEA specimens. This makes [18F]-RGD-KS a promising tracer for visualization of avl33 
integrin expression arterial tissue and enables us to recognize the target with a high target­
to-background ratio. However, further studies need to be designed to determine optimal the 
time point for blood clearance and the possibility for detection of lesions in vivo. 
A significant correlation was observed between [18F]-RGD KS in each segment and 
immunohistochemical analysis of avl33 integrin, confirming that [18F]-RGD-KS enables us to 
visualize integrin presence and quantify integrin levels in human atherosclerotic plaques. 
Addition of excess unlabeled compound resulted in six times less [18F]-RGD-KS accumulation 
in samples and indicated avl33 integrin-mediated tracer uptake. Good correlation of 
Segmental-to-total ratio with CD31 staining score (p = 0.67, P = 0.002) was demonstrated 
in our study. 
138 
RGD-Plaque 
CD31 immunostaining was used as an endothelium-specific immunohistochemical 
marker as indicator of new vessel formation. The correlation between segmental uptake in 
the lesion and intensity of CD31 staining confirms that 18F-RGD-K5 imaging enables us to 
not only visualize underlying pathology of atherosclerotic disease but also quantitatively 
assessing angiogenesis formation. 
In a previous study on [18F]-RGD-K5 imaging of xenograft tumor models showed a rapid 
blood clearance of the tracer which demonstrated a two hours post-injection specific uptake 
value = 0.05 - 0.15 percent injected dose per gram (Haubner, 2001). In a patient study on 
nine individuals with malignant melanoma the same pattern of rapid decline in blood activity 
was demonstrated within 79 minutes after injection (Haubner, 2005). However, the specific 
uptake value of the tracer in blood in human study was higher than that of mouse model 
(1.17% injected dose per gram). In our study average %Inc/g of [18F]-RGD-K5 in hotspot 
(after one hour incubation) was 1.30% ± 0.34 (ranging from 0.65% to 1.93). This result 
shows the potential for in vivo detection of avf33 integrin. However, the in vivo results of 
atherosclerotic plaque uptake and target-to-blood ratio in animal models and human 
subjects need to be experimentally determined. 
Molecular imaging of vulnerable plaques requires not only a highly-avid, target-specific 
probe and a high spatial resolution imaging modality, but also a deep understanding on 
predictive value of various underlying pathobiological processes in the course of disease. 
Currently, many different molecular imaging probes are being tested to reveal macrophage 
content (Masteling, 2011- Chen, 2009), VEGF abundance (Golestani, In press), and 
(Razavian, 2011) levels of matrix metalloproteinases in experimental models of 
atherosclerosis. This study was the first to examine the feasibility of avf33 integrin ex vivo 
imaging in human atherosclerotic. A better understanding on the predictive role of 
underlying processes within atherosclerotic plaque is required to judge whether or not the 





This study demonstrated the potential of integrin imaging in determination of angiogenesis 
and vulnerability in atherosclerotic plaques. Noninvasive imaging and quantification of 
angiogenesis could provide clinicians with a new tool in stratifying risk for cardiovascular 
events. The QC system has been validated and allows the tracer to be used in clinical 
studies for visualization of neoangiogenesis in oncological patients in our hospitals. 
Figure7. 1. Transversal (A), coronal (B), and saggital (C) sections of microPET image of a 
carotid endarterectomy specimen after 1 hour incubation in [18F]-RGD-K5 shows 
heterogeneous uptake along specimen. Transversal image shows that area of higher uptake 
(red) is confined within vessel wall 
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Figure7.2. Immunostaining for detection of Ov�3 integrin (A) and CD31(B) in human carotid 
endarterectomy specimens showed endothelial cells (brown) 
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Sample CD31 Integrin Segmental-
Score Score to-total 
ratio 
1 2 2 1.15 
2 2 3 1.14 
3 1 0 0.90 
4 2 1 1.68 
5 1 - 1.20 
6 1 0 1.058 
7 2 - 0.78 
8 1 - 1.06 
9 1 1 1.46 
10 2 - 1.54 
11 2 2 1.48 
12 3 2 2.62 
13 0 1 0.57 
14 0 0 0.83 
15 1 1 1.25 
16 2 1 1.12 
17 0 1 0.91 
18 0 - 0.74 
Table 7 .1 .  Semi-quantified segment-to-total accumulation of 18F-RGD-K5 PET results on 
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A new route to a strained aza-dibenzocyclooctyne has been developed. The strained 
cycloalkyne proved to react with [18F]-containing azides to give the corresponding triazoles 
in minutes. [Lys3]-bombesin was modified with the cycloalkyne and subsequently labeled 
with three [18F]-containing azides, via strain-promoted 'click' chemistry. The three resulting 
tracers proved to retain their high affinity for gastrin-releasing peptide receptors in vitro. 
Copper-free 'click' chemistry could lend some advantages to the field of radiolabeling. 
Potential contamination of labeled compounds with traces of copper is a concern when the 
classic CuAAC is used to label biomolecules. Furthermore, methodology for labeling by 
CuAAC is not amenable to extension to in vivo pretargeting methodology. To date, there has 
been one reported instance of radiochemical labeling of a peptide with [111In] for SPECT by 
a strained cyclooctyne. (Martin, 2010) Given the fast reaction parameters of the strain­
promoted azide-alkyne cycloaddition, it could be a useful means by which to label peptides 
with the short lived [18F]. 
Goal 
We envisioned the use of [lys3]-bombesin, modified with a strained alkyne, to allow for 
rapid and facile labeling with [18F] in the absence of possible copper contamination. A 
further advantage of this methodology would be the possibility to fine tune the properties of 
the resulting labeled peptide. The azide group can be designed to provide more or less 
hydrophilicity, bulk or charge to the peptide in question. The stability and in vitro binding 
affinity of the resulting tracers were to be investigated. 
Results and Discussion 
Our starting point was to find a suitable strained alkyne with the optimal balance of 
reactivity and stability. Although, as aforementioned, many options are available, some 
initial synthetic endeavors demonstrated that the synthesis of cyclooctynes is not necessarily 
trivial, nor are all of the reported cyclooctynes of appropriate stability. Van Hest and van 
Delft reported an aza-dibenzocyclooctyne, which proved to be simultaneously reactive and 
stable. ( Debets, 2009) For our purposes, which involve rapid 'clicking' of a short lived 
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radioisotope as well as eventual in vitro and in vivo studies requiring a certain degree of 




Bombesin is a 14 amino acid (Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met­
N H2) neuropeptide which binds with high affinity to the gastrin-releasing peptide receptor 
(GRPR). It has received much attention in the field of nuclear imaging as the GRPR is 
massively overexpressed on a variety of tumor cells, including breast and prostate tumor 
cells, lending it high potential as a radioligand for the diagnosis and imaging of cancer. (n 
Ananias, 2008) Much effort has been invested in the development of labeled analogues of 
bombesin. (Schroeder, 2010) Bombesin is often modified in the form of [lys3]-bombesin 
(Figure 8.1) which allows for site selective introduction of the radionuclide at the terminal 
amino group of lysine. Amino acids 7-14 are known to be essential for receptor binding, 
thus modification in the third amino acid reduces potential for interference. (Schroeder, 
2010) A variety of bombesin analogues for nuclear imaging have been synthesized, 
predominantly labeled with large metal-based radionuclides (64Cu, 1111n, 68Ga) through the 
commonly introduced chelating groups 1,4, 7, 10-tetraazacyclododecane-1,4, 7, 10-tetraacetic 
acid (DOTA) and 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA). ( Hoffman, 2009) 
Figure 8.1. [Lys3]-Bombesin 
Positron emission tomography is a nuclear imaging technique used extensively in 
diagnostic medicine and drug development. In the last decade, [18F] (t112 "'110 min) has 
been popularized as a non-metallic positron emission tomography {PET) radioisotope. With a 
longer half-life than other non-metallic radioisotopes for PET such as [11C] (t112"' 20 min) and 148 
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[13N] (t112~10 min), it has the distinct advantage of allowing for off-site production and 
transportation of the radionuclide as well as allowing for scans to be performed over several 
hours. Furthermore, due to its low positron energy, it yields images with higher resolution 
than other radionuclides. (Schirrmacher, 2007) Very few instances of [18F] labeled bombesin 
can be found in the literature, due predominantly to the synthetic challenges associated with 
the introduction of [18F] when compared with simple chelation techniques used for metallic 
radionuclides. (Zhang, 2006) Notably, the synthetic time frame is also much reduced as 
compared to metallic radionuclides such as [64Cu] (t112~12 h). A major disadvantage is the 
need for the multi-step synthetic procedures required to synthesize current prosthetic 
groups such as [18F]succinimidyl 4-fluorobenzoate ([18F]SFB) or [18F]4-fluorobenzaldehyde 
which are commonly used to introduce [18F] in the presence of a free amine. (Chang, 2005) 
Ideally, a prosthetic group should be easily synthesized, introduce the radionuclide in the 
last step of the synthesis, and should require only the mildest of conditions to attach it to 
the biomolecule of interest. Given these requirements, it was only natural that 'click' 
chemistry was utilized for the development of new prosthetic groups. 
The azide-alkyne cycloaddition has been popularized under the banner of 'click' 
chemistry since the discovery that it proceeds regioselectively at room temperature in the 
presence of catalytic Cu(I). ( Tornoe, 2002) The bioorthogonality of the azide and the 
alkyne has proven unparalleled. The robustness and versatility of this reaction along with its 
mild conditions makes it an attractive reaction for labeling target molecules with 
radionuclide containing prosthetic groups. Many groups have exploited the bioorthogonality 
of this reaction to allow for fast and straightforward labeling of sugar and peptide targets 
with [18F] and other radionuclides. (Hausner, 2008) The obvious limitation of this 
methodology for biological systems is the cytotoxicity of copper. Potential contamination of 
labeled compounds with traces of copper is a major drawback and it is not suitable for 
development of in vivo pre-targeting methodologies. In recent years, great strides have 
been made in developing copper-free chemistry through, amongst others, the use of 
strained cyclooctynes (Sletten, 2010) and in one instance has been used for the introduction 
of [111In] to a target peptide for SPECT imaging. (Martin, 2010) We envisioned the use of 




[18F] in the absence of possible copper contamination. A further advantage of this 
methodology would be the possibility to fine tune the properties of the resulting labeled 
peptide. The azide group can be designed to provide more or less hydrophilicity, bulk or 
charge to the peptide in question. Furthermore, though we focus in this work on the use of 
bombesin, we would hope that the technique would be amenable to the use of other 
biomolecules as well. We present here the first instance of [18F]-radiolabelling using copper­
free 'click' chemistry, and its application to the synthesis of a [18F]-labeled analogue of 
bombesin, a potent ligand for tumor imaging. We further demonstrate that the 'click' 
radiolabelling does not compromise the GRP receptor in vitro binding affinity in human 
prostate cancer cells. 
Material and method 
General 
All reactions were carried out in oven dried glassware unless otherwise specified. 
Lys[3]-bombesin was purchased from Sigma-Aldrich and used as received as were all other 
chemicals unless specified otherwise. 1H- and 13C-NMR spectra were recorded on a Varian 
AMX400 ( 400 and 100.59 MHz) using CDCl3 as solvent unless otherwise indicated. Chemical 
shift values are reported in ppm with the solvent resonance as the internal standard (CHCh: 
o 7.26 for 1H and o 77.0 for 13C). Data are reported as follows: chemical shifts, multiplicity 
(s=singlet, d=doublet, t=triplet, q=quartet, dd=doublet of doublets, dt=doublet of triplets, 
td=triplet of doublets, m=multiplet, br=broad), coupling constants (Hz), and integration. 
Flash chromatography was performed on silica gel. All thin layer chromatography was 
performed on Merck F-254 silica gel plates. Visualization of the TLC plates was performed 
with KMnO4 staining reagent and UV light (254 nm). Mass spectra were recorded on an AEI­
MS-902 mass spectrometer by EI (70 eV) measurements. Melting points are uncorrected. 1H 
and 13C NMR data are provided for all synthesized compounds. Spectra were in accordance 
with published experimental data and references are provided for known compounds. HRMS 
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mass data is provided for all new compounds. Reversed phase-HPlC analyses were 
performed on a Shimadzu lC-20AD VP, Waters Xterra MS C18 column (3.0 x 150 mm, 
partciel size 3.5 µm) using a gradient of MeCN/H2O (0.1 % formic acid) at a flow of 0.5 
ml/min. 
Safety 
Working with azides should always be done carefully. Organic azides, particularly those 
of low molecular weight, or with high nitrogen content, are potentially explosive. Heat, light 
and pressure can cause decomposition of the azides. Furthermore, the azide ion is toxic, 
and sodium azide should always be handled while protected with gloves. Heavy metal azides 
are particularly unstable, and may explode if heated or shaken. 
Characterization of substrates and reference compounds 
SH-dibenzo[7]annulen-S-one oxime (2) 
A solution of hydroxylamine was prepared by dissolving 15.6 g (0.22 mol, 3.1 eq) of 
NH2OH· HCI in a hot mixture of absolute alcohol (100.0 ml) and pyridine (75.0 ml). To this 
solution was added 15.0 g (0.073 mmol, 1.0 eq) of dibenzosuberenone and 20.0 ml of 
pyridine. The reaction mixture was heated at reflux for three hours, and the disappearance 
of starting material was monitored by thin layer chromatography. After completion of the 
reaction, the solvent was evaporated under reduced pressure, and the product was 
precipitated with water. The solid was filtered, washed with water (3 x 50 ml), dissolved in 
chloroform, and the organic layer was washed one further time with water. The organic 
layer was dried over Mg5O4 and the solvent evaporated to yield a pale yellow solid (15.3 g). 
Yield=95 %. mp 187 °c. 1H NMR (400 MHz, CDCl3) :  5 10.10 (s, 1H), 7.67 (m, 1H), 7.57 (m, 
1H), 7.28-7.37 (m, 6H), 6.86 (dd, ]=28.0, 4.0 Hz, 2H); 13C NMR (100.59 MHz, CDCl3) :  
156.3, 135.4, 134.5, 133.8, 130.8, 130.6, 130.5, 129.4, 129.2, 129.1, 128.9 (2C), 128.8, 





Trichlorotriazine (834.0 mg, 4.52 mmol) was added to 1.0 ml DMF in a sample vial. The 
solution was stirred, and white precipitate formed. The formation of the catalyst was 
monitored by thin layer chromatography until all of the TCT had been consumed. To this 
solution was added oxime 2 along with 10.0 ml DMF. The reaction mixture was stirred at 
room temperature for 24-72 h (depending on the amount of oxime in a given reaction). 
DMF was added if needed in cases where no solvent remained (depending on the scale of 
the reaction). The reaction was quenched with water and DCM was added to the solution. 
The organic phase was washed with saturated aqueous Na2CO3 (2 x 10 ml), 1 N aqueous 
HCI (2 x 10 ml) and brine (2 x 10 ml). The organic layer was dried over Mg5O4 and the 
solvent was removed under reduced pressure. The crude reaction mixture was purified by 
column chromatography (3 : 1 pentane:ethyl acetate, Rt : 0.65) to give a pale yellow solid 
(650.0 mg). Yield=65 %. mp 141-142 °c. 1H NMR (400 MHz, CDCl3) :  5 8.76 (s, 1 H), 7.70-
7.72 (m, lH), 7.57-7.60 (m, lH), 7.42-7.51 (m, 6H), 6.96 (s, 2H); 13C NMR (100.59 MHz, 
CDCl3) : 163.5, 134.3, 133 .0, 130.4, 130.2, 129.7, 129 .5, 129.2, 129.0, 128.7, 128.5, 128.0, 
127.7. HRMS (ESI+) (m/z) calculated for C15H12NO [M + Ht 222.0913, measured 222.0901 .  
5,6-dihydrodibenzo[b,f]azocine ( 4) 
Amide 3 (2.00 g, 9.0 mmol) was dissolved in 25.0 ml dry CH2Cl2 and 45.0 ml of a 1.0 
M solution of Dibal-H in CH2Cli was added dropwise to the solution at room temperature 
with stirring. The reaction mixture was stirred under N2 at room temperature and the 
conversion followed by thin layer chromatography until all of the starting material was 
consumed. The reaction was then carefully quenched with an aqueous solution of 
ammonium chloride. An aqueous solution of Rochelle salts was subsequently added and the 
mixture was stirred vigorously for 45 min. A further 50 ml of DCM was added and the 
organic layer collected and washed with brine. After drying over Mg5O4 the solvent was 
removed under reduced pressure to yield a yellow oil which was purified by column 
chromatography (2 : 1 pentane:ethyl acetate, Rt: 0.8). The resulting compound was a yellow 
solid (1.40 g). Yield=75 %. 1H NMR (400 MHz, CDCl3) :  5 7.24-7.62 (m, 1 H), 7. 16-7.24 (m, 
3H), 6.97 (d, J=8.0 Hz, lH), 6.88 (t, J=8.0 Hz, lH), 6.60 (t, J=7.2 Hz, lH), 6.54 (d, J=12.8 
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Hz, 1H), 6.47 (d, ]=8.4 Hz, 1H), 6.36 (d, ]=13.2 Hz, 1H), 4.59 (s, 2H), 4.29 (br s, 2H); Be 
NMR (100.59 MHz, CDC'3) :  147.1, 138.1, 136.2, 134.7, 132.7, 130.1, 128.8, 127.9, 127.6, 
127.4, 127.3, 121.7, 117.9, 117.7, 49.6. 
Methyl 4-{ dibenzo[b,f]azocin-5{6H)-yl)-4-oxobutanoate {5) 
Amide 4 (2.00 g, 9.65 mmol) was dissolved in 25.0 ml dry DCM under a N2 atmosphere. To 
the stirred solution was added triethylamine (2.67 ml, 19.3 mmol) and the mixture cooled 
to O °C whereupon methyl succinyl chloride (1.78 ml, 14.4 mmol) was added dropwise. The 
reaction was allowed to warm to room temperature, and stirred overnight. The reaction 
mixture was quenched with water and the mixture diluted with a further 20.0 ml of DCM. 
The organic layer was washed with 2 M aqueous NaOH (2 x 15 ml), 2 M aqueous HCI (2 x 
15 ml), water (2 x 15 ml) and brine (1 x 10 ml). The organic layer was dried over Mg5O4 
and the solvent was removed under reduced pressure. The resulting crude product was 
purified by column chromatography ( 4: 1 pentane:ethyl acetate, Rf: 0.4) to yield a yellow­
white solid (2.70 g). Yield=87%. mp 108 °c. 1H NMR (400 MHz, CDCl3) :  5 7.24-7.26 (m, 
SH), 7.12-7.16 (m, 3H), 6.79 (d, J=17.2 Hz, 1H), 6.61 (d, J=17.2 Hz, 1H), 5.51 (d, J=20.0 
Hz, 1H), 4.25 (d, J=20.8, 1H), 3.61 (s, 3H), 2.55-2.60 (m, 1H), 2.39-2.48 (m, 2H), 1.99-
2.10 (m, 1H); Be NMR (100.59 MHz, CDCl3) :  177.4, 170.8, 140.5, 136.4, 135.8, 134.5, 
132.6, 131.8, 130.8, 130.1, 128.5, 128.2, 128.0, 127.2, 126.9, 54.4, 51.6, 29.5, 29.0. HRMS 
(ESI+) (m/z) calculated for C20H19NO3 [M + Nat 344.1257, measured 344.1250. 
Methyl4-{11,12-dibromo-11,12-dihydrodibenzo[b,f]azocin-5{6H)-yl)-4-
oxobutanoate (6) 
Compound 5 (1.87 g, 5.82 mmol) was dissolved in dry CH2Ch (100.0 ml) under a N2 
atmosphere and the reaction vessel was cooled to O 0C.Br2 (0.93 g, 5.82 mmol) dissolved in 
5.0 ml of dry CH2Ch was added dropwise to the cooled solution and the reaction mixture 




saturated Na25O3 (10 ml) and the mixture diluted with a further 50.0 ml of CH2Cl2• The 
organic layer was washed with saturated aqueous Na25O3 (3 x 15 ml), water (2 x 15 ml) 
and brine (1 x 15 ml). The organic layer was dried over Mg5O4 and the solvent was 
removed under reduced pressure. The compound was purified by column chromatography 
(3 : 1 pentane:ethyl acetate, Rf: 0.3) to yield a dark solid (2.46 g). Yield=88%. mp 108 °c. 
1H NMR (400 MHz, CDCl3) :  5 7.70 (d, J=7.6 Hz, 1H), 7.00-7.25 (m, 6H), 6.86 (d, J=7.6 Hz, 
1H), 5.90 (d, J=9.6 Hz, 1H), 5.80 (d, J=14.8 Hz, 1H), 5.15 (d, J= lO.0 Hz, lH), 4.17 (d, 
J =14.8 Hz, 1H), 3.66 (s, 3H), 2.80-2.86 (m, 1H), 2.57-2.64 (m, 2H), 2.43-2.55 (m, 1H). 13C 
NMR (100.59 MHz, CDCl3) :  173.5, 172.0, 138.3, 137.0, 136.9, 132.8, 130.8, 130.7, 130.6, 
129.6, 129.5, 128.9, 128.8, 128.6, 60.0, 55.5, 52.5, 51.7, 30.6, 29.2. HRMS (ESI+) (m/z) 
calculated for C20H19Br2NO3 [M + Nat 503.9603, measured 503.9606. 
Methyl 4-(11,12-didehydrodibenzo[b,f]azocin-5(6H)-yl)-4-oxobutanoate 
(7) 
To a cold solution (-40 °C) of compound 6 (245.0 mg, 0.512 mmol) dissolved in 17.0 
ml freshly distilled THF under Ar atmosphere was added dropwise 1.02 ml of a commercial 
solution of tBuOK (1.0 M in THF). The progress of the reaction was monitored by GC-MS. 
After 3 h, a further 0.4 ml of tBuOK solution was added and the mixture left to react for a 
further hour. The mixture was poured onto water (15 ml) and extracted with CH2Cl2 (3 x 30 
ml). The combined organic layers were washed with brine (2 x 25 ml) and water (1 x 10 
ml). A mixture of methyl ester, and tert-butyl ester products were detected in the crude 1H 
NMR. The desired methyl ester product was isolated by column chromatography (3 :1 
pentane:ethyl acetate, Rf: 0.2) to give a clear yellow oil (109.5 mg). Yield=67 %. 1H NMR 
(400 MHz, CDCl3) :  5 7.68 (d, J=7.2 Hz, 1H), 7.48-7.50 (m, 1H), 7.27-7.49 (m, 6H), 5.16 (d, 
J=14.0 Hz, 1H), 3.67 (d, J=13.6 Hz, 1H), 3.56 (s, 3H), 2.68-2.74 (m, 1H), 2.58-2.63 (m, 
1H), 2.35-2.38 (m, lH), 1.93-1.97 (m, 1H). 13C NMR (100.59 MHz, CDCl3) :  5 173.3, 171.7, 
151.4, 148.0, 132.3, 129.3, 128.8, 128.5, 128.1, 127.7, 127.1, 125.5, 123.1, 122.6, 114.9, 
107.7, 55.4, 51.6, 29.6, 29.0. HRMS (ESI+) (m/z) calculated for C20H17NO3 [M + Nat 
342.1101, measured 342.1102. 
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4-(11,12-Didehydrodibenzo[b,f]azocin-5(6H)-yl)-4-oxobutanoic acid (8) 
Compound 7 (42.5 mg, 0.13 mmol) was dissolved in 1.7 ml dry THF. A solution of LiOH 
(6.4 mg, 0.26 mmol) in 0.6 ml H2O was added dropwise to the stirred reaction mixture. The 
progress of the reaction was monitored by thin layer chromatography and upon full 
conversion, a further 6.0 ml of H2O was added. The reaction mixture was then made basic 
to a pH of 14 using 2 M aqueous NaOH. The water layer was washed with CH2Cl2 (3 x 10 
ml) and then acidified to a pH of 2 using 2 M aqueous HCI. The aqueous layer was then 
extracted with CH2Clz (3 x 15 ml) and the resulting organic layers of this extraction 
procedure were combined, dried over Mg5O4 and the solvent was removed under reduced 
pressure. Pure product was obtained as a white solid (30.6 mg). Yield= 77 %. mp 163-164 
0c. 1H NMR (400 MHz, CDCl3) :  5 7.67 (d, J=7.2 Hz, 1H), 7.25-7.43 (m, 7H), 5.16 (d, 
J=13.6 Hz, 1H), 3.67 (d, J=13.6 Hz, 1H), 2.68-2.74 (m, 1H), 2.56-2.63 (m, 1H), 2.32-2.40 
(m, 1H), 1.94-2.00 (m, lH). 13C NMR (100.59 MHz, CDCl3) :  5 177.8, 172.6, 151.2, 147.9, 
132.5, 129.3, 128.7, 128.5, 128.1, 127.6, 127.4, 125.8, 123.2, 122.9, 115.3, 107.7, 55.9, 




Carboxylic acid 8 (26.0 mg, 0.085 mmol) was dissolved in 5.0 ml dry CH2Cl2• To this 
solution was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (0.02 ml, 0.094 
mmol) and N-hydroxysuccinimide (10.8 mg, 0.094 mmol). The reaction mixture was allowed 
to stir overnight at room temperature after which time it was diluted with a further 10 ml of 
CH2Clz. The reaction mixture was washed with citric acid (5 %, 2 x 5 ml) and with saturated 
aqueous NaHCO3 (2 x 5 ml) and brine (1 x 10 ml). The compound was then purified by 
column chromatography (1 :1 pentane:ethyl acetate, Rr: 0.5) to yield the pure compound as 
a yellow oil (28.0 mg). Yield=82 %. 1H NMR (400 MHz, CDCl3) :  5 7.68 (d, J=7.6 Hz, 1H), 
7.24-7.41 (m, 7H), 5.17 (d, J=14.0 Hz, 1H), 3.69 (d, J=14.0 Hz, 1H), 2.92-2.99 (m, 1H), 
155 
Chapter 8 
2.72-2.77 (m, lH), 2.78 (s, 4H), 2.61-2.68 (m, lH), 2.05-2 .10 (m, lH). Be NMR (100.59 
MHz, CDC'3) :  6 172.6, 170.2, 168.9, 168.3, 151.0, 147.8, 132.3, 129.1, 128.6, 128.3, 127.8, 
127.2, 125 .5, 123 .0, 122.7, 115.0, 107.5, 55.6, 29.2, 26.4, 25.5 .  HRMS (ESI+) (m/z) 
calculated for C23H18N2O5 [M + Nat 425.1108, measured 425 .1121. 
1-(Azidomethyl)-4-fluorobenzene. 
To a stirred solution of 1-(bromomethyl)-4-fluorobenzene ( 472.6 mg, 2 .5 mmol) in a 
water/acetone mixture (1 :4) was added NaN3 (1.5  eq). The resulting suspension was stirred 
at room temperature for 24 h. DCM was added to the mixture and the organic layer was 
separated. The aqueous layer was extracted with DCM (3 x 10 ml) and the combined 
organic layers were dried over Mg5O4 • Solvent was removed under reduced pressure to give 
the product as a pale yellow oil, sufficiently pure to use without further purification (374.0 
mg). Yield= 99%. Spectroscopic data is in accordance with literature values. 1H NMR ( 400 
MHz, CDCl3) :  6 7.27-7.39 (m, 2H), 7.00-7.11 (m, 2H), 4 .30 (s, 2H); Be (100.59 MHz, 
CDCl3) :  6 162.5 (d, J=130.7 Hz), 131.4, 129.9 (d, J=  45.2 Hz), 115.7 (d, J = l l0.0 Hz), 54.0; 
19F NMR (200 MHz, CDC'3) :  6 -112.3. 
Methyl 4-( 1-( 4-fluorobenzyl)-1 H-di benzo[ b, f] [ 1,2,3 ]triazolo[ 4,5-
d]azoci n-8(9 H-yl)-4-oxobuta noate (10) 
To a solution of aza-dibenzocyclooctyne 9 (80 mg, 0.25 mmol) dissolved in 5.0 ml 
CH2Ch was added 1-(azidomethyl)-4-fluorobenzene (57 mg, 0 .38 mmol). The reaction 
mixture was allowed to stir for 1 h at room temperature, after which the solvent was 
evaporated and the crude product was purified by column chromatography (1 :1 
pentane:ethyl acetate) to yield the product as a white solid (94.1 mg). Yield=80 %. Two 
isomers are formed as determined by 1H NMR (1 :1). 1H NMR (400 MHz, CDCl3) :  6 7.67-7.73 
(m, lH), 7.44-7.49 (m, 2H), 7.38-7.42 (m, l H), 7.24-7 .31 (m, lH), 7.17-7.24 (m, 2H), 6.93-
7.10 (m, SH), 5 .99 (d, J=16.9 Hz, lH), 5 .58 (s, 2H), 4.33 (d, J=16.9 Hz, lH), 3.60 (s, 3H), 
2.44 (m, lH), 2.23 (m, lH), 2.09 (m, lH), 1.80 (m, lH).  Be NMR (100.59 MHz, CDCl3) :  
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6173.2, 171.3, 163.7, 161.3, 143.1, 140.0, 135.9, 134.9, 131.8, 131.2, 130.7, 128.9, 129.6, 
129.3, 129.1, 129.0, 127.9, 127.1, 124.3, 116.0, 115.8, 52.0, 51.6, 51.4, 29.2, 28.9. HRMS 
(ESI+) (m/z) calculated for C27H23N4O3F [M + Ht 471.1827, measured 471.1789; (ESI+) 
(m/z) calculated for C27H23N4O3F [M + Nat 493.1646, measured 493.1606. 
Peptide Chemistry 
Aza-DBCO-BN 
[lys3]-bombesin (0.18 mg, 1.0 eq) was weighed into a 2.0 ml Eppendorf tube along 
with 9 (0.5 mg, 5.0 eq). 200 µl of dry DMF and 10.0 eq of diisopropylethyl amine were 
added and the resulting solution was stirred at room temperature for 24 h. The solvent was 
removed by lyophilization. Full conversion of lys[3]-bombesin could be observed by RP­
HPlC. The product was purified by preparative RP-HPlC yielding Aza-DBCO-BN in 25 % 
yield. Retention time=32.0 min. HRMS (ESI+) (m/z) calculated for C90H123N23O205 [M + Ht 
1878.9108, measured 1878.9078. 
Radiochemistry General 
[18F] fluoride was obtained by proton bombardment of an [180] enriched water target 
via the 18O(p,n)18F reaction. The radioactivity was trapped by passing the target water 




( 4.5 mg) and Kryptofix 222 (20 mg) was used to elute the [18F]-fluoride from the cartridge 
into a conical glass vial. This eluate was evaporated to dryness by three consecutive 
azeotropic distillations after with acetonitrile (3 x 500 µL) under a gentle stream of nitrogen 
gas (130 °C). Analytical as well as semipreparative RP-HPLC was performed for monitoring 
and purification. Isolation of radiolabeled peptides was performed using a reversed-phase 
RP-C18 column (4.6 mm x 250 mm, 10 µm). The flow was set at 2.5 ml/min using a 
gradient system starting from 90% solvent A (0.01 M phosphate buffer, pH=6.0) and 10% 
solvent B (acetonitrile) (0-2 min) and ramped to 45% solvent A and 55% solvent B at 35 
min. The analytic HPLC was performed using the same gradient system but with a reversed­
phase Grace Smart RP-C18 column (4.6 mm x 250 mm, 5 µm) and a flow of 1 ml/min. 
Results and Discussion 
Synthesis and radiolabelling 
The reaction with cyclooctyne modified bombesin was performed in DMF at room 
temperature and proceeded to completion in 15 min. The resulting tracer was also purified 
by RP-HPLC yielding the desired triazole tracers: [18F]-BnTOxBN (retention time=16 min), 
[
18F]-BuTOxBN (retention time=19 min) and [18F]-PEGTOxBN (retention time=22 min) 
with radiochemical yields of 31 %, 37% and 19%, respectively. The specific activities were 
62 GBq/µmol, 57 GBq/µmol , 60 GBq/µmol. 
Cell culture. 
The GRPR-positive PC-3 human prostate cancer cell line (ATCC, Manassas, Virginia, 
USA) was cultured at 37 °C in a humidified 5 % CO2 atmosphere. The cells were cultured in 
RPMI 1640 (Lonza, Verviers, France) supplemented with 10 % fetal calf serum (Thermo 
Fisher Scientific Inc., Logan, Utah, USA) and subcultured twice a week after detaching with 
trypsin-EDT A. 
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In Vitro Competitive Receptor-Binding Assay. 
In vitro GRPR binding affinities and specificities of BN(l-14) were assessed via a 
competitive displacement assay. Experiments were performed with PC-3 human prostate 
cancer cells according to a method previously described. ( Schroeder, 2008) The 50% 
inhibitory concentration (IC50) values were calculated by fitting the data with nonlinear 
regression using GraphPad Prism 5.0 (GraphPad Software, San Diego, California, USA). 
Experiments were performed with triplicate samples. Results were plotted in sigmoidal 
curves for the displacement of [18F]-BnTOxBN, [18F]-BuTOxBN and [18F]-PEGTOxBN 
as a function of increasing concentration of BN(l-14). The tracers displayed high affinity for 
binding to GRPRs within PC-3 cell with IC50 values of 29 nM , 30 nM and 40 nM for [
18F]­
BnTOxBN, ( Figure 8.1) [18F]-BuTOxBN, (Figure 8.2) and [18F]-PEGTOxBN, ( Figure 
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Figure 8.3. Competitive Binding Assay on PC-3 cells with [18F]-PEGTOxB 
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Octanol/Water Partition Coefficient Study. 
Water partition coefficients were determined at pH =7.4. 5 µL containing 500 kBq of the 
radiolabeled compound in PBS was added to a vial containing 1.2 ml 1-octanol and PBS 
(1 :1). After vortexing for 1 min, the vial was centrifuged for 5 min at 10 000 rpm to ensure 
complete separation of layers. Then, 40 µL of each layer was taken in a pre-weighed vial 
and measured in the y-counter. Counts per unit weight of sample were calculated. The lop P 
values were found to be 1.27, 0.26 and -0.43 for [18F]-BnTOxBN, [18F]-BuTOxBN and 
[18F]-PEGTOxBN, respectively. 
Our starting point was to find a suitable strained alkyne with the optimal balance of 
reactivity and stability. Van Hest and van Delft reported an aza-dibenzocyclooctyn 7, which 
proved to be simultaneously reactive and stable (Debets, 2009). For our purposes, which 
involve rapid 'clicking' of a short lived radioisotope and eventual in vitro and in vivo studies, 
it appeared an ideal choice. We opted for an alternate and shorter synthetic route to our 
target molecule 9 (Scheme 8.1). Starting from commercially available dibenzosuberenone 1, 
oxime 2 can be formed in 95% yield by refluxing in the presence of hydroxylamine 
hydrochloride. The crucial step of this synthesis is the subsequent Beckmann rearrangement 
giving amide 3 in 67% yield. (Luca, 2002) The amide was reduced with Dibal-H to amine 4. 
Amine 4 is thus reached in three steps, rather than five, starting with the very inexpensive 
precursor 1 (lg~l €) rather than 2-ethynylaniline (lg~SS €) as published. A short linker 
can be introduced by reaction of 4 with methyl succinyl chloride in the presence of 
triethylamine. Bromination proceeds smoothly in 88% yield, followed by subsequent 
debromination with a solution of potassium tert-butoxide in THF. Basic hydrolysis affords 
carboxylic acid 8. To allow us to couple the strained alkyne to our peptide, we form the 
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Scheme 8.1. Reagents and conditions: a) NH2OH· HCI (3.0 eq), pyridine/ethanol (1:1), 
reflux; b) TCT (1.0 eq), DMF, r.t. ; c) Dibal-H (5.0 eq), CH2Cli, r.t.; d) Et3N (2.0 eq), methyl 
succinyl chloride (1.5 eq), CH2Cli, r.t. ; e) Br2 (1.0 eq), CH2Cl2, 0 °c; f) 1.0 M tBuOK in THF, 
THF, -40 °c, Ar atm.; g) LiOH (2.0 eq), H2O, r.t.; h) EDC (1.1 eq), NHS (1.1 eq), CH2Cl2, 
r.t.; TCT= trichlorotriazine, DMF= dimethylformamide, Dibal-H= diisobutyl aluminum 
hydride, THF= tetrahydrofuran, EDC= N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide, 
NHS= N-hydroxysuccinimide. 
Of key importance to the field of radiochemistry is high reactivity, allowing for the rapid 
introduction of the short-lived radiolabel under biocompatible conditions. Before proceeding 
with the modification of bombesin, we tested the reactivity of the aza-benzocylooctyne with 
several fluorine containing azides in pseudo in vivo conditions (Scheme 8.2). Strained alkyne 
7 could be reacted with a [18F]-labeled azide by simply stirring the two reactants together in 
a mixture of human plasma and DMSO. We found that alkyne 7 could be fully converted to 
the corresponding triazoles within 15 min. With the hydrophilic [18F]-PEGylated azide 10, 
triazole 11 was isolated with a radiochemical yield (RCY) of 42 %. With the more lipophilic 
[18F]-fluorobenzyl azide 12, product was isolated with an RCY of 31 %. Furthermore, it is 
key to note that the reaction is performed in human plasma. Considering the eventual 
application of radiolabelling in vivo, it was important to confirm that the selected strained 
alkyne was not too fragile to withstand any exposure to a biological environment. Given that 
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with alkyne 7 full conversion to triazoles in less than 15 min could be achieve, we 
concluded that the reaction was fast enough for the desired time scale for labeling with 
[1BF]. 
37 °C, 15 min J
�a 
plasma/DMSO 
10, 1 .0 eq 





11 ,  RCY=42 % 
� 
37 •c, 15 min 
plasma/DMSO .. 
1 2, 1 .0 eq 
13, RCY=31 % 
Scheme 8.2. Strain-promoted 'click' chemistry for labelling with [18F]. 
Thus, succinimidyl ester 9 was conjugated to lys[3]-bombesin under basic conditions 
(Scheme 8.3). Full conversion to the product Aza-DBCO-BN was achieved after 24 h as 
determined by RP-HPLC, and subsequently Aza-DBCO-BN was purified by RP-HPLC and 
characterized by mass (ESI-MS). With the target bombesin analogue modified with a 
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Scheme 8.3. Modification of bombesin with 9. 
Three [18F]-containing azides were selected to react with Aza-DBCO-BN (Scheme 4). 
As indicated, one advantage of this methodology is the ease with which the properties of 
the resulting peptidic tracer can be modified by simply changing the azides. [18F]-PEGylated 
azide 10, [18F]-fluorobenzyl azide 12 and [18F]-fluoroazidobutane 14 were reacted with 
Aza-DBCO-BN at room temperature in DMF for 15 min, during which time complete 
conversion of the starting material could be detected by radio-TLC to give triazoles [18F]­
PEGTOxBN (15), [18F]-BnTOxBN (16) and [18F]-BuTOxBN (17), respectively. The 
logarithmic partition coefficients were determined for all three tracers and were found to be 
-0.43, 1.27 and 0.26, respectively. This provides us with tracers ranging from the quite 
hydrophilic [18F]-PEGTOxBN to the more hydrophobic [18F]-BnTOxBN. 
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The binding affinity of all three tracers for gastrin-releasing peptide receptors was 
tested using PC3 human prostate cancer cells. The in vitro binding was determined by 
performing a competitive receptor binding assay with the receptor specific radioligand 
[125I]-tyr[4]-BN (a displacement assay). The 50 % inhibitory concentrations (IC50) were 
determined to be 40 nM, 29 nM and 30 nM for 15, 16, and 17, respectively (Figure. 8.3). 
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Scheme 8.4. Aza-dibenzycyclooctyne modified bombesin labeled with various [ 18F]­




Thus we were able to achieve rapid radiolabel ling of bombesin with [18F] using a very 
straightforward protocol. Simple stirring of the radionuclide-containing azide with the 
modified bombesin analogue for 10-15 min at room temperature suffices to reach the target 
peptides in modest to good yields. Furthermore, the azide can be readily varied, as we have 
shown from a more l ipophilic aromatic azide to a hydrophilic PEGylated azide. As a result, 
peptides with different properties are readily accessible from the same modified peptide 
al lowing for rapid modification and fine tuning. In this way, the optimal l ipophil icity for 
cel lular uptake and metabolic clearance can be achieved. To the best of our knowledge, 
this is the first example of [18F]-radiolabelling using copper-free click chemistry. We have 
also developed a simplified and relatively inexpensive route to the target aza­
dibenzocyclooctyne hopefully rendering it more accessible for future use in a clin ical setting. 
Although we describe herein the modification and labell ing of bombesin and demonstrate 
that it maintains high affinity for the targeted receptors, ideal ly, this methodology would be 
applied to imaging via pre-targeting. For molecules with longer pharmacokinetics such as 
antibodies, and thus not amenable to the use of the short-lived [18F], it would be highly 
advantageous to be able to administer the [18F] radionuclide to the target in vivo. In this 
way, the use of radionuclides for imaging such targets will not be limited to the longer-l ived 
metal l ic radioisotopes, and higher resolution images can be achieved using [18F] . Studies 
along these lines wil l  be reported in due course. 
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There is a huge need for specific PET-radiopharmaceuticals. The discipline of 
radiochemistry involves a set of unique challenges that the chemist must consider: short 
synthetic time frames (as the radionuclide is constantly decaying), very small amounts of 
radioactive reagents, and limited available methods of characterization. Superimposed on 
these challenges is the stringent requirement that the products be consistently pure and 
that the results be reproducible as ultimately the protocols may be used to prepare 
compounds for injection in patients. Therefore new radiochemistry needs to be developed. 
In this thesis, the preparation of several receptor binding ligands is described via the 1,3-
dipolar cycloaddition of azides and alkynes, also called a click reaction for [18F]­
radiolabelling of Positron Emission Tomography (PET). The work described in this thesis 
meets the challenges in radiochemistry that are focused on: 
Short synthesis time 
Very small amount of reagents 
Easy and reliable synthesis 
Versatility of the labeling method. 
Therefore the copper-catalyzed 1,3-dipolar cycloaddition of alkynes and azides (CuAAC) 
and the copper-free cycloaddition promoted by ring strain have proven to be both reliable 
and orthogonal ligation methods. The CuAAC reaction meets the challenges mentioned 
above such as being fast; it can be applied under a wide range of conditions, and is 
selective. In a field where simple and fast reactions are crucial, it is only normal that "click" 
chemistry emerged as an excellent radiolabeling technique. 
Throughout this thesis, two main goals were pursued: The first is to develop click chemistry 
methodology for the synthesis of PET tracers with focus on 18F as radionuclide and the 
second part was to apply click chemistry for the synthesis and evaluation of biologically 
active molecules. 
In chapter 3, we performed 1,3-dipolar cycloadditions in the presence of copper(!) and 
we optimized our radiolabeling procedure to reach high radiochemical yields (RCY). In 
addition we accelerated the CuAAC reaction by the addition of MonoPhos ligand. MonoPhos, 
a simple phosphoramidite ligand, which had the effect of significantly reducing reaction 
times in combination of very low amounts of reagents. Conjugation of [18F]fluoroalkynes to 
various amounts (> 0.01 mg) of acetylenes or azide via Cul mediated 1,3-dipolar 
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cycloaddition yielded the desired 18F-labeled triazole products in 10 min with yields of 54-
99% and excellent purity radiochemical purity (97-99%). The total synthesis time was 30 
min from the end of bombardment. In conclusion, a highly versatile fast ligand-accelerated 
copper catalyzed click reaction for the introduction of 18F was developed. 
In chapter 4, we described a new PET tracer for cerebral beta-adrenergic receptors 
based on the 18F-click methodology described in chapter 3. (Scheme 9.1) This work focused 
on exploiting the selectivity of the CuAAC by combination with an enzymatic transformation. 
A racemic epoxide can be stereoselectively ring opened with an azide to produce 
azidoalcohols. 'Click chemistry' was successfully applied to the synthesis of 18F-fluorination of 
(R)-1-( (9H-carbazol-4-yl)oxy)-3-4( 4-( (2-(2-(fluoromethoxy)-ethoxy)methyl)-lH-1,2,3-triazol-
1-yl)propan-2-ol (18F-FPTC) resulting in excellent radiochemical yields purity (97-99%). A 
tracer based on the new motif �-hydroxytriazole design was synthesized reteining its affinity 
for cerebral �-adrenergic receptors (AR). FPTC demonstrated high in vitro binding affinity 
for the �-AR. The high affinity (IC 50 = 50-60 nM) and moderate lipophilicity (logP +2.48 ) 
as important criteria predict the suitability of a the compound for in vivo imaging. However 
the ex vivo biodistribution and microPET images showed that these criteria proved 
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Scheme 9.1. Synthesis of 18F-FPTC 
Click reaction 
CuS04, Na ascorbate 
Monophos 
In the study described in chapter 5, we developed a modified bombesin, a peptide 
which has a high affinity for the gastrin releasing peptide receptor (GRPR) which is 
particularly overexpressed on several kind of tumor cells, such as prostate cancer. Bombesin 
is a 14 amino acid peptide sequence peptide. Amino acids 7-14 are considered to be the 
sequence responsible for binding to the GRP-receptor. We used the 1,3-dipolar cycloaddition 
to label the peptide modified at the [lys3]-position. A terminal alkyne was attached to the 
[Lys3] residue of the 14 amino acid peptide sequence, where [18F] was readily introduced 
using a complementary azide. ( Scheme 9.2) The tracer proved to have good in vitro 
properties. But preclinical data demonstrated that no tumor uptake could be measured. 
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In chapter 6, we focused on the synthesis of the Siemens imaging biomarker 18F-RGD­
KS. This cyclic peptide contains an amino acid sequence which is a well known binding motif 
for integrin !l:'v�3 involved in cellular adhesion to the extracellular matrix. We developed an 
improved "click" chemistry method using Cu(I)-Monophos as catalyst to conjugate 
[
18F]fluoropentyne to the RGD-azide precursor yielding 18F-RGD-KS. (Scheme 9.3) A 
comparison is made with the registered Siemens method with respect to synthesis, I purification and quality control. [18F]RGD-KS was obtained after 75 min overall synthesis time with an overall radiochemical yield of 35% (EOB). The radiochemical purity was > 98 
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Scheme 9.3. A) Production of 5-[18F]fluoro-1-pentyne: nucleophilic substitution between 
pentynyl tosylate and anhydrous [18F]fluoride in ortho-dichlorobenzene (a-DCB). B) 
MonoPhos Cu(I)-catalysed Huisgen cycloaddition of [18F]fluoropentyne with the RGD-KS 
azide precursor resulting in the 1,4-disubstituted triazole [18F]RGD-K5. 
In chapter 7, for the first time demonstrated the potential of integrin imaging in 
determination of angiogenesis and vulnerability in atherosclerotic plaques. Noninvasive 
imaging and quantification of angiogenesis could provide clinicians with a new tool in 
stratifying risk for cardiovascular events. The QC system has been validated and allows the 
tracer to be used in clinical studies for visualization of neoangiogenesis in oncological 
patients in our hospitals. 
In chapter 8, we were able to achieve rapid radiolabelling of bombesin with [18F] using 
a very straightforward protocol using copper-free click conditions. Simple stirring of the 
radionuclide-containing azide with the modified bombesin analogue for 10-15 min at room 
temperature sufficed to reach the [18F]-target peptides in modest to good yields. 
Furthermore, the azide can be readily varied, as we have shown, from a more lipophilic 
aromatic azide to a hydrophilic PEGylated azide. (Scheme 9.4) As a result, tracers with 
different properties are readily accessible from the same substrate allowing for rapid 
modification and fine tuning. In this way, the optimal lipophilicity for cellular uptake and 
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metabolic clearance can be achieved. Although we describe herein the modification and 
labelling of [lys3]-bombesin and demonstrate that it maintains high affinity for the targeted 
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Scheme 9.4. Aza-dibenzycyclooctyne modified bombesin labeled with various [18F]­
bearing 
Azides. Reagents and conditions: a) K[18F], MeCN, 110 °c; b) DMF, r.t. 
175 
Chapter 9 
In conclusion Click chemistry is a highly valuable approach for biomedical application. 
One of the unique and important properties of click chemistry is its bio-orthogonal 
character. Covalent and rapid linkage of two components under environmentally friendly, 
nontoxic conditions are properties that are completely complementary to the development 
of novel agents for the development of both imaging and therapeutic products. 
Ideal ly, methodologies which are adaptable to a wide range of target molecules and 
prosthetic groups can be developed. The advantages gained from the intrinsic simplicity of 
such protocols would be achieved economically, practical ly and would benefit the fields of 
nuclear imaging and medicine. 
Click chemistry may offer the perfect platform for such advances in labelling due to its 
exquisite selectivity and tolerance to a wide range of conditions. 
In addition applications of Cu-free click chemistry include mammalian disease models 
where the bioavailability and pharmacokinetic properties of the reagents become important. 
The cyclooctynes that are currently employed for Cu-free click chemistry are not very 
soluble in aqueous solutions. The hydrophobicity of these cyclooctyne scaffolds could also 
promote binding to membranes or nonspecific binding to serum proteins, thereby reducing 
their bioavailable concentrations and increasing the noise in PET-images. 
Final ly the suitability of azide labeling and Cu-free click chemistry should enable 
applications in many areas of glycobiology. For example, direct imaging of glycan trafficking 
under conditions of cel l stimulation or pharmacological intervention has been demonstrated 





Click chemistry is applied in diverse areas such as bioconjugation, drug discovery, 
materials science, and radiochemistry. Click chemistry has increasingly found applications in 
many aspects of drug discovery, by generating lead compounds through combinatorial 
methods. Bioconjugation via click chemistry is also employed in proteomics and nucleic 
research. In radiochemistry, selective radiolabeling strategies of biomolecules for imaging 
and therapy have been realized. 
The work presented in this PhD-thesis has resulted in versatile methodology based on click 
chemistry to prepare PET-tracers. The evaluation of these PET-tracers is already underway 
and forthcoming in vivo study results will provide grounds for further radiopharmaceutical 
development in this field. This chapter describes applications where click chemistry can play 
an important role in the near future. 
Application for multimodality imaging tracers 
In the near future, click chemistry can be further developed as a versatile synthetic 
method to produce dual modality probes for PET-MRI and PET-optical imaging. Using the 
versatile Cu catalyzed azide alkyne cycloaddition, the radionuclide 18F can be rapidly 
introduced to a molecule already bearing the necessary functionalities for MRI or optical 
imaging. 
Concepts for PET scanners integrated into an MRI tomograph have emerged and the 
first commercially available cameras have entered the market. The excellent soft-tissue 
contrast of MRI and the multifunctional imaging options it offers, such as spectroscopy, 
functional MRI, and arterial spin labeling, complement the molecular information of PET. 
PET can verify the localization of probes where concentration is too low to detect by MRI, 
making it a powerful tool for probe development. The combination of MRI and PET is 
particularly synergistic because MRI can not only provide anatomical context for the PET 
images but also allow high-resolution imaging of probe distribution. 
Dual PET-MRI biomarkers i.e. tracers that are visible with PET as well as with MRI can add 
an extra dimension. The superior sensitivity of PET over MRI, with a factor of > 1000, 
imposes constraints on the design of these dual PET-MRI biomarkers. Magnetic 
nanoparticles that are coupled to radionuclides are feasible and can be imaged with PET in 
combination with MRI. Here, the radiolabelled part of the nanoparticle is used to spot a 
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region of interest inside the body and to quantify biomarker uptake. Then, with MRI, the 
correct localization of the dual modality probe inside the target region is performed, based 
on the MRI contrast produced by the biomarker. Furthermore, biomarkers that allow PET 
and MRI labeling might be of interest for cross-validation studies. 
In addition to PET-MRI, PET and optical imaging are a promising combination for dual 
imaging technology as well. They both have high sensitivity resulting in a PET-optical probe 
that can be present in low quantities while still allowing good images from both techniques. 
The deep tissue imaging of PET and the longer lasting optical imaging allows for the 
possibility for the localization of a disease with PET and then the visual guidance of 
fluorescence during surgery all with one probe. A particular advantage is offered when using 
short lived isotopes such as 1 1C and 18F resulting in low radiation dose for the patient and 
possibility for repeated measurements. The fluorescent label gives information about the 
distribution and metabolic breakdown of the labeled drug or tracer during a longer period 
even after decay of the radioactivity. Thus far the synthesis of dual modality probes has 
mainly focused on the use of long lived isotopes. While these are useful isotopes, they have 
the intrinsic disadvantage of exposing the subject to radioactivity for longer periods of time. 
Short lived isotopes present an extra challenge to the synthesis since the introduction and 
subsequent purification of the isotope has to occur within a small time frame, preferably less 
than an hour. 
Dual PET-MRI-tracers could be prepared by coupling the 18F-alkyne or azide to inorganic 
nanoparticles. It has already been shown that "click" nanoparticles were able to stably 
circulate for hours in vivo after intravenous injection (>5 h circulation time), extravasate 
into tumors, and penetrate the tumor interstitium. 
Cross-linked, fluorescent, superparamagnetic iron oxide nanoparticles have been 
derivatized with an azido-PEG group. So conjugation with 18F-alkynes to these azido-PEG 
nanoparticles via cycloaddition would be feasible. This strategy opens the way to attach 
different tags, resulting in nanoparticles suitable for multimodality imaging, including MRI, 
PET and optical imaging. The synthetic difficulties that arise with the use of short lived 





In vivo copper-free click application for pretargeting 
The bioorthogonality of the Cu(I)-catalyzed click chemistry reaction and the fact that it 
proceeds readily in water at various pHs makes it suitable for biological applications. The 
main disadvantage is that copper is cytotoxic so this type of reaction cannot be performed in 
vivo and requires purification to eliminate traces of copper before labelled molecules can be 
monitored in biological systems. This is why considerable effort has been put into 
developing click reactions that proceed rapidly without copper, the so-called Cu-free click 
chemistry. For instance, an alkyne that is sufficiently reactive in the absence of copper 
catalysis can be obtained by introducing ring strain and/ or electron withdrawing groups. 
The group of Bertozzi in particular has done significant work in this area, and have 
synthesized a library of cyclooctynes with varying properties and reactivities. A great 
challenge will be to utilize the copper free click reaction in vivo for pretargeting purposes in 
antibody imaging. Pretargeting is a multistep process so far used in radioimmunotherapy 
and imaging oncology that separates antibody targeting as first step from the radionuclide 
targeting in the second step. 
Bispecific antibodies with radiolabeled peptides and streptavidin conjugates/fusion 
proteins with radiolabeled biotin have been examined clinically with promising initial results. 
The benefit of using 18F in pretargeting is that it is a radionuclide with very favourable 
properties regarding half life, availability, and spatial resolution. The idea is to first 
administer an azide or alkyne derivatized antibody. At the optimal time point where specific 
over non-specific binding is maximal (usually a few days) the 18F-radiolabelled counterpart is 
injected and should click on to the derivatized antibody. 
Since the alkyne-azide cycloaddition will likely be too slow under in vivo copper-free 
conditions, more efficient click chemistry methods should be investigated for such as the 
inverse electron demand Diels-Alder cycloaddition connecting tetrazine and norbornene. 
Applying such a click chemistry approach, modification of an antibody can be performed 
with norbornene. The complementary tetrazine can be modified with the appropriate leaving 
group for [18F]-fluorination or a chelator for radiometallations. In addition to [18F]-strategies, 
introduction of chelators could help in making comparisons between bioconjugates labeled 
with different radiometals, because the chelator modified antibodies are synthesized using 
identical ligation conditions. 
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Pretargeting strategies could also be applied to nanoparticles and multimodality 
biomarkers. New chemistry is required to optimize nanoparticles design and manufacturing 
and to optimize the formation of a site-specific stable bioconjugate linkages between the 
nanoparticles and the targeting molecules, and between the nanoparticles and the PET 
radionuclide. Therefore several click chemistry methods are already being developed. Novel 
nanoparticle materials are being developed that have the intrinsic ability to bind to PET 
radionuclides either in vitro or in vivo allowing pretargeting approaches. Non-nanoparticle 
approaches are also being developed in which single targeting molecules can be labelled 
with both paramagnetic contrast and radionuclides. Once general production methods have 
been developed, specific targeted dual modality probes will be synthesized. 
In conclusion, possible applications using click chemistry holds many challenges in the 








Er is een grote behoefte aan specifieke PET-radiofarmaca. Binnen het vakgebied van de 
radiochemie zijn er een aantal uitdagingen voor de chemicus, te weten korte synthesetijden 
(omdat het radionuclide snel vervalt), kleine hoeveelheden radioactief gemerkt reagentia en 
beperkte karakterisatiemogelijkheden. Bovenop deze uitdagingen bestaat er nog de vereiste 
dat de producten zeer zuiver moeten zijn en de resultaten reproduceerbaar, omdat de 
radiofarmaca worden gebruikt voor humane studies. Nieuwe radiochemische methoden 
moeten daarom worden ontwikkeld. In dit proefschrift wordt de synthese van een aantal 
receptor liganden beschreven met behulp van de 1,3-dipolaire cycloadditie van azides en 
alkynen, ofwel een klikreactie voor [18F] voor gebruik voor Positron Emissie Tomografie 
(PET). Het werk dat is beschreven in dit proefschrift richt zich op de volgende uitdagingen in 
radiochemie: 
Korte synthesetijd 
Zeer kleine hoeveelheden reagentia 
Eenvoudige en betrouwbare synthese 
Brede toepasbaarheid van de methode 
De koper-gekatalyseerde 1,3-dipolaire cycloadditie van alkynen en azides (CuAAC) en 
de koper-vrije cycloadditie geactiveerd door ringspanning bleken betrouwbare 
labellingsmethoden te zijn. De CuAAC reactie voldoet aan de uitdagingen zoals eerder 
genoemd. De reactie is snel, selectief en kan worden toegepast in aanwezigheid van 
verschillende reactieomstandigheden. Daarom is klikchemie uiterst geschikt als 
labellingsmethode voor PET-radiofarmaca. 
In dit proefschrift worden twee doelen nagestreefd: het eerste doel was de ontwikkeling van 
een 18F-klikchemie methode om PET-radiofarmaca te maken, het tweede doel was om de 
klikchemie toe te passen op biologisch actieve moleculen. 
In hoofdstuk 3 voerden we 1,3-dipolaire cycloaddities uit in aanwezigheid van koper(I). 
We optimaliseerden de labellingsprocedure om hoge radiochemische opbrengsten te halen. 
Daarnaast versnelden we de CuAAC reactie door toevoeging van het ligand MonoPhos. 
MonoPhos, een eenvoudige phosphoramidiet ligand, verkortte de reactietijden in combinatie 
met zeer lage hoeveelheden reagentia. De conjugatie van [18F]fluoroalkynen aan 
verschillende hoeveelheden (> 0.01 mg) azides gaven de gewenste 18F-triazoolproducten in 
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10 min met opbrengsten van 54-99% en goede zuiverheid (97-99%). De totale 
synthesetijd was 30 min vanaf het einde van bestraling. Geconcludeerd kan worden dat een 
goed toepasbare klikreactie gekatalyseerd door koper(I) en MonoPhos is ontwikkeld om 
18F-radiofarmaca te maken. 
In hoofdstuk 4 beschreven we een nieuwe PET tracer voor beta-adrenerge receptoren 
in de hersenen, gemaakt met behulp van de 18F-click methode beschreven in hoofdstuk 3 
(Schema 9.1). Het werk richtte zich op de combinatie van klikchemie en een enzymatische 
omzetting. Racemisch epoxide kan stereoselectief geopend worden met een azide om 
zodoende azidoalcoholen te produceren. Klikchemie werd succesvol toegepast op de 
synthese van (R)-1-( (9H-carbazol-4-yl)oxy)-3-4( 4-( (2-(2-(fluoromethoxy)-ethoxy)methyl)­
lH-1,2,3-triazol-1-yl)propan-2-ol (18F-FPTC) met hoge radiochemische opbrengst en 
zuiverheid. FPTC bezit de nieuwe structuur �-hydroxytriazole waarbij bleek dat de affiniteit 
voor de beta-adrenerge receptoren behouden bleef. De redelijk hoge affiniteit (IC 50 = 50-
60 nM) en geschikte lipofiliciteit (logP +2.48 ) zijn twee belangrijke criteria om te 
voorspellen of de tracer geschikt is voor in vivo beeldvorming. Helaas lieten de ex vivo 
biodistributie en microPET beelden zien dat deze criteria onvoldoende waren om beta­
adrenerge receptoren in de hersenen af te beelden. 
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140°C, 1 5  min, DMSO 
Scheme 9.1. Synthese van 18F-FPTC 
Click reaction 
CuS04, Na ascorbate 
Monophos 
In een studie beschreven in hoofdstuk 5 ontwikkelden we gemodificeerd bombesine, 
een peptide dat een hoge affiniteit heeft voor de gastrine afscheidende peptide receptor 
(GRPR) die in verhoogde concentraties voorkomt op verschillende soorten tumor cellen, 
zoals in prostaat kanker. Bombesine is een peptide van 14 aminozuren. De aminozuren 7-14 
zijn verantwoordelijk voor binding aan de GRP-receptor. Wij gebruikten de 1,3-dipolaire 
cycloadditie om het peptide te labellen op de [lys3]-positie. Een terminale alkyn werd 
verbonden aan het [Lys3] residu van de 14 aminozuur peptide, waar [18F] werd 
ge'introduceerd als complementaire azide (Scheme 9.2). De tracer bezat goede vitro 




Schema 9.2. Fluoro Triazolyl Lysine 3 Bombesine (FfBN3) 
In hoofdstuk 6 hebben we ons gericht op de synthese van de Siemens imaging 
biomarker 18F-RGD-KS. Dit cyclische peptide bevat een aminozuurvolgorde waarvan bekend 
is dat het bindt aan U'v�3 integrines, die een rol spelen in celadhesie aan de extracellulaire 
matrix. We hebben een verbeterde "klik" chemie method ontwikkeld met gebruik van Cu(I)­
Monophos als katalysator om [18F]fluoropentyn aan de RGD-azide precursor te koppelen, 
met als resultaat het product 18F-RGD-KS (Schema 9.3). Deze methode is vergeleken met de 
geregistreerde Siemens methode wat betreft de synthese, zuivering en kwaliteitscontrole. 
[
18F]RGD-KS werd verkregen na 75 min synthesetijd en een radiochemische opbrengst van 





K2CO3 , Kryptofix[2.2.2] 
[1 8F fluoride] .,,,� 
____ ,#' 
_ 1aF 
o-DBC,1 10'C .Y 
Scheme 9.3. A) Productie van s-[18F]fluor-1-pentyn: nucleofiele substitutie tussen pentynyl 
tosylaat en gedroogd [18F]fluoride in ortho-dichloorbenzeen ( o-DCB). B) MonoPhos Cu(I)­
gekatalyseerde Huisgen cycloadditie van [ 18F]fluoropentyn met de RGD-KS azide precursor 
resulterend in 1,4-disubstitueerd triazool [18F]RGD-KS. 
In hoofdstuk 7 is voor de eerste keer de mogelijkheid van integrine beeldvorming voor 
het bepalen van angiogenese en kwetsbaarheid van atherosclerotische plaques beschreven. 
Niet-invasieve beeldvorming en kwantificatie van angiogenese kunnen artsen een manier 
geven om risico's bij cardiovasculaire ziekten in te schatten. Het kwaliteitscontrole systeem 
voor RGD-KS is gevalideerd en biedt nu de mogelijkheid om de tracer toe te passen in 
klinische studies naar neoangiogenese bij kankerpatienten. 
In hoofdstuk 8 hebben we een snelle [18F]-labellingsmethode beschreven voor 
bombesine met [18F] waarbij gebruik werd gemaakt van reactiecondities zonder 
koperkatalyse. Het [18F]-azide en het alkyn-gemodificeerde bombesine werden 10-15 min bij 
kamertemperatuur geroerd. Hierdoor werd het [18F]bombesine in redelijk tot goede 
opbrengsten gemaakt. Als bijkomend voordeel kon het azide warden gevarieerd wat betreft 
lipofiliciteit (Schema 9.4). Het resultaat was dat tracers met verschillende eigenschappen 
eenvoudig beschikbaar zijn gekomen vanuit hetzelfde substraat. Op deze manier kan een 
optimale lipofiliciteit voor celopname en metabole klaring warden verkregen. We beschrijven 
hier de verandering en labeling van [Lys3]-bombesine en laten zijn dat de hoge affiniteit 
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voor de receptoren behouden blijft. De methode zou in de toekomst kunnen warden 








Scheme 9.4. Aza-dibenzycyclooctyn gemodificeerde bombesine gelabeled met 
verschil lende [18F]-azides. Reagentia en condities: a) K[18F], MeCN, 1 10 °c; b) DMF, r.t. 
Geconcludeerd mag warden dat klikchemie een waardevolle manier is voor biomedische 
toepassingen. Een van de unieke eigenschappen van klikchemie is het bioorthogona le 
karakter. Een snelle covalente koppeling van twee componenten onder milieuvriendelijke en 
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niet-toxische condities die volledig complementair zijn en kan warden gebruikt voor de 
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N,N'-diisopropylethylamine 
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Epidermal rowth factor receptor 
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(fluoromethoxy)-ethoxy)methyl)-lH-1,2,3-triazol-1-yl)propan-2-ol 
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Radio chemical yeild 
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